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RESUMEN 
El cáncer de mama sigue siendo en nuestros días la segunda causa de muerte por cáncer en mujeres y el 
cáncer más común entre las mujeres, siendo por tanto una entidad bajo una intensa investigación. El cáncer de 
mama hereditario comprende aproximadamente el 5-10% de todos los casos de cáncer de mama. Las 
mutaciones germinales en los dos genes de alta susceptibilidad más importantes, BRCA1 y BRCA2, junto con 
las mutaciones en otros genes de susceptibilidad pueden explicar sólo el 40% de los casos. Por lo tanto, la 
etiología de los casos de cáncer de mama que se presentan en familias de alto riesgo no atribuible a 
mutaciones en alguno de los genes de susceptibilidad conocidos, tumores de tipo BRCAX, se desconoce. 
Estos tumores son muy heterogéneos en cuanto a su morfología, histología, perfiles moleculares y 
comportamiento clínico. En los últimos años han tenido una gran importancia la identificación de los perfiles 
de expresión de microRNA (miRNA) para la clasificación de los cánceres humanos, y se ha descrito la 
desregulación de miRNAs implicada en importantes procesos biológicos. En concreto, en el cáncer de mama, 
los perfiles de expresión de miRNA se asocian a subtipos específicos o características biológicas, como la 
presencia de receptores hormonales, el estado de HER2, las metástasis, la progresión o la proliferación. Sin 
embargo, se sabe muy poco sobre el papel de los miRNAs en la patogénesis del cáncer de mama hereditario. 
Con el propósito de delinear los mecanismos responsables de la tumorigénesis del cáncer de mama hereditario 
hemos adoptado una variedad de enfoques que incluyen análisis de expresión de miRNAs de forma masiva o 
individual,  análisis de mRNA y expresión de proteínas así como estudios funcionales. 
De esta forma hemos establecido el patrón de expresión global de miRNAs y de mRNAs después de la 
reconstitución del gen BRCA1 en la línea celular HCC1937, posteriormente hemos integrado estos datos para 
así modelar parejas de miRNAs y genes regulados por estos diferencialmente expresados  definir redes 
funcionales afectadas en estas células. Nuestros datos sugieren un papel de BRCA1 en la modulación de una 
serie de miRNAs e indirectamente de cientos de genes, a su vez promueven la represión de diferentes vías de 
señalización como las mediadas por NF-kB y  MAPK. Hemos identificado el gen TRAF2 como nueva diana 
para los miR-146, miR-99 y miR-205, y hemos demostrado que estos miRNAs son suficientes para modular la 
actividad de la vía de NF-kB en células de cáncer de mama. Por último, nuestros datos ponen de manifiesto la 
importancia de un enfoque integrado para el estudio de expresión de miRNAs y genes, para la identificación 
de vías de señalización alteradas y genes candidatos que pudieran ser importantes en el desarrollo del tumor. 
La pérdida de expresión específica de  ciertos miRNAs encontrada en los tumores primarios sugiere su papel 
en la tumorigénesis así como podrían ser importantes para el desarrollo de futuras terapias  
En la actualidad no existen prácticamente estudios que describan de forma amplia la expresión de 
miRNAs en los tumores de mama hereditarios. Mediante el uso de microarrays de sondas LNA hemos 
establecido  los perfiles de miRNAs en una serie de carcinomas primarios de mama hereditario de mama así 
24 | P a g e   
como de un grupo de los tejidos de mama normales, y de tumores de mama esporádicos. El análisis de estos 
perfiles ha puesto de manifiesto  una serie de miRNAs que se expresan de forma aberrante en los carcinomas 
de mama hereditarios, incluyendo la disminución de expresión de ciertos miRNAs previamente implicadas en 
el cáncer de mama esporádico, lo que implica una vía común de la progresión del tumor, independientemente 
de los sucesos iniciadores. La mayor parte de los miRNAs diferencialmente expresados mostraron en su 
mayoría una reducción significativa de la expresión en los tumores comparando  con el tejido normal. Uno de 
estos miRNAs encontrados es el miR-30c, que potencialmente contribuye a la formación de tumores malignos 
de mama mediante la liberación de la supresión del gen KRAS, lo que sugiere que este miRNA, y 
probablemente de forma conjunta con otros miRNAs, puedan funcionar como supresores tumorales en cáncer 
de mama a través de la regulación del gen KRAS y por tanto de la vía de señalización de MAPK. 
Por otra parte hemos establecido una clasificación de los diferentes subtipos de tumores de mama 
hereditarios, BRCA1, BRCA2 y BRCAX, así como de tumores de mama esporádicos y tejidos normales en 
función de sus perfiles de miRNA de expresión revela una clara separación entre los grupos. Hemos 
identificado un gran número de miRNAs expresados diferencialmente entre los tumores de mama con 
mutación en BRCA1/2 y los que no tiene mutación, que puede servir como punto de partida para el desarrollo 
de biomarcadores de diagnóstico que potencialmente pudieran ser útiles para discriminar entre los tumores 
con mutación en BRCA1/2  y facilitando la identificación de las personas en situación de riesgo de ser 
portadores de la mutación. Además los perfiles de expresión de los tumores BRCAX revelaron una 
heterogeneidad clara, con 4 subgrupos definidos por aparentes firmas de miRNAs específicos y diferentes 
características histológicas que sugieren diferentes vías en la evolución de estos tumores. 
En resumen, nuestros resultados abren nuevas perspectivas en los mecanismos que están detrás de la 
desregulación BRCA1 y aportan nuevas ideas sobre la heterogeneidad molecular de los tumores de mama 
hereditarios que podrían ser la base para futuras investigaciones en el desarrollo de biomarcadores de 
diagnóstico y la comprensión de la etiología de los tumores BRCAX. 
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SUMMARY 
Breast cancer continues to be the second leading cause of cancer deaths in women today and being the 
most common cancer among woman, it is an object of intensive research.  Hereditary breast cancer comprises 
approximately 5-10% of all breast cancer cases. Germline mutations in two high susceptibility genes BRCA1 
and BRCA2, along with mutations in other susceptibility genes can account for only up to 40% of cases. Thus, 
the etiology of breast cancer cases that arise in high-risk families not attributable to mutations in any know 
breast cancer susceptibility gene, BRCAX-type tumors, is unknown. These tumors are highly heterogeneous 
in terms of their morphology, histology, molecular profiles and clinical outcomes. In recent years microRNA 
(miRNA) expression profiling calls great attention for classification of human cancers, and microRNA 
deregulation has been implicated in important biological processes. Specifically, in breast cancer, miRNA 
expression profiles were associated to specific subtypes or biological features such as hormone receptor, 
HER2 status, metastasis, progression or proliferation. However, very little is known regarding the role of 
microRNAs in hereditary breast cancer pathogenesis.  With the purpose of delineating the mechanisms 
responsible for hereditary breast tumorigenesis we have adopted a variety of approaches including high- and 
low-throughput microRNA, mRNA and protein expression analysis and functional studies.  
We have established the global miRNA and mRNA expression pattern after BRCA1 reconstitution in 
HCC1937 cells, and integrated the data to model differentially expressed miRNA and genes into functional 
networks. Our data suggest a role for BRCA1 in modulating a number of miRNAs and indirectly hundreds of 
genes, in turn promoting the repression of NF-κB and MAPK signaling pathways. We have identified TRAF2 
as a novel target gene for miR-146, miR-99 and miR-205, and shown that these miRNAs are sufficient to 
modulate NF-κB pathway activity in breast cancer cells.  Finally, our data underscores the importance of an 
integrated approach to study of miRNA and gene expression, for identification of altered signaling pathways 
and promising candidate genes. Down-regulation of these miRNAs also in primary tumors suggests their role 
in tumorigenesis and as potential targets for future treatment development. 
At present there are no studies describing miRNA expression in hereditary breast tumors. We have 
performed LNA-based microRNA microarray profiling in a series of primary hereditary breast carcinomas 
and normal breast tissues. The microRNA analysis revealed a series of aberrantly expressed microRNAs in 
hereditary breast carcinomas including downregulation of several miRNAs previously implicated in sporadic 
breast cancer, implying a common pathway of tumor progression irrespective of the initiating events. These 
miRNAs mostly showed significant reduced expression in tumors comparing to normal breast tissue. One of 
these miRNAs, miR-30c, potentially contributes to breast malignancy formation through release of KRAS 
suppression suggesting that this miRNA, and likely other miRNAs also targeting KRAS/MAPK signaling, 
may function as tumor suppressors in breast cancer. 
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Classification of breast tumors from different genetic subtypes, BRCA1, BRCA2 and BRCAX, sporadic 
breast carcinomas and normal tissues based on their microRNA expression profiles revealed clear segregation 
between the groups. We have identified a large number of miRNAs differentially expressed between BRCA1/2 
mutation positive and mutation negative breast tumors, which can serve as a starting point for the 
development of biomarkers of diagnosis that would potentially discriminate between mutation positive tumors 
and facilitate identification of individuals at risk of being mutation carriers. Hierarchical clustering of BRCAX 
tumors revealed clear heterogeneity, with 4 apparent subgroups defined by specific miRNA signatures and 
different histological characteristics suggesting different paths in tumor evolution.  
In summary, our findings bring new insights in the mechanisms behind BRCA1 deregulation and new 
ideas on the molecular heterogeneity of hereditary breast tumors that hold the basis for future research into 
development of diagnostic biomarkers and understanding the etiology of BRCAX tumor. 
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El cáncer de mama es una enfermedad compleja y heterogénea originada a partir de una proliferación 
anormal y desorganizada de las células que componen el tejido mamario. El cáncer de mama es la segunda 
causa de muerte más frecuente por cáncer en todo el mundo en las mujeres y es el cáncer más común en las 
mujeres. La incidencia de cáncer de mama en países desarrollados es más alta que en los países en desarrollo. 
También es el cáncer más frecuente en las mujeres españolas;  con una tasa de incidencia estandarizada por 
edad de 51 casos por 100.000 mujeres al año, ocupa una posición intermedia entre Europa Occidental y los 
países de Europa del Este. Sin embargo, la incidencia de cáncer de mama está aumentando alrededor del 2-3% 
por año (Polan, 2007). Los cambios en el comportamiento reproductivo y el estilo de vida, junto con la 
introducción de la terapia de reemplazo hormonal se consideran responsable en parte de esta tendencia (Parkin 
y Fernández, 2006). Aproximadamente el 77% de los casos de cáncer de mama ocurren en mujeres mayores 
de 50 años de edad. Existen varios factores bien establecidos que se han asociado con un mayor riesgo de 
padecer cáncer de mama: historia hereditario de la enfermedad, nuliparidad, menarquía precoz, edad avanzada 
y antecedentes clínicos de cáncer de mama. Los avances en el diagnostico, tratamiento médico y quirúrgico 
durante los últimos 4 décadas son responsables de la tendencia decreciente de las tasas de mortalidad, a pesar 
de no disminuir la incidencia. Sin embargo, en aproximadamente el 30% de las mujeres inicialmente 
diagnosticadas en estadios tempranos de la enfermedad, la enfermedad progresa a estadios más avanzados o 
metastatiza, siendo la principal causa de mortalidad relacionada por el cáncer de mama. 
 La gran mayoría de los casos de cáncer de mama son esporádicos, mientras que el cáncer de mama 
hereditario representa sólo el 5-10% de los casos. Las mutaciones en dos genes de alta susceptibilidad, BRCA1 
y BRCA2, explican aproximadamente el 25% de todos los cánceres de mama hereditario, y las mujeres que 
portan mutaciones en estos genes tienen un riesgo de desarrollar cáncer de mama a lo largo de su vida que es 
aproximadamente 10 veces mayor que el de la población general. Otros genes de susceptibilidad a cáncer de 
mama incluyen TP53 y PTEN - asociados con síndromes de cáncer poco frecuentes, mutaciones en el CHEK2, 
NBS1, RAD51C,  BRIP1 y PALB2  que están asociados con la duplicación de los riesgos de cáncer de mama. 
Las mutaciones en estos genes representan un pequeño porcentaje y junto con recién identificados variantes de 
baja susceptibilidad no explican más de 10% de los casos de cáncer de mama que se producen en las familias 
que no llevan mutaciones en los genes BRCA1 o BRCA2. Por tanto existe un grupo mayoritario de cáncer de 
mama hereditario en el que la susceptibilidad genética no puede ser atribuida a mutaciones en los genes 
estudiados hasta el momento, este grupo se conoce como BRCAX. 
Los microRNAs son un grupo de RNAs de cadena sencilla de pequeño tamaño (aprox. 22 nt) que no 
codifican para proteínas, sino que intervienen en la regulación de RNAs mensajeros. Los microRNAs son 
sintetizados inicialmente como transcritos primarios que tienen una estructura en forma de bucle con una 
horquilla formada por bases complementarias (pri-microRNAs). Estos son procesados luego en el núcleo por 
la enzima Drosha y DGCR8 que corta parte de la secuencia formando los pre-microRNAs. Los pre-
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microRNAs se exportan al citoplasma donde son de nuevo procesados para formar RNAs muy cortos de doble 
cadena por la enzima Dicer. Estos se unen al complejo RISC que separa las dos cadenas, formando los 
microRNAs maduros.  Actualmente hay recogidos mas de mil miRNAs humanos en la última versión de la 
base de datos miRBase v.18.0 . A pesar de que el número de miRNAs ha ido aumentando rápidamente y 
probablemente siga haciéndolo, para la mayoría de los miRNAs descritos quedan aún por identificar cuáles 
son los genes diana a los que regulan. 
El principal mecanismo de acción descrito de los miRNAs es mediante la unión de los miRNAs maduros 
al extremo 3’ no codificante de los mRNAs a los que regula, lo cual resulta en la represión transcripcional o 
degradación de RNA mensajero de estos genes. En cualquier caso, el resultado es la disminución de la 
expresión de la proteína codificada por el gen regulado por miRNAs. Está descrito que cada miRNA puede 
regular múltiples genes, así como un mismo gen puede verse regulado por diferentes miRNA. Aunque la 
función de los miRNAs aun no está bien conocida, parecen ser importantes para un gran número de procesos 
biológicos, como diferenciación, regulación de la proliferación celular o apoptosis, existiendo numerosos 
trabajos sobre el papel de los miRNAs en cáncer. La mayoría de los estudios de los miRNAs en tumores se 
han basado en la comparación de la expresión que estos muestran en tumores y en muestras normales. 
Algunos miRNAs se sobreexpresan en determinados tipos tumorales y tienen potencial oncogénico, mientras 
que otros parecen actuar como supresores de tumores y están ausentes o reprimidos.  
En cuanto al papel de los miRNAs en tumores de mama, hasta este momento se han realizado diversos 
estudios de expresión de miRNAs tanto en líneas celulares como en tejidos normales y tumorales de cáncer de 
mama. Los perfiles de expresión de miRNAs en cáncer de mama esporádico han permitido identificar 
miRNAs importantes en el desarrollo de estos tumores, que difieren significativamente en muestras tumorales 
y normales, como mir-10b, mir-125b, mir-145, que se encuentran reprimidos o el mir-21 o mir-155 que están 
consistentemente sobreexpresados. Además se ha encontrado que los cambios de expresión de miRNAs 
parecen definir, de forma similar a lo encontrado con los perfiles de expresión de genes codificantes, los 
diferentes subtipos histológicos (lobulares/ductales, ER+/ER-) y moleculares (luminar A, luminar B, basal-
like, HER2+) descritos hasta el momento (13). Sin embargo, es muy poco lo que se sabe del papel de los 
miRNA en cáncer de mama hereditario. 
 
 INTRODUCTION 
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1. CANCER 
Cancer is a genetic disease that arises from an accumulation of mutations in critical genes. It is defined as 
a malignant neoplasia (tumor), characterized by an abnormal growth and unregulated proliferation of cells that 
tend to invade surrounding tissues and metastasize to distant sites. Although cancer encompasses many 
different tumor types, classified by their cellular origin, they all share common hallmarks which comprise a 
number of biological capabilities acquired during the multistep development of human tumors. These 
common traits include sustained proliferative signaling, evasion of growth suppressors, resistance to apoptotic 
signals, replicative immortality, sustained angiogenesis, reprogrammed energy metabolism, evasion of 
immune destruction, genomic instability and increased mutagenesis, inflammation, invasiveness and ability to 
form metastasis (Hanahan and Weinberg, 2011).  
2. BREAST CANCER  
2.1.  Mammary gland and biology of breast cancer 
Human breasts (mammary glands) are reproductive organs specialized for milk production. Each 
mammary gland is divided into 15 to 20 lobes, each containing many smaller lobules. The basic units of the 
mammary gland are the terminal duct lobular units (TDLUs) that coalesce forming a single large duct. TDLUs 
produce the fatty breast milk that flows, post-partum from the lobules through ducts to the areola.  Fat and 
connective tissue fill the spaces between the lobules and ducts, and together with the lymphatic tissue make 
the mammary gland (Figure 1A). Ductal mammary epithelium is comprised of several cell lineages, including 
secretory luminal epithelial cells and contractile myoepithelial basal cells that reside on basal membrane. The 
mammary epithelium is maintained by the presence of multipotent mammary stem cells. Mammary epithelial 
cells organize into three-dimensional structures, which are strongly dependent on a polarized morphology, 
specialized cell–cell contacts and specific attachments to an underlying basement membrane (Figure 1B).     
Breast cancer is a complex disease resulting from abnormal and disorganized proliferation of cells that 
compose breast tissue.  About 95% of malignant breast tumors are carcinomas, which originate from the 
epithelium of the mammary gland. Neoplastic transformation of a carcinoma typically proceeds from a 
benign, well-differentiated localized tumor, carcinoma in situ, to invasive cancer that penetrates basal 
membrane infiltrating the surrounding tissue, and ultimately to metastatic tumor that disseminates to other 
parts of the body through lymphatic and blood vessels.  
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Figure 1. A) The anatomy of the breast: sagittal section of the mammary gland. Adapted from 
©Encyclopaedia Britannica 2010; B) Schematic depiction of normal breast epithelium and surrounding 
stroma. Adapted from Bertos et al, 2011.  
                    
2.2. Breast cancer heterogeneity 
2.2.1.  Morphological and histological subtypes 
Breast carcinomas exhibit a wide range of morphological phenotypes and specific histopathological types 
have particular prognostic or clinical characteristics. The vast majority of breast tumors are adenocarcinomas 
originating from mammary epithelium (Cancer.gov, Breast cancer Facts & Figures 2011-2012). Traditionally, 
breast cancer is classified by pathologists on it histological appearance together with criteria such as clinical 
features and anatomic sites. In terms of their anatomic localization, breast tumors are classified as in situ 
carcinomas, confined within the ducts or acini, and invasive or infiltrating carcinomas, that break through the 
basal membrane into surrounding tissues. In terms of their histology, the latest edition of the WHO 
classification of breast cancers recognizes the existence of at least 17 distinct histological special types. The 
majority of in situ carcinomas are ductal carcinomas in situ (DCIS) (83%), while lobular carcinomas in situ 
(LCIS) are much less common. The most common invasive breast tumor types are infiltrating ductal (70%) 
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and lobular (6%) carcinomas, while the rare histological subtypes such as medullary, mucinous, papillary, 
tubular, and other special subtypes contribute only a small proportion (Ellis, 2003).  
The staging system for breast cancer is based on the TNM (Tumor, Node, Metastasis)-classification and 
reflects the extent of spread of the cancer when it is first diagnosed. The TNM classification of tumors uses 
information on tumor size and how far it has spread within the breast and nearby organs (T), lymph node 
involvement (N), and the presence or absence of distant metastases (spread to distant organs) (M).  Once the 
T, N, and M are determined, a stage of 0, I, II, III, or IV is assigned, with stage 0 being in situ, stage I being 
early stage invasive cancer, and stage IV being the most advanced.  In general, TNM stage is inversely 
correlated with the prognosis. Furthermore, taking into consideration the grade of the tumor, based on the 
assessment of tubule formation, nuclear pleomorphism and mitotic index, breast carcinomas can be classified 
as: well differentiated - grade 1 tumors, moderately differentiated - grade 2 tumors, and poorly differentiated -
grade 3 tumors. Tumor grade indicates tumor aggressiveness and has been recognized as an independent 
prognostic factor. (Oldenburg et al., 2007; Weigelt and Reis-Filho, 2009).   
2.2.2. Molecular subtypes 
In the past decade great advances in gene expression profiling using microarray technology have led to 
better understanding of breast tumor heterogeneity. Initial study by Perou and colleagues revealed previously 
unknown molecular stratification of breast tumors into reproducible molecular subtypes of breast cancer with 
different biological features, clinical outcomes and responses to therapy. The groups included two ER 
negative groups: basal-like, characterized by expression of cytokeratine-5 and cytokeratine-17; ErbB2 tumors, 
overexpressing ERBB2 (HER2) and related genes; and normal-breast like tumors, expressing genes from 
adipose and other non-epithelial cells. The ER positive tumors, at first classified as a single group, were 
subsequently subclassified into at least two different groups: Luminal A (with high levels of expression of 
cytokeratine-8 and cytokeratine-18) and in Luminal B differing by level of ER expression and higher 
proliferation rate (Perou et al., 2000; Sorlie et al., 2001; Sorlie et al., 2003). The molecular subgroups have 
been extended to also include a sixth subgroup which has been named the claudin- low group, based on its 
low expression level of tight junction genes (the claudin genes).  
Most ER-positive, low-grade tumors may be grouped into a luminal subclass, characterized by a high 
expression level of luminal CKs (CK 8/18/19), ER, PR, BCL2, P27KIP1, a low expression level of TP53 and 
ERBB2, and a low grade. This subclass groups about 65–75% of breast cancers. Basal breast tumors comprise 
about 15–20% of all breast cancers and are ER- and PR negative, have a low level of luminal CKs, BCL2, 
P27, HER2 and a high expression level of P53 and of the basal CKs 5/6 and 17. Most of these tumors have a 
high grade. HER2-overexpressing tumors are generally characterized by a low, if any, expression level of ER, 
PR, and P53. These subtypes can be distinguished to an extent based on few immunohistochemistry markers 
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as: luminal A (ER+ and/or PR+, HER2-), luminal B (ER+ and/or PR+, HER2+), basal-like (ER-, PR-,  HER2-
, CK5/6+ and/or EGFR+ ), HER2 (ER- and PR-, HER2+) (Abd El-Rehim et al., 2005; Callagy et al., 2003; 
Gown, 2009; Tang et al., 2009) 
There have been great expectations that gene expression profiles may be used as a tool to define the 
signature of cancer and predict the prognosis and response to treatment, and that this knowledge might also 
allow for the development of treatment strategies based on an individual's tumor characteristic (Sorlie et al., 
2001; Stingl and Caldas, 2007); (Sotiriou et al., 2003)). In fact, basal-like tumors and HER2 positive tumors 
were associated to short survival and bad prognosis, while luminal A subtype had the best prognosis. Without 
a doubt, identification of a specific breast cancer subtype characterized by amplification and/or over 
expression of ERBB2 gene (HER2 tyrosine kinase receptor) has lead to development of targeted therapy 
Herceptin® (trastuzumab) with great clinical success. Furthermore, several prognostic multi-gene classifiers 
have been developed and some are approved for clinical use, that although do not outperform standard 
prognostic factors, can complement them in clinical decision making (Rakha and Ellis, 2011). 
2.3. Breast cancer epidemiology and risk factors 
Breast cancer is the second most common cancer and the leading cause of cancer death in women. The 
global burden of breast cancer exceeds all other cancers and the incidence rates of breast cancer are increasing 
(DeSantis et al., 2011). In 2008 it was estimated that worldwide, 1.38 million women were diagnosed with 
breast cancer, accounting for around a tenth (10.9%) of all new cancers and nearly a quarter (23%) of all 
female cancer cases. Female breast cancer incidence rates vary considerably, with the highest rates in Western 
Europe (89.7 per 100,000 women) and the lowest rates in Eastern Africa (19.3 per 100,000 women) (Ferlay, 
2008). Spain occupies an intermediate position between Western and Eastern European countries with 51 
cases in 100000 women per year; however, the breast cancer incidence is increasing around 2-3% per year 
(Polan, 2007). In general, incidences rates are high (>80 per 100,000) in developed regions of the world 
(except Japan) and low (<40 per 100,000) in most of the developing regions. Breast cancer risk typically 
increases for women who migrate from low to high risk countries suggesting a strong effect for lifestyle 
and/or environmental factors. The range of mortality rates is much lower (approximately 6-19 per 100,000) 
because of the more favorable survival of breast cancer in (high-incidence) developed regions due to better 
education, implementation of better screening programs, and more effective therapy. As a result, breast cancer 
ranks as the fifth cause of death from cancer overall. Nevertheless it is still the most frequent cause of cancer 
death in women in both developing and developed regions (Ferlay, 2008).  
There are many different factors that can modify the lifetime risk of breast cancer (Cancer Research UK, 
2012; Cuzick, 2008).  Age is by far the strongest risk factor (after female gender) for breast cancer.  It has 
been estimated that 1 out of 8 women will develop breast cancer during their lifetime. Estimated risk increases 
exponentially with age above 50 years, with 81% of cases occurring in women aged 50 years and over.. 
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Demographic factors and ethnicity influence the high variability of breast cancer risk. A large part of variation 
in risk of breast cancer between developed and less developed countries can be explained by the fact that 
women in developed countries have fewer children on average and a limited duration of breastfeeding. Breast 
density is another strong independent risk factor for breast cancer. Women with the more dense breasts (less 
fat and connective tissue component) have almost five times higher risk of breast cancer than women with the 
least dense breasts. Reproductive factors that increase the risk of breast cancer include long menstrual history 
(early age of menarche and late age of menopause), nuliparity, more than 30 years of age at first full-term 
pregnancy, no or short breastfeeding period. The use of oral contraceptives (OCs) increases the risk of breast 
cancer in current and recent users, but there is no significant excess risk ten or more years after stopping use. 
Women currently taking hormonal replacement therapy (HRT) have a temporary 66% increased risk of breast 
cancer compared to non-users, with risk returning to that of a never-user within five years. Non-reproductive 
lifestyle factors, such as body mass index (BMI), alcohol consumption, physical activity, diet, medical 
radiation exposure, working night-shifts, have all been associated to modifying the risk of breast cancer.  
Previous breast disease is indicative of a 3- to 4-fold higher risk of developing a new cancer in the other 
breast or in another part of the same breast.  Family history of breast cancer suggests increased risk depending 
on number of affected members. Having one first-degree relative (mother, sister, or daughter) with breast 
cancer approximately doubles a woman's risk. Having two first-degree relatives increases her risk about 3-
fold. However, over 85% of women who have a close relative with breast cancer will never develop the 
disease, and more than 85% of women with breast cancer have no family history of it. Genetic factors 
contributing to increased breast cancer risk are conferred by a presence of germline mutations in one of known 
breast susceptibility genes. 
3. HEREDITARY BREAST CANCER  
3.1.  Breast cancer families  
Family history of breast cancer is a strong indicator of an increased risk, and the existence of families 
with excess breast cancer cases has been recognized since the Roman ages (Broca, 1866); (Le Dran, 1757). A 
large majority of breast cancer cases are sporadic, usually detected in older patients (>55 years), while 
approximately 5% of breast cancer cases arise in patients with strong familial aggregation of breast tumors 
with various affected members throughout several generations. These cases are known as hereditary breast 
cancer cases, and follow a pattern of autosomal dominant inheritance in multiple affected members, have 
earlier age of onset, and/or present bilateral tumors. In case there is a suggestive family history but the number 
or the distribution of cancers is not definitive and the age of onset is variable, families are described as having 
familial cancer (Berliner and Fay, 2007). 
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3.2.  Genetic susceptibility to breast cancer 
Heritability studies on monozygotic and dizigotic twins clearly indicated the existence of strong genetic 
component (Lichtenstein et al., 2000; Peto and Mack, 2000), and early segregation analysis favored a highly 
penetrant autosomal dominant genetic model. This was confirmed when, in the early 1990s, two high 
susceptibility genes, BRCA1 at chromosome 17q21, and BRCA2 at chromosome 13q12, have been identified 
through linkage studies and positional cloning without any previous knowledge of their biological function 
(Miki et al., 1994; Wooster et al., 1995). At first, it was thought that mutations in these two genes will explain 
up to 80%  of familial breast cancer cases (Easton et al., 1995; Ford et al., 1995), but subsequently it was 
shown that they were responsible for only 20-30% of cases depending on a population in question (Serova et 
al., 1997). In the following years, the quest for novel susceptibility genes through linkage studies was 
intensified, but has yielded no reproducible results. However, another approach based on mutational screening 
of candidate genes selected based on their potential functional impact, has lead to identification of several rare 
susceptibility genes conferring moderate risk, that altogether account for additional 10% of familial breast 
cancer cases. Failure to identify novel high-susceptibility gene that would explain a significant portion of the 
remaining cases strengthened the notion that remainder of familial breast cancer follows a polygenic model 
where various different genes with incomplete penetrance are causative of the disease or that is due to 
cumulative effect of common low penetrance susceptibility genes. Finally in the last decade, with the advent 
of new technologies, the latter hypothesis was subject of intense investigation through genome-wide case-
control association studies (GWAS) in large international collaborative projects. This strategy led to 
identification of a number of low-risk common variants that are presumably responsible for additional 10% of 
remaining familial breast cancer cases.  
Current genetic landscape of breast cancer susceptibility consists of two high-risk (>10-fold) 
susceptibility genes, several rare intermediate-risk (2-4 fold) genes, and a number of common low-penetrance 
(< 2-fold risk) alleles. Still, approximately 65% of breast cancer cases arising in high-risk breast cancer 
families are unaccounted for (Figure 2). This represents a big “black box” not only in terms of underlying 
biology of these tumors, but is also a major problem for genetic counseling of these patients and their families. 
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Figure 2. Genetic landscape of breast cancer susceptibility  
3.2.1. High-risk breast cancer susceptibility genes BRCA1 and BRCA2 
Linkage analysis in large breast cancer family pedigrees lead to mapping of breast cancer susceptibility 
gene to 17q21 in 1990  (Hall et al., 1990) and  in 1994. by positional cloning BRCA1 gene was identified as 
first causative breast cancer gene (Miki et al., 1994). Linkage analysis and positional cloning lead to mapping 
and identification of BRCA2 in 1994 and 1995, respectively. (Wooster et al., 1995; Wooster et al., 1994) More 
than 1000 different sequence alterations have been reported in both genes, and novel ones are continuously 
deposited in the BIC database (Breast Cancer Information Core). Mutations are scattered throughout the large 
coding regions of the genes, making mutation screening challenging both technically and financially. Vast 
majority of reported mutations are small insertions or deletions, nonsense mutations, or alterations affecting 
the splice-site. Many missense substitutions have also been identified, but their role in carcinogenesis is much 
harder to establish, and therefore, most of them are classified as variants of unknown significance (VUS).  
Mutation frequencies in BRCA1 and BRCA2 vary between different populations, but are generally very 
rare with approximate prevalence of 1 in 860, and 1 in 740, respectively (Antoniou et al., 2002) and are are 
estimated to account for a relatively small percentage (20-25%) of familial risk (Thompson and Easton, 2004).  
Geographically or culturally isolated ethnic groups, such as Ashkenazi Jewish, Iclandic and Finnish 
populations, have much higher prevalence of population-specific founder mutations (Abeliovich et al., 1997; 
Thorlacius et al., 1996). Women with mutations in either BRCA1 or BRCA2 have a predicted lifetime risk of 
breast cancer between 37-85%, and a lifetime risk of ovarian cancer between 15-40% (Antoniou et al., 2003; 
Ford et al., 1995; Struewing et al., 1997). These estimates vary depending on the study design, patient 
ascertainment method, population in question, and in addition, additional genetic factors may modify risk in 
BRCA1/2 mutation carriers. Furthermore, BRCA1/2 mutation carriers who have had breast cancer have a 65% 
risk to develop a second primary breast cancer. Male carriers have four-fold increased risk for prostate cancer 
and a 100-fold increased risk for breast cancer (6%) compared to that of general population. BRCA1/2 
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alterations also confer  increased risk for occurrence of other cancer types including pancreatic, fallopian tube, 
stomach, colon and prostate cancer for BRCA1 (Thompson and Easton, 2002), and stomach gallbladder, bille 
duct, pancreatic, pharynx and prostate cancer for BRCA2 carriers (van Asperen et al., 2005).  
During the past decade many of the cellular and biochemical functions of the BRCA1- and BRCA2-
proteins have been discovered characterizing them as tumor suppressors. Both genes are generally considered 
to be ‘caretaker’ genes that act as sensors of DNA damage and participate in the repair process. Specifically, 
both BRCA1 and BRCA2 are necessary for double-stranded DNA breaks by homologous recombination. 
Their inactivation allows other genetic defects to accumulate and leads to genetic instability. Apart from 
DNA-repair BRCA1 roles include protein ubiquitylation, chromatin remodeling, cell cycle checkpoint control 
and transcriptional regulation. Biallelic mutations in  BRCA2 (FANCD1) cause a rare type of Fanconi anemia 
(FA), a recessive syndrome characterized by chromosomal instability, congenital malformations, progressive 
bone failure, hypersensitivity to DNA crosslinking agents and cancer susceptibility (Taniguchi and D'Andrea, 
2006) (Litman et al., 2005). Homozygosity for BRCA1-inactivating mutations, however, results in embryonic 
lethality, implying the functional differences between the two proteins. 
 
 
 
Figure 3. BRCA1 and BRCA2 functional domains. A) The BRCA1 N-terminus contains a RING domain that associates 
with BARD1 and a nuclear localization sequence (NLS). The central region contains a CHK2 phosphorylation site while 
the C-terminus of BRCA1 contains: a coiled-coil domain that associates with PALB2; a SQ/TQ cluster domain (SCD) 
that contains ATM phosphorylation sites and a BRCT domain that binds Abraxas, CtIP and BRIP1. B) The N-terminus 
of BRCA2 binds PALB2, and the central region contains BRC repeats that bind RAD51. The BRCA2 DNA-binding 
domain facilitates binding to both single- and double-stranded DNA. The C terminus contains an NLS and a CDK 
phosphorylation site that also binds RAD51. Adpated from Roy et al, Nature Reviews Cancer, 2012. 
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3.2.2. Other rare high-risk breast cancer susceptibility genes  
In addition to BRCA1 and BRCA2, mutations in several genes related to rare highly penetrant hereditary 
cancer syndromes are also associated with increased risk of breast cancer. Germline mutations in the TP53 
gene, which encodes for a protein involved in cell cycle control and apoptosis, are  implicated in Li-Fraumeni 
syndrome, a rare autosomal dominant syndrome with an increased risk of several childhood and adult cancers, 
including breast cancer (Li and Fraumeni, 1969). Although highly penetrant, the Li-Fraumeni syndrome and 
germline mutations in TP53 are very rare, and on overall account for less than 1% of all breast cancer cases 
(Sidransky et al., 1992). Germline mutations in PTEN, a tumor suppressor gene have been identified in 
families with Cowden syndrome, another rare autosomal dominant cancer syndrome that has been associated 
with hereditary breast cancer among other cancer types (Liaw et al., 1997). Up to 75% of women with 
Cowden’s syndrome have benign breast disease and the lifetime risk of invasive cancer is estimated to be 25-
50% with an average age of diagnosis between 38 and 46 years old (Brownstein et al., 1978). Peutz-Jighers 
syndrome is an autosomal dominant hereditary cancer syndrome caused by germline mutations in 
STK11/LKB1 gene, and is associated with a variety of cancer types including breast cancer (Boardman et al., 
1998). It is a very rare syndrome which account for a very small percentage of breast cancer cases, conferring 
a 29-50% risk by the age of 65 (Lim et al., 2003). In 2010, a novel high-risk susceptibility gene, the Fanconi 
Anemia (FA) gene RAD51C, was identified, showing that a heterozygous mutation in present in 
approximately 1.5% to 4% of all families predisposed towards breast and ovarian cancer, with high or 
moderate penetrance (Meindl et al., 2010) . Subsequently several studies in different populations were 
performed in order to validate the finding. However, some have failed to detect clearly deleterious mutations 
in RAD51C while discarding missense mutations (Clague et al.; Zheng et al.), others have indeed reported 
highly penetrant mutations albeit at a lower percentage than one described in the initial study (Pelttari et al., 
2011) The most recent study, in a large number of breast and/or ovarian families confirmed the existence of 
both clearly deleterious and functional missense mutations confirmed by functional assays in similar 
frequencies (1.3%) (Osorio et al., 2012). Like high-risk susceptibility genes BRCA1 and BRCA2, RAD51C 
plays a central role in DNA damage repair as a tumor suppressor gene (Figure 2).  
3.2.3. Rare moderate-risk susceptibility genes 
Apart from these cancer syndromes, mutations in several other genes have been shown to double the risk 
of breast cancer. These include rare mutations in CHECK2, ATM, NBS1, RAD50, BRIP1 and PALB2.  
First report of a truncating mutation, 1100delC in CHECK2 (Cell Cycle Checkpoint Kinase 2) gene has 
been identified in a single breast cancer family by  candidate gene approach association study, with a reported 
frequency of  0.5 - 2 % in northern Europe population, conferring an approximately 2-fold increased risk of 
breast cancer (Meijers-Heijboer et al., 2002). Other CHEK2 mutations have been subsequently associated with 
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similarly increased risk of breast cancer in other populations, although reported frequencies reported vary in 
different populations (Desrichard et al., 2011; Walsh et al., 2006). Germline mutations in ATM gene are 
responsible for the ataxia-telangiectasia (AT) syndrome, a recessive hereditary neurodegenerative disorder 
that is associated with cerebellar ataxia, telengiectasis, immunodeficiency and genomic instability and 
increased risk for cancer.  However, heterozygous mutation of ATM does not lead to the AT phenotype but 
carriers have a two to five fold risk of breast cancer (Khanna, 2000). A rare protein-truncating mutation in 
NBS1, first identified in Polish breast cancer patients is associated with approximately 2-fold increased risk. 
Rare mutations in BRIP1 (FANCJ) were also identified in breast cancer families (Seal et al., 2006) Truncating 
mutations in RAD50 were identified in northern Finland conferring a 4-fold increased risk of breast cancer 
(Heikkinen et al., 2006). And finally, PALB2 (FANCN) truncating mutations have been associated with a 2.3-
fold increased risk for breast cancer (Rahman et al., 2007).   Of note, biallelic mutations in PALB2 (FANCN) 
and BRIP1 (FANCJ) cause Fanconi anemia (FA) (Taniguchi and D'Andrea, 2006) (Litman et al., 2005).  
BRIP1 encodes a DEAH helicase that interacts with the BRCT domain of BRCA1 and has BRCA1-dependent 
DNA-repair and checkpoint functions. PALB2 co-localizes with BRCA2, promoting its localization and 
stability in key nuclear structures, which in turn facilitates BRCA2 functions in DNA repair. 
3.2.4. Low-penetrance common variants  
In the past two decades more than 1000 reports have been published on associations between candidate 
genes and risk of breast cancer. However this research area has been problematic because of the many 
associations that have been published to date, few have been established beyond reasonable doubt. These data 
were recently comprehensively evaluated in a meta-analysis study linking more than 50 variants in 40 genes 
to the risk of breast cancer (Zhang et al., 2011). One of the major limitations to the candidate gene case-
control association studies is that gene selection is based on the present body of knowledge, which is limited. 
The development of necessary technology in recent years, along with completion of large scale projects that 
made whole genome linkage disequilibrium and  single nucleotide polymorphism (SNP) data  publically 
available  such as International HapMap Project ( http://hapmap.ncbi.nlm.nih.gov/) and 1000 genomes project 
(http://www.1000genomes.org/ ), enabled the application of agnostic approaches such as genome-wide case 
control association studies (GWAS) using SNPs as tags. Given that for detection of low risk variants of tens of 
thousands of cases and control samples are required in order to reach sufficient statistical power, large 
international consortia and collaborative projects have been formed that facilitated these type of studies. 
So far around 20 common alleles have been associated with low risk of breast cancer through GWAS 
studies in different populations (Fanale et al., 2012; Zhang et al., 2011). All alleles identified are common in 
general population with minor allele frequencies (MAF) ranging from 0.15 to 0.5, majority of which is 
conferring less than 1.5-fold relative risk. A major obstacle in the interpretation of these results is that it is not 
clear if those variants associated are causal SNPs, or merely tags for a potential “real” susceptibility gene 
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located in the region of linkage disequilibrium proximal to the SNP identified. So far only confirmed 
association to a functional SNP in FGFR2 gene has been established through epidemiological and functional 
studies (Meyer et al., 2008). However, most of other associated SNPs are located in intronic or intergenic 
regions and the mechanisms by which these variants may influence breast tumorigenesis are largely unknown. 
Perhaps the most challenging aspect of these studies is the clinical utility of the variants identified. Their 
high prevalence in the general population in combination with very low risk, rule out the utility of single 
variants for breast cancer risk assessment, however, the combined effects may be useful for risk prediction 
and could facilitate the stratification of population according to associated risk. These women could 
potentially be candidates for cancer-preventative therapies and increased surveillance, since despite all 
improvements in the treatment of advanced-stage tumors, early diagnosis and prevention have the most 
dramatic effect on overall disease-specific outcome. Still, there is a long way to go before this approach could 
be implemented in the clinics. 
3.2.5. Prospects and challenges for identification of novel susceptibility genes 
Approximately one third of families with four or five breast cancers occurring in males or females do not 
carry a mutation in BRCA1 or BRCA2 (Ford et al., 1998). On this basis, it is likely that other breast cancer 
susceptibility genes remain to be discovered. However, there is also an emerging impression that currently 
unexplained genetic risk in multiple-case families without BRCA1 or BRCA2 mutations is unlikely to be due 
to mutations in a small number of major breast cancer susceptibility genes, but rather represents a 
heterogeneous mix of polygenic effects and rare mutations in a range of genes that confer high risk in some 
families (Pharoah et al., 2008). The heterogeneous nature of genetic risk in non-BRCA1/2 families poses a 
challenge to the identification of causative genes as evidenced by an absence of clear positional signals 
emerging from genome wide linkage studies in this group (Smith et al., 2006). In this regard, it is noteworthy 
that the occurrence of ovarian cancer and male breast cancer in a proportion of multiple case breast cancer 
families played an important role in the initial discovery of BRCA1 and BRCA2 as it focused the search for 
these genes on families that had an increased chance of shared genetic features on the basis of a common 
phenotype (Narod and Foulkes, 2004). The absence of other distinctive phenotypes amongst non-BRCA1/2 
families have been an impediment to further gene discovery. Perhaps the most comprehensive strategy for the 
discovery of breast cancer susceptibility genes is the whole genome/exome sequencing of breast cancer 
families that would capture the complete spectrum of genomic alterations conferring increased risk of breast 
cancer. This approach is already bearing fruit, with the recent identification of a novel breast cancer 
susceptibility gene XRCC2 (Park et al., 2012), not surprisingly involved in homologous recombination DNA 
repair. However, the major limitation of high-throughput sequencing studies is the data analysis of the vast 
amount of information obtained, and discrimination of “causative” alterations from “passenger” ones through 
functional studies and/or mutational screening in large numbers of multiple-case families. Several studies 
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using this technology are underway and we can expect an explosion in the field in the recent future, hopefully 
unraveling the architecture of breast cancer susceptibility. 
3.3.  BRCA1/2  mutation testing and genetic counseling in breast cancer families 
So far, the only breast susceptibility genes present in sufficient population frequencies and conferring 
high enough risk of breast cancer to be eligible for genetic testing are BRCA1 and BRCA2. However, genetic 
testing for BRCA1 and BRCA2 mutations is laborious, complex and expensive, given that these are very large 
genes without “hot-spot” regions, and last but not least, it is emotionally stressful for the families. Finally, 
only approximately 30% of families test positive (CNIO, Familial Cancer Unit). It is therefore imperative to 
identify predictive risk factors and/or biomarkers that associate with a positive mutation status so that the 
screening could be directed to individuals and families with a high likelihood of carrying a mutation. 
Identifying breast cancer patients at increased risk for carrying a mutation in the BRCA1 and BRCA2 
genes is an important objective in clinical practice. Although age at diagnosis, family history of breast and/or 
ovarian cancer, and ethnicity are all essential parameters to consider when assessing risk, there are limitations 
as to how well such factors accurately predict BRCA1/2 status, even when quantitative risk models are 
applied. According to Spanish Society for Medical Oncology the criteria for referral of high-risk breast cancer 
families to undergo genetic testing for BRCA mutations are: at least one case of breast cancer diagnosed 
before 40 years of age; breast and ovarian cancer diagnosed in the same patient; two or more breast cancer 
cases, one of which is bilateral or diagnosed before 50y of age; breast cancer diagnosed before 50 years of age 
or bilateral and an ovarian cancer in a first degree relative (FDR) or second degree relative (SDR); tree or 
more cases of breast and/or ovarian cancer in FDR or SDR; a history of breast cancer in a male relative and 
one case of breast and/or ovarian cancer in a FDR or SDR; Ashkenazi Jewish heritage with any FDR (or any 
two SDR) with breast or ovarian cancer; and TN subtype of breast cancer in young patients  (<35 y). 
Several models that estimate the probability of carrying a BRCA mutation have been developed that rely 
on family history and patients’ characteristics. Although these algorithms have acceptable levels of sensitivity, 
their specificity is clearly suboptimal (Farshid et al., 2006). There are data to suggest that based on the current 
algorithms for genetic testing, 20% of routine patients attending a multidisciplinary breast cancer clinic would 
have a probability sufficiently high by at least one algorithm to be offered genetic testing (Shannon et al., 
2002). Furthermore, population-based studies have suggested that the reliance of the current genetic 
algorithms on family history may also be problematic, as up to 9.5% of women with BRCA1 or BRCA2 
mutations and breast cancer diagnosed before the age of 50 do not have any obvious history of familial early-
onset breast cancer or familial ovarian cancer (Frank et al., 2002). 
Developing an effective approach to the identification of high-risk individuals is the key to preventing 
and/or providing early diagnosis of cancer in this patient population. Women carrying mutation in BRCA 
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genes are candidates for additional risk reduction measures such as intensive screening, prophylactic surgery 
or chemoprevention. The benefits of genetic analysis are, besides improving management in individuals with 
identified mutation, that the family members that test negative can be released from the greater-than-average 
cancer risk. Without a doubt, the time and effort expended for a hereditary cancer syndrome diagnosis may 
significantly reduce both morbidity and mortality in breast cancer. 
3.4.  Characterization of familial breast tumors 
3.4.1. Histopathology 
Breast tumors arising in women carrying a BRCA1 or BRCA2 mutation have distinct histopathological 
features and also differ from age-matched sporadic and BRCAX tumors (Lakhani, 1999; Lakhani et al., 1998). 
BRCA1 tumors are often poorly differentiated ductal carcinomas (grade 3) with higher mitotic count, greater 
degree of nuclear pleomorphism and less tubule formation than age-matched sporadic tumors, and have higher 
incidence of medullary carcinoma than BRCA2 tumors or sporadic cases. (Lakhani et al., 2000; Vargas et al., 
2011). BRCA1 tumors more frequently have a prominent lymphocytic infiltrate, foci of necrosis and pushing 
margins. Interestingly, breast tumors associated with BRCA1 hypermethylation are histopathologically similar 
to those that are caused by germline mutations in BRCA1, in that they are high grade, infiltrating ductal breast 
cancers that do not express ER (Esteller et al., 2000).  Contrasting with BRCA1 tumors, BRCA2 and BRCAX 
tumors are more heterogeneous and express an extended phenotype spectrum that is closer to that exhibited by 
sporadic tumors. However,  BRCA2 tumors are more frequently moderately or poorly differentiated 
carcinomas (grade 2 and 3) than age-matched controls, but this has been attributed mainly to a decreased 
tubule formation, while no difference is generally seen for mitotic count and nuclear polymorphism (Lakhani 
et al., 2000; Vargas et al., 2011).  BRCAX tumors are generally of lower grade (27-50% are grade 1) than 
BRCA1/2 and even sporadic breast tumors, show more tubule formation, lower mitotic index and less 
pleomorphisam, and have excess of lobular carcinomas in comparison to BRCA1/2 and sporadic cases. (Da 
Silva and Lakhani, 2010; Lakhani et al., 2000). 
3.4.2. Gene expression profiles 
To date, there have been only a handful of studies aimed to identify gene signatures that could be specific 
to BRCA1, BRCA2, or BRCAX hereditary breast tumors and the number of samples analyzed was generally 
low due to limitations in acquisition of the necessary fresh tumor material.  In the seminal study by Hedenfalk 
et al. primary tumors from seven carriers of a BRCA1 mutation, eight carriers of a BRCA2 mutation, and seven 
patients with sporadic cases of breast cancer were analyzed by gene expression profiling. Gene expression 
profiles of BRCA1, BRCA2, and sporadic tumors differed significantly from each other, and set of 176 genes 
was identified that could distinguish the BRCA1 genotype from the BRCA2 genotype. Genes involved in 
DNA repair and apoptosis that participate in the activation of cellular responses to stress were more highly 
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expressed in BRCA1 tumors, as compared to BRCA2 (Hedenfalk et al., 2001). Tumors from BRCA1 
mutation carriers have been shown to be similar to the basal subtype of cancers (Sorlie et al., 2003). In a small 
series of 16 BRCAX tumors, gene expression profiling identified at least two classes, and differentiated them 
from BRCA1 and BRCA2 tumors.  (Hedenfalk et al., 2003).  In the study by Fernandez-Ramires et al gene 
expression profiling of 14 BRCA1 tumors showed segregation mediated by ER status where ER negative 
tumors sowed overrepresentation of genes involved in the immune response, mostly NFκB-related genes and 
cell cycle genes (Fernandez-Ramires et al., 2009).  Bene et al have shown that BRCA2-associated tumors 
express genes involved in cell adhesion, and extra-cellular matrix remodeling with activation of MAPK 
signaling pathway (Bane et al., 2009). Analysis of gene expression in small series of BRCAX tumors 
confirmed the heterogeneity of this group, demonstrating that they can be stratified into at least 2 groups 
(BRCAXa and BRCAXb) that can be classified as luminal A and luminal B. BRCAXa group showed 
additional pathway alterations relating them to BRCA1 tumors (Fernandez-Ramires et al., 2010).  
3.4.3. Immunohistochemical features 
Many studies have shown that BRCA1 tumors are more often negative for ER (73-90%), PR (80%) and 
HER2 (0-3.7%) expression, TP53 mutated and positive for cytokeratin 5/6 compared with sporadic tumors 
and familial non-BRCA1/2 tumors (BRCAX). Based on their characteristics, most BRCA1 tumors are to be 
classified in the basal subtype. On the other hand, tumors arising in BRCA2 mutation carriers do not differ 
from controls with regard to ER and PR expression. Thus, ER and PR expression has been reported in around 
65% and 40–60% of BRCA2 tumors, respectively.  BRCA1 tumors show high proliferative index, evaluated 
by Ki-67 and overexpression of protein that promote cell cycle progression, such as cyclins E, A or B1. 
Interestingly cyclin D1 expression is downregulated in BRCA1 tumors in comparison to sporadic, which can 
be explained by its regulation by estrogen and progesterone. Also BRCA1 tumors underexpress proteins 
related to the inhibition of cyclin-CDK complexes (p16, p27 and p21). In BRCA2 tumors, the expression of 
proteins related to cell cycle is similar to that observed in sporadic ER- tumors. BRCA2 tumors show 
frequently CCND1 amplification unlike BRCA1 tumors and overexpress apoptotic markers, BCL2 and BAX 
BRCAX -related tumors are significantly more often positive for BCL2 compared with BRCA1- and BRCA2-
related tumors.. A greater incidence of TP53 mutations (23-62%) has been found in BRCA2 tumors compared 
to sporadic breast cancer. It appears to be difficult to distinguish BRCAX tumors from sporadic tumors and 
BRCA2 tumors. BRCAX tumors are more frequently ER+ (73-75%), PR- (54-67%) and BCL2 positive (55%) 
but TP53 negative (78-96%). In this respect they clearly differ from BRCA1 tumors, but are not significantly 
different from BRCA2 tumors. BRCAX tumors are less frequently P53 and ERBB2-positive than sporadic 
tumors.  Differences among studies can be partly explained by different selection criteria for the BRCAX 
group, the use of slightly different antibodies or the number of different antibodies used. However, it can also 
reflect the extensive heterogeneity in the BRCAX group. Honrado et al demonstrated that BRCAX tumors 
may be classified on the basis of 25 immunohistochemical markers into the five main molecular subgroups 
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previously identified by expression profiling analysis (luminal A, luminal B, basal-like, normal breast-like and 
HER2), in addition they can be stratified into high grade ER- tumors expressing proteins related to 
proliferation and cell cycle progression, and low grade ER+ tumors overexpressing some cyclin-CDK 
complex inhibitors, antiapoptotic and luminal proteins.   (Honrado et al., 2006; Honrado et al., 2005; Palacios 
et al., 2003; Palacios et al., 2008; Vargas et al., 2011)  
3.4.4. Copy number variation and LOH 
Specific somatic genetic aberrations determined by metaphase comparative genomic hybridization 
(CGH) analysis  on chromosome 3p (losses), 3q (gain) and 5q (losses) could distinguish BRCA1  related 
tumors from control tumors with a sensitivity of 96% and a specificity of 76% (Wessels et al., 2002). 
However, metaphase CGH analysis could not reliably distinguish between BRCA2-associated breast tumors 
and control tumors or BRCA1-associated breast tumors (van Beers et al., 2005). Based on array CGH analysis 
which has a higher resolution 169 significant BAC clones were identified which enabled discrimination 
between BRCA1, BRCA2 and sporadic tumors to some degree. Using hierarchical clustering methods, 
BRCA1-associated tumors were tightly clustered and separated from sporadic cases, whereas BRCA2-tumors 
showed a somewhat higher similarity with the sporadic cases, although they still displayed a genomic profile 
of their own (30% of BRCA2-tumors clustered within the control or BRCA1-group) (Jonsson et al., 2005). All 
studies showed that BRCA1- associated tumors have the highest frequency of copy number alterations. In 
familial non-BRCA1/2 associated tumors a significant higher incidence of 8q-gains, 19p-gains, 19q-gains and 
8p-losses was observed compared to sporadic tumors.(Gronwald et al., 2005). The study of LOH in 100 
BRCAX tumors found LOH frequencies higher than 40% at 1q41, 4p16, 11q23.3, 16p13,16q24, 
17p12,21q22,22q11 and 22q13, with the highest frequency at 22q13 that was also specifically lost in BRCAX 
tumors. 
3.4.5.  Methylation profiles  
A recent study on genome wide methylation profiles in 33 familial breast tumors (11 BRCA1, 8 BRCA2 
and 14 BRCAX) demonstrated that different germline mutations can lead to different epigenetic profiles in 
breast tumors. Tumors with germline BRCA1 mutation exhibited specific methylation profile, while BRCA2 
and BRCAX tumors were mixed in the unsupervised cluster. Methylation profiling did not predict intrinsic 
subtypes defined by gene-expression profiling in the same sample set, however it predicted mutation status 
with greater accuracy (64%) than did the gene expression data (29%). Furthermore, BRCAX tumors were 
subdivided into 2 major classes based on their methylation profiles not correlating with intrinsic subtypes 
determined by gene expression profiling (Flanagan et al., 2010).  Another study on DNA methylation of 
selected genes was quantified in  99 familial breast tumors with known BRCA1 or BRCA2 mutations 
formalin fixed, paraffin embedded primary tumors, showing that methylation status was correlated to distinct 
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tumor characteristics at diagnosis including ER status (+/-), HER2 status (+/-), nodal involvement (+/-) and 
tumor stage, as well as important clinical outcomes at follow up including cancer recurrence (yes versus no) 
and the development of distant metastases (Swift-Scanlan et al., 2011). 
4. MICRORNAS AS NEW CLASS OF GENE EXPRESSION REGULATORS 
4.1.  microRNA biogenesis and function 
The discovery of the first miRNA lin-4 in Caenorabditis elegans in 1993  (Lee et al., 1993) has changed 
once again our notions of gene regulation adding a new level of complexity in cell signaling pathways and 
marked a new era in cancer research. MicroRNAs are an abundant class of small ~22nt long single-stranded 
non-coding RNA molecules. The biogenesis of miRNA involves a complex protein system (Figure 3), 
including Pol II-dependant transcription into a long single stranded pre-miRNA, followed by processing by 
RNase III complex Drosha/DGCR8 into a short hairpin RNA which is then exported from the nucleus by 
RanGTP/Exportin5. Once in the cytoplasm it is processed by another RNase III Dicer/TRB protein complex, 
into a double stranded short RNA and subsequently incorporated into RNA-induced Silencing Complex 
(RISK) formed by members of the Argonaute family where one of the stands is preferentially incorporated 
while other is degraded giving rise to a functional RNA-induces silencing complex (RISC) (Kim, 2005).  
miRNAs act as negative regulators at post-transcriptional level by binding at the 3’ untranslated regions 
(3’UTRs) of their mRNA-targets. Depending on the level of complementarity between miRNA “seed” 
sequence and its target, they trigger either translational repression, or mRNA degradation (He and Hannon, 
2004). Several reports also demonstrated existence of functional miR target sites in coding regions and 
5’UTRs, effects of miRs upon transcription and chromatin structure, and of up-regulation of mRNA 
translation. The exact mechanisms of miRNA function are still far from being fully understood and are a 
matter of active research. With more than 1500 reported human  miRNAs (miRBase 18.0 release, Nov2011) 
they represent one of the largest classes of gene regulators, accounting for 1-5% of all expressed human genes, 
and it is estimated that they are regulating two thirds of the protein coding genes (Friedman et al., 2009). 
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Figure 3. miRNA biogenesis and function. Adapted from Esquela-Kersher, 2006 
 
4.2.  MicroRNA expression deregulation in cancer 
 There is a growing body of evidence demonstrating that miRNAs are involved in crucial biological 
processes including development, differentiation, apoptosis and proliferation (Calin et al., 2005). Impaired 
miRNA expression has been extensively implicated in tumorigenesis (Calin et al., 2004a). Abnormal 
expression of miRNAs has been found in both solid and hematopoietic tumors by various genome-wide 
miRNA expression analysis techniques (Liu et al., 2004); (Volinia et al., 2006)). miRNAs have been proposed 
to contribute to oncogenesis since they can function either as tumors suppressors (as is the case for miR-15a 
and miR-16-1) or oncogenes (as is the case for miR-155 or members of the miR-17–92 cluster) (O'Donnell et 
al., 2005). The downregulation or deletion of a miRNA that targets an oncogene leads to tumor formation, and 
vice versa, the amplification or over-expression of a miRNA that targets a tumor suppressor results in 
tumorigenesis (Calin et al., 2002; Cimmino et al., 2005). Recently, miRNA expression profiling calls a great 
attention to define various types of cancers. miRNAs seem to classify tumors of different origin more robustly 
than mRNA based expression profiling  (Calin and Croce, 2006; Liu et al., 2004). Furthermore, miRNAs have 
one great practical advantage over mRNA; they are relatively well preserved in formalin-fixed paraffin-
embedded tissues presumably due to their small size and possibly a sheltered micro-environment (Hasemeier 
et al., 2008) 
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4.3. MicroRNAs in breast cancer 
Specifically, in breast cancer, several studies have identified aberrantly expressed miRNAs in sporadic 
breast tumors in comparison to normal breast tissue.  The seminal study of miRNA expression in 86 breast 
tumors and normal tissues identified numerous miRNAs deregulated in breast cancer, defined a signature 
discriminating between normal and malignant breast tissues (Iorio et al., 2005). Ever since a growing number 
of studies (Farazi et al., 2011; Fassan et al., 2009; Persson et al., 2011; Sempere et al., 2007; Volinia et al., 
2006; Volinia et al., 2012) based on different technologies have reported on miRNAs deregulated in breast 
cancer (Table 1). In spite of certain discrepancies in the signatures, there are several recurring miRNAs (e.g. 
let-7a, miR-125a, miR-125b, miR-143, miR-145, miR-100, miR-10b, miR-101, miR-205, miR-210, miR-29b, 
miR-497, miR-99a, miR-99b) demonstrating a remarkable reproducibility of miRNA deregulation in sporadic 
breast cancer. For many of these miRNAs constantly deregulated in breast tissue, important biological 
functions and molecular targets have been experimentally determined; these are comprehensively reviewed in 
(O'Day and Lal, 2011). Indeed, many of them, such as miR-21, miR-155, miR-145 and let-7 family are 
deregulated in multiple types of cancer, including colon, lung and liver cancers (Lujambio and Lowe, 2012). 
In addition, miRNA expression was correlated with histopathological features such as estrogen receptor 
and progesterone receptor status (miR-30) and tumor stage (miR-213 and miR-203). The differential 
expression of several let-7 isoforms was associated with histopathological features including  progesterone 
receptor status (let-7c), lymph node metastasis (let-7f-1, let-7a-3, and let-7a-2), or high proliferation index 
(let-7c and let-7d) in breast tumor samples (Iorio et al., 2005). Mattie et al. (Mattie et al., 2006) identified 
unique sets of miRNAs associated with breast cancers currently defined by their HER2 status or their ER/PR 
status. Significantly, there was overlap between the miRNAs identified in these profiles and Iorio’s panel. 
Many other studies have identified miRNAs related to specific biological processes and features altered in 
breast cancer.  For example,  miR-206, miR-221 and miR-222 were identified as regulators of ER expression, 
and were find to be overexpressed in ER-negative tumors (Foekens et al., 2008; Zhao et al., 2008).Others such 
as, miR-335 and miR-126 were associated with increased metastatic potential, and their expression were lost 
in patient with recurrent disease (Tavazoie et al., 2008). Furthermore, miRNA signatures seem to define, 
similarly to what has been found by expression profiling of coding genes, different histological 
(lobular/ductal, ER+/ER-) and molecular (luminal A, luminal B, basal-like, HER2+) subtypes described so far 
(Blenkiron et al., 2007).  
Finally, miRNAs hold great promise for use as clinical biomarkers. Owing to their small sizes, miRNAs 
are highly resistant to degradation and can be easily extracted from nearly every cell and tissue type. Indeed, 
miRNAs have been shown to be well preserved in archived formalin-fixed paraffin-embedded sections up to 
10 years old (Li et al., 2007), allowing the retroactive analysis of patient samples. Second, a relatively small 
number of miRNA allows for a robust classification of human cancers (Lu et al., 2005) and outperforms 
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mRNA signatures in this respect. Third, miRNA detection requires only a small quantity of total RNA for 
analysis by qRT-PCR and it can be detected by in situ hybridization on routine paraffin sections and has 
immediate potential to be developed as standardized clinical laboratory test.  Moreover, circulating miRNAs 
can easily be measured in whole blood or serum (Heneghan et al., 2010). Several studies have identified 
cancer-specific miRNAs elevated in the circulation of cancer patients opening up the possibility of using them 
as noninvasive biomarkers of disease and therapy response. 
However, very little is known about the role of miRNAs in familial breast cancer. miRNA expression  
analysis of hereditary breast cancer can potentially be used for classification purposes, as well as to expand 
upon our knowledge of differences between different forms of hereditary breast cancer. Likewise it could 
provide better understanding of the biology of these tumors. BRCAX tumors exhibit histological and 
molecular heterogeneity that miRNAs could help decipher. 
 Table 1. miRNAs deregulated in s breast tumors in comparison to normal breast tissue             
miRNA   nº of cases   Method Reference 
up-regulated   down-regulated   tumor normal       
miR-21   let-7a   6     Bead-based flow cytometry; 
Northern blot 
Lu et al, Nature, 
2005 
miR-213, miR-210, miR-206, miR-203, miR-202, miR-
196, miR-191, miR-155, miR-149, miR-136, miR-128b, 
miR-122a, miR-34, miR-21, miR-9, let-7i 
  miR-204, miR-145, miR-143, miR-125a, miR-125b, miR-
101, miR-10b, let-7a, let-7d, let-7f 
  76 10   miRNA microarray; 
Northern blot 
Iorio et al, Cancer 
Res, 2005 
miR-213, miR-210, miR-199b, miR-181a, miR-155, 
miR-146, miR-122a, mir-31, miR-29a, miR-29b, miR-
29c, mir-21, miR-17-5p 
  miR-224, miR-205, miR-125b, miR-145, miR-140, miR-
130a, miR-100, miR-30c, miR-16, miR-10b, let-7a 
  79     miRNA microarray Volinia et al, 
PNAS, 2006 
miR-21   miR-451, miR-145, miR-205, let-7a   100     miRNA microarray; 
Northern blot; ISH 
Sempere et al, 
Cancer Res, 2007 
miR-26a, miR-26b, miR-499-3p, miR-607, miR-135b, 
miR-616, miR-769-5p, miR-330-5p, miR-132, miR-149, 
miR-557, miR-29b, miR-657, miR-483-3p, miR-371-3p, 
miR-593, miR-596 
  miR-145, miR-92a, miR-99b, miR-214, miR-191, miR-454, 
miR-10a, miR-195, miR-10b, miR-130a, miR-374a, miR-
146b-5p, miR-146a, miR-181c, miR-218, let-7g, miR-15b, 
miR-125a, miR-223, miR-99a, miR-140, miR-126, miR-
199b, miR-100, miR-199a, miR-125b 
  28*     miRNA microarray Fassan et al, Breast 
Cancer Res, 2009 
miR-196a*, miR-196a, miR-345*, miR-493, miR-301a*, 
miR-1250, miR-1268, miR-629*, miR-25*, miR-181b, 
miR-769-3p, miR-181a*, miR-200a, miR-429, miR-182, 
miR-183*,mR-21, miR-210 
  miR-135a, miR-489, miR-452, miR-244*, miR-585, miR-
1260, miR-27a*, miR-23a*, miR-223, miR-18a, miR-935, 
miR-1255b, miR-15b*, miR-215, miR-1249, miR-10b, 
miR-125b, miR-99a, miR-26a, miR-105, miR-130a, miR-
125a, miR-101, miR-143, miR-100, miR-145*, miR-218, 
miR-584, miR-139-5p, miR-218*, miR-376a*, miR-378*, 
miR-1179, miR-335, miR-145, miR-140, miR-126, miR-
101*, miR-328, miR-378, miR-139-5p, miR-106a, miR-
144*, miR-451, miR-486-5p, miR-551b 
  5 5   Massively parallel 
sequencing 
Persson et al, 
Cancer Res, 2011 
miR-21, miR-142-3p, miR-1425p   miR-22, miR-125a, miR-99a, let-7a, miR-451, miR-144, 
miR-145, miR-143, miR-143*, miR-320, miR-378, miR-
497, miR-16 
  168 11   Massively parallel 
sequencing 
Farazi et al, Cancer 
Res, 2011 
                  
miR-361-5p, miR-21, miR-374a, miR-96, miR-183, 
miR-374b, miR-16, miR-142-5p, miR-429, miR-182, 
miR-15b, miR-106b, miR-200c, miR-107, miR-32, miR-
26b, miR-223, miR-30d, miR-128, miR-200b, miR-342, 
miR-340, miR-155, miR-142-3p, miR-29c, miR-20a, 
miR-29b, miR-19a, miR-92a, miR-425, miR-210, miR-
221 
  let-7b, miR-127-3p, miR-320, let-7c, miR-652, miR-378, 
miR-143*, miR-99a, miR-497, miR-376a-3p, miR-145, 
miR-574-3p, miR-193b, miR-221, miR-140-3p, miR-100, 
miR-22, miR-324, miR-423-3p, miR-145*, let-7d, miR-
193a-5p, miR-423-5p, miR-28-5p, miR-125b, miR-376c, 
miR-185, miR-452, miR-125a, miR-451 
  80 6   Massively parallel 
sequencing 
Volinia et al, 
PNAS, 2012 
*male breast cancer vs. gynecomastia; in bold letters are miRNAs found to be deregulated in at least two studies 
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Little is known about the role of miRNAs in hereditary breast cancer. In this study we will sought to 
examine , on one hand, the expression profiles using microarray technology in BRCA1, BRCA2 and 
BRCAX-type hereditary tumors. This could allow for a better classification, to one obtained by using 
mRNA microarrays, and could provide better understanding of the biology of these tumors. BRCAX 
tumors exhibit histological and molecular heterogeneity that miRNAs could help decipher. The 
identification of key target genes or pathways regulated by significant miRNAs would give as a better 
understanding of the mechanisms of tumorigenesis. On the other hand, given the importance of BRCA1 
deregulation in both hereditary and sporadic breast tumors, we are interested in investigating the effects 
of BRCA1 expression on global miRNA expression.  
Therefore, the specific aims for the elaboration of this theses project were: 
1. To explore the effect of BRCA1 mutation on miRNA expression in breast cancer cell lines  
a. To identify differentially expressed miRNAs and mRNAs induced by BRCA1 gene 
b. To integrate expression data to identify biological processes and pathways modulated by 
BRCA1 
c. To perform functional studies on selected miRNAs and their target genes. 
 
2. To identify differentially expressed miRNAs between normal breast tissue and hereditary tumors.  
a. To determine biological processes and pathways altered in response to differential miRNA 
expression 
b. To perform functional studies on selected miRNAs and their target genes. 
 
3. To establish the microRNA expression profile for the different subtypes of hereditary breast cancer. 
a. Identify differentially expressed miRNAs between different tumor subgroups, BRCA1, 
BRCA2 and BRCAX 
b. Analyze the heterogeneity of BRCAX group  
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 MATERIALS AND METHODS 
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1. PATIENTS AND SAMPLES INCLUDED IN THE STUDY 
1.1. Sample proceedings and ethics statement 
Breast cancer tissue samples used in this thesis were collected through collaborations with Spanish 
Hospitals and centers of investigation.  The three different studies in this thesis were carried out using 
two different sample series:  
Fresh-frozen (FrFr) breast tissue samples were acquired from Fundacion Jimenez Diaz and 
Hospital Clinico San Carlos  in Madrid,  Institut Catala d’Oncologia in Barcelona, Centro de 
Investifgacion del Cancer from Salamanca and Instituto dei Tumori in Milan. Breast tissues were 
obtained immediately after surgical excision, snap-frozen and preserved in blocks with OCT (polyvinyl 
matrix), for subsequent evaluation and section. Percentage of tumor cells in the tissue was estimated by a 
pathologist reviewing 5 μm sections stained by hematoxiline and eosin.  Only tumors samples with more 
than 80% of tumor cells were analyzed by microarray. 
Formalin-fixed paraffin embedded (FFPE) breast tissue samples were acquired through several 
participating Spanish hospitals and centers: Gregorio Marañon, Hospital San Pablo, Fundacion Jimenez 
Diaz, Hospital La Paz, H Santa Caterina (Girona), P. de Hierro, H. Severo Ochoa, H. Ramón y Cajal.  
Normal breast tissues were obtained after breast reduction surgery from healthy individuals with no 
family history of breast cancer. FFPE tumor tissues were stained by hematoxylin and eosin and 
examined by the pathologist. Marked the tumoral area was separated into a new block and 3 x 30μm 
sections were made for subsequent RNA extraction. 
Informed written consent was obtained from all individuals involved in this study to perform 
genetic studies and to use exceeding material for research, and the research project has the approval of 
the ethics committee of the Spanish National Cancer Research Centre (CNIO), Comité de ética de la 
investigación y de bienestar animal del Instituto de Salud Carlos III.  
 
1.2. Accrual  of familial breast cancer patients 
Patients belonging to high-risk breast cancer families and were selected according to Asociacion 
Española Contra el Cancer (AECC) inclusion criteria: families with at least three females affected with 
breast cancer; or at least two first-degree females affected with breast cancer (at least one of them 
diagnosed before 50); or at least one case of female breast cancer and at least one case of either ovarian, 
female bilateral breast or male breast cancer.  All patients have undergone full BRCA1/2 gene testing for 
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mutations and large rearrangements using standard procedures (Bradbury and Olopade, 2007; Osorio et 
al., 2000). Individuals with no mutations identified in BRCA1 or BRCA2 genes were designated as 
BRCAX.  
1.3. Samples cohorts included in different studies 
During the elaboration of this thesis three different studies were performed including variable 
number of samples.  
First study: thirteen hereditary breast cancer cases harboring BRCA1 mutations, as well as 4 
normal breast tissues from formalin fixed paraffin embedded (FFPE) tumor tissue series, were used to 
check the expression of selected miRNAs.  
Second study: a total of 54 fresh-frozen breast tissues were used. Sample series analyzed by 
microRNA microarray profiling included 22 frozen hereditary breast tumors consisting of 3 BRCA1-
mutated, 5 BRCA2 and 14 non-BRCA1/2 (BRCAX) samples, and 14 normal breast tissues including 3 
from BRCA1-mutation carriers, 5 from BRCA2-mutation carriers, 1 normal breast tissue from contra-
lateral breast of patient with BRCAX-type tumor, and 5 normal breast tissues obtained after breast 
reduction surgery from healthy individuals with no family history of breast cancer. The tissue collection 
used for validation included 18 paired fresh frozen samples from sporadic breast tumors and their 
adjacent normal breast tissue counterparts.  
Third study: a series of 80 formalin–fixed paraffin-embedded (FFPE) breast tissues comprised of 
66 familial breast primary tumors from 13 BRCA1 mutation carriers, 10 BRCA2 mutation carriers and 
43 BRCAX tumors; 10 sporadic breast carcinomas and 6 normal breast tissues obtained after breast 
reduction surgery from healthy donors with no family history of breast cancer were analyzed by 
microRNA microarray profiling.  
2. BREAST CANCER CELL LINES AND FUNCTIONAL STUDIES 
2.1. Breast cancer cell lines 
Breast cancer cell lines were used as a model to study functional effects of gene and miRNA 
expression. Parental HCC 1937, derived from hereditary BRCA1 mutated breast tumor and HCC 
1937/BRCA1wt stably expressing full length BRCA1, were kindly provided by Dr. J. Chen (Yale 
University School of Medicine Department of Therapeutic Radiology, New Haven, USA). Normal 
Human Mammary Epithelial Cell line (HMEC) was purchased from Clonetics (San Diego, CA). The 
MDA-MB-436 cell line was kindly provided by Dr. K.S Massey-Brown from Department of 
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Pharmacology and Toxicology, University of Arizona, Tucson, USA,. MCF-7 breast cancer cell line was 
obtained from Cancer Epigenetic Group at Spanish National Cancer Centre, Madrid, Spain.  
2.2. Maintenance and subculturing of cells 
HCC 1937 cell lines were cultured in Dulbecco Modified Eagle’s Medium (DMEM) supplemented 
with 10%FBS (Fetal Bovine Serum, Gibco-BRL, Grand Island, NY, USA), while derived HCC 
1937/BRCA1w was maintained in DMEM/F12 with 10% FBS. HMEC cells were grown in, Mammary 
Epithelial Growth Medium - MEGM (Clonetics) supplemented with growth factors SingleQuots 
(Clonetics) in absence of FBS. Both MCF7 and MDA MB 436 cell lines were cultured in RPMI 
supplemented with 10% FBS. Breast cancer cell lines were cultured in corresponding media and 
maintained at 37ºC in 5% CO2. All media were supplemented with fungizone, and 
penicillin/streptomycin (Gibco-BRL). Cells were passaged at approximately 80-90% confluence.  
 
2.3.  miRNA transfections 
miRNAs were routinely transfected into cells using Oligofectamine reagent (Invitrogen, San Diego, 
CA). Pre-miRNA oligonucleotides (pre-miR-146a, pre-miR-99b, pre-miR-205, miR-30c and scramble 
control) were purchased from Ambion (Austin, Texas, USA).  For experiments in 6- well plates, 100 000 
cells/well were plated in 2ml of growth media without antibiotics to a density of 50-60%, 24 hours prior 
to transfection. For experiments in 24-wells approximately 40000 cell/well were seeded in a 500ul of 
antibiotic-free media to a density of 40%, 24 hours pior to transfection. Stock transfection mixes were 
made according to manufacturer’s instructions. Briefly, 2.5ul of Oligofectamine reagent was diluted in 
500ul of Opti-MEM I Medium with L-glutamine (Invitrogen, CA, USA) and incubated 5 minutes at RT. 
In another tube pre-miRNA was diluted with Opti-MEM to a final concentration of 50nM. Both mixes 
were incubated together for 30 minutes at RT to allow complex formation between miRNA and lipids. 
To transfect cells the growth media was removed and replaced with 0.5ml of Opti-MEM media, and 
500ul of the appropriate transfection mix. Control cells were treated with a scramble miRNA (Ambion). 
Cells were incubated at 370C for 12h after which time media was replaced with the same volume of fresh 
full growth media. At 48 hours after transfection cells were harvested for mRNA and/or protein analysis. 
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2.4. Luciferase reporter assays 
2.4.1. Construction of reporter vectors  
1.1.1.1. Molecular cloning of pGL3-KRAS 3’UTR vector 
Expression vector pGL3-Control from Promega (Figure 3) was used for molecular cloning of 
KRAS gene 3’ untranslated region (3’UTR) downstream of Firefly luciferase gene.  3’UTR sequence of 
the KRAS was retrieved through NCBI nucleotide database. A 300bp fragment of the 3’UTR region of 
KRAS gene containing miR-30c binding site, was amplified by PCR from human genomic DNA, and 
cloned into a modified pGL3-Control vector (Promega) at the SacII and EcoRI site, immediately 
downstream of the luciferase stop codon. Primer sequences used to amplify this region were RAS3UTR-
F: 5’CACGAATTCCACACCCCCACAGAGCTAAC3’ and RAS3UTR-R: 
5’TTCCCGCGGTGTTTGATATGACCAACATTCCT 3’.  
 
 
Figure 3. pGL3-Control-Modified cloning vector 
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1.1.1.2. Reporter vector for TRAF2 3’UTR 
Expression vector OmicsLink miRNA Target Clone (GeneCopoeia, Rockville, MD) was purchased 
from GeneCopoeia (GeneCopoeia, Rockville, MD). The miTarget vector expressed full length TRAF2 
3’UTR cloned downstream of Firefly luciferase gene stop codon and Renilla Luciferase gene (Figure 4 ) 
 
 
Figure 4. Vector backbone of miTarget miRNA 3' UTR target clones (GeneCopoeia) 
 
 
The plasmid constructs were propagated by transformation of JM109 E.Coli bacterial strain, by 
adding 3ul of DNA to 20ul of bacteria, incubating 10min on ice, haeat-shocked at 42ºC for 30s and 
grown in 10ml of LB media (10g/l triptone, 5g/l of yeast extract, 10 g/l of NaCl, pH7.0) at 37ºC 
overnight with shaking at 300rpm.  purified by miniprep (QIAGEN) and used in subsequent luciferase 
reporter assay. Correct vector construction was verified by restriction digestion and direct sequencing. 
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2.4.2. Transfections and luciferase reporter assay 
To verify direct binding of the miRNA of interest to its target gene we performed target in vitro 
assays using luciferase reporter system (Figure 5).  
Pre-miRNA oligonucleotides (pre-miR-146a, pre-miR-99b, pre-miR-205 and scramble control) 
were purchased from Ambion (Austin, Texas, USA). For luciferase reporter target in vitro assays 250 ng 
OmicsLink miRNA Target Clone (GeneCopoeia, Rockville, MD) containing Renilla Luciferase and 
TRAF2 3’UTR cloned downstream of Firefly luciferase gene, together with 25 pmol (50 nM) of pre-
miRNA oligonucleotides, were transfected using Lipofectamine 2000 reagent (Invitrogen, San Diego, 
CA) into HCC1937 cells in a 24-well plate format following manufacturer’s instructions. HCC1937 cells 
were co-transfected with the TRAF2 3’UTR reporter construct along with each individual pre-miRNA 
(Ambion), combination of miRNAs, scramble control or mock transfected. Cells were grown for 48h, 
after which cells were harvested and luciferase activity was assayed with Dual-Luciferase Assay System 
(Promega) according to manufacturer’s instructions. Experiments were performed in triplicate and 
normalization was performed using Renilla luciferase activity. 
To assess miRNA-30c regulation of KRAS gene expression we carried out dual-luciferase reporter 
assay by co-transfecting MDA-MB-436 cells with 25 pmol of pre-miR-30c or scramble control 
(Ambion), along with 500 ng of KRAS 3’UTR- firefly luciferase construct and 7.5 ng of Renilla 
luciferase vector, using Lipofectamine 2000 (Invitrogen) per well, according to the manufacturer’s 
protocol in a 24-well plate format. Cells were grown for 48h, after which luciferase activity was assayed 
with Dual-Luciferase Assay System (Promega). Experiments were performed in triplicate and Renilla 
luciferase activity was used for transfection variation normalization. 
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Figure 5. Outline of the luciferase reporter assay. Firefly luciferase gene with 3’UTR region of interest cloned 
immediately downstream of the stop codon, codes for an oxidative enzyme that converts luciferin substrate into 
oxiluciferin in a reaction that emits light.  Photon emission is detected by luminometer, and the signal intensity is 
directly proportional to the amount of the enzyme. In the presence of a miRNA that binds to the 3’UTR and 
induces either mRNA degradation or translational inhibition, production of luciferase enzyme is reduced/abolished 
resulting in lower signal emission. 
 
2.5. Cell proliferation assays 
Cell proliferation rate was assessed by using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) assay. MDA-MB-436 cells were seeded in 24-well plates one day before transfection at 
30-40% confluence in antibiotic-free media. Cells were transfected in triplicate independent experiments 
using Oligofectamine (Invitrogen) with 50 nM of pre-miR-30c/pre-miR-Scramble oligonucleotides or 
mock transfection control. Cells were incubated in 1µg/µl MTT Formazan (Sigma-Aldrich) diluted in 
500 μl normal culture medium at 37ºC for 5h.  The assay is based on the cleavage of the yellow MTT 
tetrazolium salt to purple formazan crystal by metabolicly active cells. The formazan is then solubilized 
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with DMSO, and the concentration determined by optical density at 570 nm by means of a standard 
microplate absorbance readers (Bio-Rad, Hercules, CA, USA). Cell viability was determined at 24, 48, 
72, 96, 120 or 144 hours after transfection. Each value represents the average of triplicate wells in 
representative of 3 independent experiments. 
2.6. Cell based multi-pathway activity assays 
2.6.1. Experimental procedure 
Using Cignal Multi-Pathway Reporter Assay Kit (SABiosciences, MD, USA) we evaluated 
activation of ten different cancer related pathways (Figure 6). The HCC1937 and HCC1937/BRCA1 
were reverse-transfected with the transcription factor-responsive reporter, negative control, and positive 
control constructs using SureFECTTM (SABiosciences) according to manufacturer’s instructions. The 
change in the activity of each signaling pathway is determined by comparing the normalized luciferase 
activities of the reporter in BRCA1-null versus BRCA1-wt expressing HCC1937 cells. For assessment 
of miRNA effect on pathway activation, 200 pmol of pre-miR-146a, pre-miR-99b, pre-miR-205 or 
negative control were co-transfected along with pathway reporter in HCC1937 cells. The transfection 
efficiency was monitored by GFP expression, using fluorescence microscopy. At least three independent 
transfections were carried out in triplicate for each of the conditions tested with each reporter assay.  
2.6.1. Statistical analysis 
Statistical analysis was performed using SPSS version 17.0 (SPSS Inc, Chicago, Illinois). All 
results are expressed as mean ± standard deviation (SD) of at least three independent experiments. Non-
parametric Mann–Whitney U-test and parametric bilateral t-test were used for statistical hypothesis 
testing. Nominal two-sided p-values less than 0.05 were considered statistically significant.  
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Figure 6. Overview of the Cignal Reporter Assay procedure. The plate format of the Cignal Multi-Pathway 
Reporter Arrays are delivered in a 96-well cell culture plate (A). Each reporter and control assay is dried down in 
each column of the plate (8 wells per assay). The modulation of a signal transduction pathway results in a change in 
the activity of a downstream transcription factor (B). The pathway-focused transcription factor-responsive 
luciferase reporters consist of a combination of specific transcription factor binding sites and basic promoter 
elements that drive the expression of a luciferase gene (C). This alteration in transcription factor activity affects its 
ability to bind a specific DNA target sequence, which in turn changes the expression level of luciferase enzyme. A 
change in the expression of luciferase enzyme can be easily monitored by a change in luminescence intensity. 
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3. PROTEIN-BASED ASSAYS 
3.1. Protein extraction and quantification 
For western blot analysis cells were transfected with 50nM pre-miRNA oligonucleotides as 
described in chapter 2.3. Cells were grown for 48h after transfection, and harvested for protein 
extraction.  Cells were trypsinized and after 2min resuspended with corresponding growth media with 
10% FBS. Cells were collected into 15ml conical tubes, washed with 1x PBS and centrifuged at 1200 
rpm for 5 minutes. Cell lysates were prepared by resuspending cell pellets in 40ul RIPA buffer (Sigma-
Aldrich) with protease inhibitors (Roche) per 106 of cells. Cells were sonicated for 30sec (cycle: 15s 
sonicate 15s rest)  and incubated for 30 minutes at 4ºC, followed by centrifugation at 20000g for 20 
minutes at 4ºC. Supernatant was collected and protein concentration was measured by Bio-Rad protein 
assay (Bio-Rad laboratories) using bovine serum albumin (BSA) (Pierce) to create a standard curve with 
known concentrations of protein.  
3.2. Immunoblotting 
Equal amounts of protein (50µg) were separated by SDS-PAGE on 4-12% pre-casted gels NuPAGE 
Bis-Tris Gel (Invitrogen, Carlsbad, CA) at 120V for 1 hour using the XCell SureLock Mini-Cell 
(Invitrogen) electrophoresis cell. Proteins separated on the gel were electrotransferred during 1h at 30V 
to nitrocellulose membrane (Watman) using 1x NuPAGE Transfer buffer (Invitrogen) with 20% 
methanol. Equal loading of proteins was verified by Ponceau S staining with 0.1% Ponceau red in 5% 
acetic acid for 2 min. Ponceau S was washed out with 1xTBS with 0.05% Tween detergent and the 
membranes were blocked with 5% non-fat dry milk in 1xTBS with 0.05% Tween detergent for 1 h at 
room temperature.  The membranes were then washed three times for 5 minutes with 1xTBS with 0.05% 
Tween detergent and incubated with primary antibody for 1 hour at room temperature. The following 
primary antibodies were used for protein detection: mouse monoclonal antibody against KRAS (F234, 
Santa Cruz) at 1/200 dilution, mouse monoclonal antibody against TRAF2 (C-20, Santa Cruz) at 1/500 
dilution and mouse polyclonal antibody against GAPDH (CNIO, Monoclonal Antibodies Unit) at 1/50 
dilution. Next, membranes were washed three times for 5 minutes with 1xTBS with 0.05% Tween 
detergent and incubated with the corresponding horseradish peroxidase (HRP) conjugated (Dako, 
Glostrup, Denmark) secondary antibody at 1/1000 dilution for 1 hour at room temperature.  The antibody 
visualization was carried out with enhanced chemiluminescence (ECL) Detection System (Dako) and 
BiomaxLight membranes (Kodak). Membranes were scanned and signal was quantified using Image J 
program. Protein content was determined relative to loading control signal.  
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3.3. Tissue microarrays 
A subset of FFPE samples (41) was included in tissue microarrays (TMA) described previously in 
(Honrado et al., 2006; Honrado et al., 2005; Palacios et al., 2003). Representative areas of the tumors 
were selected on hematoxylin and eosin-stained sections and marked on individual paraffin blocks 
(Figure 7). Two tissue cores (1 mm in diameter) were obtained from each specimen. The tissue cores 
were arrayed into a receptor paraffin block using a tissue microarray workstation (Beecher Instruments, 
Silver Spring, MD), as described previously (Hardisson 2003). A hematoxylin and eosin-stained section 
of the array was reviewed to confirm the presence of morphologically representative areas of the original 
lesions. 
 
 
Figure 7. Tissue microarray construction. Adapted from Hedenfalk et al. 2003, PNAS. 
3.4. Immunohistochemistry  
Imunochistochemical information on tumor grade, estrogen receptor (ER), progesterone receptor 
(PR), human epidermal growth factor receptor 2 (HER2/ErbB2) gene expression and/or amplification, 
BRCA1 methylation, Ki-67, p53 and EGFR was available for 41 samples from tissue microarray (TMA) 
described previously in (Honrado et al., 2006; Honrado et al., 2005; Palacios et al., 2003). For remainder 
of samples (15) information on tumor grade, ER, PR, HER2/ErbB2 status was obtained from either 
hospital pathology report when available, or by staining individual tumor sections using same criteria as 
described in (Honrado et al., 2006).  
Immunohistochemical staining on TMA sections was performed by the EnVision method with a 
heat-induced antigen retrieval step with help of the Immunohistochemistry Unit at CNIO. Staining 
results were assessed by a pathologist. Tumor grade was assessed based on Bloom-Richardson scoring 
system. ER and PR were scored based on two-stage scoring system: positive (1) for >10% of ER/PR 
positive cells and negative (0) for less than 10%, as described previously. Ki-67 expression was 
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classified according to 3-stage scoring system: 0-5%, 6-25% and >25%. HER2 was called positive either 
by detection of ERBB2 gene amplification by FISH analysis and/or 3+ staining by DAKO system on 
HercepTestTM. Where duplicate cores gave discordant results, the higher score was used. Tissue cores 
that failed to adhere to the glass slide were uninterpretable and were excluded. Breast cancer cases were 
classified into four subtypes based on IHC-model  (Tang P. et al, 2009) as: luminal A  (ER+ and/or PR+, 
HER2− ); luminal B  (ER+ and/or PR+, HER2+); Triple Negative  (ER−, PR−, HER2−)  and Her2/neu 
overexpressed/amplified  (ER−, PR−, HER2+ ). Full information on immunohistochemical data in breast 
cancer samples is represented in Supplementary Tables 1 and 2. 
3.5. Statistical analysis 
The χ2-test and Fisher’s exact test were employed for the analysis of the homogeneity of the 
distribution of the expression of immunohistochemical markers, tumor grade and subtypes between the 
groups of tumors. Fisher’s exact test permits calculation of precise probabilities in situation where 
sample sizes are small so the normal approximation and χ2-square calculations are liable to be 
inaccurate. Two-tailed Fisher’s exact test was used for pair-wise comparison of markers to detect 
differences between two groups of tumors.  The statistical program SPSS 13.0 (SPSS Inc, Chicago, IL, 
USA) and R/Bioconductor were used for this analysis. 
 
4. RNA EXPRESSION ANALYSIS 
4.1. RNA extraction and quantification 
Total RNA was extracted from cell lines and fresh-frozen tissue using Trizol (Invitrogen) according 
to manufacturer’s instructions. RNA from FFPE tissue samples was extracted using miRNeasy FFPE kit 
(QIAgen) according to the manufacturer’s instructions. RNA quantity and quality from FFPE tissues was 
assessed by NanoDrop ND.1000 UV-VIS-Spectrophotometer version 3.2.1 (Nanodrop Technologies, 
Wilmington, DE, USA). RNA quantity and quality from fresh-frozen samples was determined using the 
RNA 6000 Nano Assay kit on an Agilent 2100 BioAnalyzer (Agilent Technologies, Palo Alto, CA, 
USA). Samples used for mRNA expression microarray analysis had an average RNA integrity number 
value of 9 and a minimum RNA integrity number value of 7.  
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4.2. Real time quantitative PCR analysis (qRT-PCR) 
4.2.1. Detection of mRNA by q RT-PCR 
One microgram of total RNA was reverse transcribed using MMLV Reverse Transcriptase 
(Invitrogen) and random hexamer primers following manufacturer’s instructions. In brief, first template 
RNA was incubated with 500ug/ml of hexamers at 70°C for 5 minutes, and placed on ice. Subsequently 
the following components were added in an order: MMLV buffer 1X, dNTPs (Fermentas) (1mM, final 
conc.), RNAsin (20u) (Promega), 40U of MMLV enzymes (Invitrogen) to reach a final volume of 20ul. 
The reaction mixture was incubated 2h at 42°C. The cDNAs were subjected to quantitative RT-PCR 
assay with the use of FAM/NFQ fluorescently labeled probes TaqMan (Roche Universal Probe library, 
Roche) and TaqMan Universal PCR Maser Mix (PE Applied Biosystems) in an ABI Prism Sequence 
Detection System 7900HT (Applied Biosystems) using the oligonucleotides  and probes listed in Table 
__. Briefly, the q-RT-PCR set up included 2µl cDNA, 2xMaster Mix, Primer set (20µM) and the 
TaqMan probe (10µM) in a final volume of 12µl. The amplification conditions consisted of an initial 
step at 95 ºC for 10 min, followed by 50 cycles of 15 s at 95 ºC and 1 min at 60 ºC. Negative controls 
were present in all series of PCRs and all assays were carried out in triplicates. Relative expression was 
calculated using the comparative Ct method. Normalization of the samples was carried out with the 
internal using ß-actin was used as internal control. 
 
Table 2. Oligonucleotide primers used for mRNA qRT-PCR 
Gene name Primers Sequence (5’-3’) 
KRAS Forward primer: tggacgaatatgatccaacaat 
  Reverse primer tccctcattgcactgtactcc 
  Universal ProbeLibrary         #62 
      
TRAF2 Forward primer: gcatacccgccatcttctc 
  Reverse primer gcgttcaggtagatacgcagaca 
  Universal ProbeLibrary         #11 
      
β actin  Forward primer: ccaaccgcgagaagatga 
  Reverse primer ccagaggcgtacagggatag 
  Universal ProbeLibrary         #64 
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4.2.2. Detection of microRNAs by  qRT-PCR 
For miRNAs quantitative RT-PCR analysis was performed using miRCURY LNATM microRNA 
PCR System (Exiqon A/S, Vedbaek, Denmark). First, 25ng of total RNA was reverse-transcribed using 
miRNA-specific primers and First-strand cDNA Kit (Exiqon), and the cDNA was used as a template for 
the quantitative PCR reaction using miRNA-specific LNATM PCR primer and Universal PCR primer. 
Briefly, master mix was prepared consisting of  2μl of miR-specific primers, 0.5 ul of dNTPs, 0.5ul of 
RNase inhibitor and 0.5ul of reverse transcriptase; 3ul of the master mix were added to 2ul (25ng) of 
total RNA to a final volume of 5ul. Reaction was incubated at 50ºC for 40 minutes, and heat inactivated 
at 85ºC for 5 minutes. The cDNA was diluted in 1/10 ratio and used for quantitative PCR reaction. The 
reaction mix for the qPCR included 3ul of LNA™ SYBR® Green Master Mix 0.3ul of LNA™  miRNA 
specific primer and 0.3ul of Universal PCR primer Real-time quantitative PCR was performed with the 
Sequence Detection System 7900HT (Applied Biosystems) using the miRCURY LNA™ SYBR® Green 
Master Mix (Exiqon) following the manufacturer’s instructions. The amplification conditions consisted 
of an initial step at 95 ºC for 10 min, followed by 50 cycles of 20 s at 95 ºC and 1 min at 60 ºC. Negative 
controls were included to all series of PCRs and all assays were performed in triplicates. All experiments 
were performed in triplicate and the mean of triplicates was used. Normalization was done with 
SNORA66 RNA and 5S rRNA. Relative expression was calculated using the comparative Ct method. 
4.3. Microarray hybridization 
4.3.1. mRNA expression profiling 
Messenger RNA expression profiling was done with Agilent 44 K Whole Human genome Oligo 
Microarray (Agilent Technologies, Palo Alto, CA) containing 45,015 features representing 41,000 
unique probes in a dual-color reference sample experimental design. cDNA preparations, hybridizations, 
washes and detection were done as recommended by the supplier. For whole genome transcriptional 
profiling, total RNA from samples and Universal Human Reference RNA (Stratagene, La Jolla, CA, 
USA) were used for amplification and labeling using the Low RNA Input Linear Amplification Kit 
(Agilent Technologies) following the Enhanced Oligonucleotide Microarray Labeling and Hybridization 
protocol established by Genomic Unit at the Spanish National Cancer Research Centre. Briefly, 500ng of 
total RNA was reversed transcribed to double-strand cDNA using a poly dT-T7 promoter primer. At 
first, template RNA and quality-control transcripts of known concentration and quality were denatured at 
65ºC for 10 min and incubated for 2 hours at 40ºC with 5x First strand Buffer, 0.1 M DTT, 10 mM 
dNTP, MMLV RT, and RNase-out. The MMLV RT enzyme was inactivated at 65ºC for 15 min. cDNA 
products were then used as templates for in vitro transcription to generate fluorescent cDNA. cDNA 
products were mixed with a transcription master mix in the presence of T7 RNA  polymerase and 
Cyanine 5 (Cy5) labeled or Cyanine 3 (Cy3) labeled-CTP and incubated at 40ºC for 2 hours. Labeled 
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cRNAs were purified using QIAGEN’s RNeasy mini spin columns and eluted in 30ul of nuclease-free 
water. For each hybridization equal amounts of  Cy3 labeled cRNA (reference) and of Cy5 labeled 
cRNA (samples) were mixed, fragmented, and hybridized onto an Agilent 4×44 K Whole Human 
genome Oligo Microarray. Specifically, 1ug of Cy3 labeled cRNA (reference) and 1ug of Cy5 labeled 
cRNA (carriers or controls) were mixed along with 10x Blocking Agent and 25x Fragmentation buffer to 
a final volume of 45ul. After 30 minute incubation at 60C the RNA fragmentation step was stopped by 
adding 2XGE Hybridization buffer HI-RPM.    
4.3.2. miRNA expression profiling 
Microarray expression profiling of microRNAs was performed using miRCURY LNATM 
microRNA Array v.11.0 – hsa, mmu & rno (Exiqon A/S, Vedbaek, Denmark), in a single-color 
experimental design. The miRCURY LNATM microRNA Array v.11.0 – hsa, mmu & rno contains 
capture probes for all microRNAs in human, mouse, rat and their related viruses as annotated in 
miRBase Release v.11.0 including 1940 capture probes, in 4 replicates, representing 831 human 
miRNAs annotated in miRBasev.11 database and 434 hsa- miRPlus probes (Exiqon proprietary). Forty 
three control capture probes are included in the probe set (ten spike-in control probes to ensure optimal 
labeling and hybridization, seven negative control capture probes and twenty six capture probes 
complementary to small nuclear RNAs). Labeling and hybridization procedure was performed as 
recommended by manufacturer, using miRCURY LNA™ microRNA Power Labeling Kit (Exiqon). 
First, 300ng of total RNA was treated with Calf Intestinal Alkaline Phosphatase (CIP) to remove the 5’-
phosphates from the microRNA termini prior to labeling with Hy3 green fluorescent dye. Second, a Hy3 
fluorescent label is attached enzymatically to the 3’-end of the microRNAs in the total RNA sample. 
This is followed by an enzyme inactivation step after which the sample is ready for hybridization. 
Labeling reaction was performed using 2ul of CIP treated total RNA, 1.5ul   of Hy3 fluorescent dye, 2ul 
DMSO and 2ul of labeling enzyme, reaction was incubated at 16ºC for 1h and heat inactivated by 
incubation at 65ºC for 15 minutes and left at 4ºC until hybridization step. Labeled samples were 
subsequently loaded onto a miRNA microarray slide and hybridized over 16h at 56ºC. A set of 10 
synthetic spike-in RNAs were added to total RNA sample prior to labeling and later used for quality 
control for RNA labeling reaction and inter-array reproducibility. Washing of the slides was performed 
according to manufacturer´s instruction. Washed slides were dried by centrifuging at 1200 rpm for 5 
minutes. 
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4.3.3. Array scanning and microarray data extraction 
Processed slides were scanned with Agilent Array scanner (Agilent Technologies), with the laser set 
to 635nm, at Power 80 and PMT 70 setting, and a scan resolution of 10μm. To avoid ozone bleaching, 
microarrays were scanned in an ozone-free environment (less than 2 ppb ozone). Fluorescence intensities 
on scanned images were quantified using Agilent Feature Extraction software (version 9.5.3) (Agilent 
Technologies). For miRNA data extraction we have used the modified Exiqon protocol, while for 
mRNA data extraction  the GE2-v5_95_Feb07 protocol was used. Reproducibility and reliability of each 
single microarray was assessed using Quality Control report data. 
5.  MICROARRAY DATA ANALYSIS 
5.1. Background subtraction and log transformation 
Background subtraction is the first step in adjusting the raw data towards comparability. It has 
consistently been found to correct log ratios preventing underestimation of the observed changes in 
signal intensities. Average values of the replicate spots were background subtracted using Normexps 
background correction method that is a convolution model assuming that background signals are 
normally distributed while the sample signals are exponentially distributed. Processed intensity data 
from miRNA array were than log2 transformed and subjected to further analysis. For mRNA expression 
data, expression ratios were calculated (Cy5 processed signal was divided by Cy3 processed signal) and 
log2 transformed.  
5.2. Deposition of microarray raw data in public databases 
Microarray datasets used in the study have been deposited at Gene Expression Omnibus (GEO) 
database (http://www.ncbi.nlm.nih.gov/geo/info/linking.html) under GEO accession number: 
GSE30822, and GSE32922. 
5.3. Microarray data normalization  
When running experiments that involve multiple high density oligonucleotide arrays, it is important 
to remove sources of variation between arrays of non-biological origin, such as dye bias and differences 
in labeling, hybridization and scanning, which can occur when performing an array experiment. 
Normalization is a process for reducing this variation and to make data of different sources comparable. 
Normalization is performed on data from individual arrays (intra-slide normalization) and on data from a 
set of arrays (inter-slide normalization).  
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Expression data from mRNA microarray were normalized using Lowess and quantiles methods for 
intra-array and inter-array normalization, respectively. Lowess (Locally Weighted Scatterplot 
Smoothing) is the use of a locally established regression to smooth the M/A (log ratio/log mean-
intensity) scatterplot toward a linear distribution to eliminate the dye- and label-specific variances. Raw 
data obtained from miRNA microarray experiment were quantile normalized for inter-array variability. 
The Lowess algorithm works under the assumption that the majority of the signals between samples do 
not differ and it enforces equal overall means on all signal intensities. Quantile normalization is based on 
the assumption that two sets of closely related data should sort themselves in a linear fashion forming a 
diagonal when plotted against each other. The goal of the quantile method is to make the distribution of 
probe intensities for each array in a set of arrays the same and it enforces an equal intensity distribution 
on the data. 
 
Figure 8. Expression data point distribution prior to and post normalization 
5.4. Microarray data pre-processing 
Gene patterns containing missing values were discarded. Additionally a filter procedure eliminated 
genes with uniformly low expression or with low expression variation across the experiments, retaining 
20 374 genes and transcripts.  miRNA data was preprocessed to eliminate miRNAs with uniformly low 
expression or with low expression variation (SD<0.3) across the experiments, retaining 466 miRNA 
genes (306 hsa-miR + 160 hsa-miRPlus).  
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6. BIOINFORMATIC AND STATISTICAL ANALYSIS  
6.1. Class discovery analysis 
Average linkage hierarchical cluster analysis using Pearson correlation with uncentered metrics was 
performed using Gene Cluster (Eisen et al., 1998) and data were visualized by Treeview v.1.6 
(http://rana.stanford.edu/software; Stanford University, USA). The level of expression of each miRNA in 
each sample, relative to the median level of expression of that gene across all the samples was 
represented using a red-black-green color scale. Green corresponds to expression value below median, 
black equal to median, and red above the median.   
Consensus Clustering module available in the Gene Pattern suite (Reich et al., 2006) was used  for 
class discovery and clustering validation. This method facilitates the discovery of biologically 
meaningful clusters by assessing the stability of the discovered clusters by means of resampling 
techniques. The consensus clustering analyses were run with a KNN means algorithm was applied, with 
2, 3, 4, and 5 centroids using 500 resampling iterations. The consensus among the multiple runs is 
assessed and summarized in a consensus matrix and ΔG plot. This matrix is used as a visualization tool 
to estimate the composition and number of the clusters, and the ΔG plot indicates the change in free 
energy with every additional group added. 
6.2. Differential expression analysis 
Differential expression analysis was performed with linear models (limma) implemented in the 
POMELO II tool, available in Asterias web server (http://asterias.bioinfo.cnio.es). The estimated 
significance level (p value) was corrected for multiple hypotheses testing using Benjamini & Hochberg 
False Discovery Rate (FDR) adjustment. Differential expression analysis was performed with linear 
models (limma) t-test implemented in the POMELO II tool, available in Asterias package 
(http://asterias.bioinfo.cnio.es) (Morrissey and Diaz-Uriarte, 2009). The estimated significance level 
(unadjusted p-values) were corrected for multiple hypotheses testing using Benjamini and Hochberg 
False Discovery Rate (FDR) adjustment (Benjamini et al., 2001). Those miRNAs with FDR <0.05 were 
selected as significantly differentially expressed, while for mRNAs, FDR<0.01 was set as threshold.  
6.3. Databases and miRNA repositories 
miRBase (http://microrna.sanger.ac.uk) is a central repository for all reported and experimentally 
detected  miRNA genes(Griffiths-Jones, 2004; Griffiths-Jones et al., 2008). It was initiated at the 
Welcome Trust Sanger Institute and is currently hosted and maintained at the University of Manchester. 
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It comprises three services: miRBase:Sequences provides information about over 9000 miRNAs from 
103 species, including the sequences and genomic locations of the miRNAs; miRBase:Targets provides 
miRNA target predictions based on the miRanda algorithm; and miRBase:Registry is a service that 
assigns names to novel miRNA genes according to a defined miRNA nomenclature. 
Several publically available databases contain information on experimentally validated miRNA 
target genes obtained from literature data mining. The list of confirmed miRNA target genes was 
compiled from: Tarbase v.5c (DIANA lab, http://diana.cslab.ece.ntua.gr/tarbase/), miRecords 
(http://mirecords.biolead.org/) and miTarBase (http://mirtarbase.mbc.nctu.edu.tw/index.html ). 
6.4. miRNA target prediction 
A number of computational prediction programs have been developed to identify putative miRNA 
targets based on sequence complementarity between the miRNA and its potential mRNA target 3’ 
untranslated region (3’UTR) (Bartel, 2009). Near perfect complementarity in the seed region at the 5’ 
end 2-8 nucleotide position of the miRNA seems to be the most important factor for miRNA target 
prediction (Figure 9 left). Furthermore pairing to the 3’ region of the miRNA can also compensate for a 
mismatch in the seed region. These so called “3’-compensatory sites” are centered on miRNA 
nucleotides 13-17 (Figure 9 right). In an attempt to increase target prediction specificity some prediction 
algorithms are relying on target site evolutionary conservation and thermodynamic stability of the RNA-
RNA duplex. To determine potential mRNA targets for specific miRNAs we have used several 
publically available target prediction algorithms, namely, miRanda (microRNA.org), TargetScanS 
(www.targetscan.org), DIANA microT (http://diana.cslab.ece.ntua.gr/microT/) and PicTar 
(http://pictar.mdc-berlin.de/). 
 
Figure 9. Types of miRNA target sites. Adapted from Bartel DP, Cell 2009. 
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6.5. Integration of miRNA and mRNA gene expression signatures 
For each differentially expressed miRNA, a contingency table relating the miRNA and its predicted 
gene targets was produced using miRBase Targets Release v. 5.0 (http://www.mirbase.org/; Faculty of 
Life Sciences, University of Manchester), taking into account whether these targets were included in a 
consistent gene expression signature (down-regulated targets for upregulated miRNAs and vice versa). 
Fisher’s exact test was used for significance analysis. Those miRNAs whose Fisher’s exact test result 
indicated a p <0.05 were selected for further analysis on the basis of their non-random association with 
the gene expression signature of interest. To identify statistically significant associations between 
differentially expressed miRNAs (both t-test and Fisher’s exact test p<0.05) and enriched pathways 
(FDR< 0.05), a ranked list was built. Down-regulated miRNAs were tested for their association with 
upregulated genes, whereas upregulated miRNAs were tested for their association with down-regulated 
genes. The ranked target list of the differentially expressed genes was subjected to pathway enrichment 
analyses using Ingenuity Pathway Analysis 7.6 software (Ingenuity Systems, Redwood City, CA). 
Interaction networks were built and depicted using Cytoscape bioinformatics software (Shannon et al., 
2003) (http://www.cytoscape.org).  
6.6. Functional annotation and gene set enrichment analysis 
Several different bioinformatic tools have been used for biological interpretation and the analysis of 
pathways associated to defined lists of genes. These included DIANA miRPath, Ingenuity Pathway 
Analysis® and DAVID.  
Ingenuity Pathway Analysis® (http://www.ingenuity.com/products/pathways_analysis.html) was 
used to gain insight into global molecular networks and canonical pathways specific to significantly 
associated miRNA-mRNA gene pairs differentially expressed between BRCA1 proficient and deficient 
cells. The ranking of genes was performed with t-test, with an absolute mode for gene list sorting. Gene 
sets are defined based on prior biological knowledge, e.g., published information about biochemical 
pathways (KEGG, Biocarta, Reactome) or co-expression in previous experiments, and are manually 
curatted and stored in the Ingenuity Knowledge Database®.  False discovery rate (FDR, q value) is 
computed in by the IPA program. Those pathways showing FDR <0.15, a well-established cut-off for the 
identification of biologically relevant gene sets (Subramanian et al., 2005), were considered significantly 
enriched between classes under comparison. Pathways that have less than 15 gene members or over 500 
were excluded from the analysis.  
DIANA miRPath pathway enrichment analysis (Papadopoulos et al., 
2009)(http://diana.cslab.ece.ntua.gr/) was used to gain insight into global molecular networks and 
canonical pathways related to differentially expressed miRNAs between normal and tumor samples. 
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DIANA miRPath is a web-based computational tool developed to identify molecular pathways 
potentially altered by the expression of single or multiple microRNAs. The software performs an 
enrichment analysis of multiple microRNA target genes comparing each set of microRNA targets to all 
known KEGG pathways. Those pathways showing p-value <0.05, were considered significantly 
enriched between classes under comparison.  
The Database for Annotation, Visualization and Integrated Discovery (DAVID ) v6.7 bioinformatic 
algorithm (http://david.abcc.ncifcrf.gov/) was used for the functional annotation  analysis  of Gene 
Ontology (GO) terms associated with a given gene list of  confirmed mRNA targets within each miRNA 
cluster specific for different BRCAX tumor subtypes (Huang da et al., 2009). GO functional categories 
with p-values under 0.05 after correction for multiple hypotheses testing by Benjamini and Hochberg 
were considered as statistically significant. 
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 RESULTS 
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In continuation, results obtained during the course of this thesis, from January 2009 until June 2012, 
shall be presented. In total three different studies have been performed, implementing various techniques 
including miRNA and mRNA expression profiling, IHC, and cell-based functional studies in various 
series of breast tissue samples, as described in Materials and Methods. In summary: 
 
The first study is focused on the integration analysis of miRNA and mRNA expression profiles, and 
identification of BRCA1-modulated pathways and miRNA target genes in two isogenic cell lines, 
proficient and deficient for BRCA1 expression. (Tanic et al, Breast Cancer Res Treat, 2011) 
 
The second study is centered on the analysis of miRNA expression profile in a series of 36 fresh-frozen 
breast tissues (22 breast tumors and 14 normal breast tissues), describing miRNAs deregulated in tumors 
versus normal breast tissues, identifying deregulated pathways and novel miRNA target genes. (Tanic et 
al, PloS One, 2012) 
 
The third and the final study is based on the miRNA expression profiling in a series of 80 FFPE breast 
tissues, focusing on the analysis of miRNAs differentiating between different genetic subgroups, 
BRCA1 and BRCA2 mutation carriers, BRCAX and sporadic breast tumors, and the analysis of BRCAX 
tumor heterogeneity, resulting in a miRNA-based molecular sub-classification of BRCAX tumors. 
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RESULTS PART I  
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1. INTEGRATION OF BRCA1-MODULATED MIRNA AND MRNA 
EXPRESSION PROFILES  
Germline BRCA1 mutations are a well known factor of susceptibility to breast and ovarian cancers 
(Bertwistle and Ashworth, 1998; Rahman and Stratton, 1998). Somatic inactivation of BRCA1 is 
common in sporadic breast cancer with ~40% of sporadic breast tumors showing decreased levels of 
BRCA1 mRNA/protein expression (Esteller M, 2000;Turner, 2007; Wei M, 2008), with approximately 
20% of sporadic breast tumors showing complete loss of BRCA1 protein expression (Taylor J, 1998), 
emphasizing the importance of BRCA1 deregulation in breast pathogenesis. Incredible versatility of 
BRCA1 functions has been demonstrated so far, including DNA damage repair/recombination, cell cycle 
control (Deng, 2006), chromatin remodeling and ubiquitylation (Huen et al., 2010) and regulation of 
both transcriptional activation and repression (Cable et al., 2003; Chapman and Verma, 1996).  
The first objective of this thesis project was to identify miRNAs and miRNA-mRNA interaction 
networks dependant on BRCA1 expression status. By integration analysis of genome-wide miRNA and 
gene expression data determined by microarray technology, we aimed to reveal underlying biological 
processes and pathways, and to identify new miRNA target genes potentially implicated in BRCA1-
associated tumorigenesis. 
1.1. Study material and model system of BRCA1 reconstitution  
The model system used in this study consisted of paired isogenic cell lines deficient and proficient 
for BRCA1 expression, HCC1937 cell line derived from hereditary BRCA1 mutated breast tumor and 
HCC1937/BRCA1wt stably expressing full length wild-type BRCA1 mRNA (Huang et al., 2009; Huen et 
al., 2007), that were kindly provided by Dr. J. Chen (Yale University School of Medicine Department of 
Therapeutic Radiology, New Haven, USA) (Figure 10). In addition 13 formalin fixed paraffin 
embedded (FFPE) tumor tissues from hereditary breast cancer cases harboring BRCA1 mutations, as well 
as 4 normal breast tissues from mammary reduction surgery, were selected to check the expression of 
interesting miRNAs. 
 
Figure 10.  Cell model system used for the study - cell line HCC 1937/BRCA1mut/- and its isogenic counterpart 
with reconstituted wild-type BRCA1 protein expression HCC 1937/BRCA1wt.  
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1.2. Significantly modulated mRNAs and miRNAs in response to BRCA1 
reconstitution  
To determine the effect of BRCA1 reconstitution on miRNA and mRNA profiles, whole genome 
transcriptional profiling and global miRNA expression profiling was performed in the BRCA1-deficient 
HCC1937 breast cancer cell line and its isogenic counterpart HCC1937/BRCA1wt, stably expressing 
wild-type BRCA1. A total of 8845 genes demonstrated statistically significant (FDR <0.01) differential 
expression, representing a 26% shift in global gene expression, with 4710 transcripts downregulated and 
4135 transcripts upregulated in BRCA1-proficient cells relative to BRCA1-deficient HCC1937 breast 
cancer cells (Figure 12A). The full list of differentially expressed genes is shown in Supplementary 
Table 3. 
In contrast, miRNA expression profiles exhibited very high similarity in the two isogenic cell lines, 
with a Pearson correlation coefficient of R2=0.93 (Figure 1c). Differential expression analysis showed 
that only 9 miRNAs (miR-99a, miR-99b, miR-138, miR-146a, miR146b, miR-205, miR-302b*, miR-
923 and miR-1290) were significantly differentially expressed between the cell lines with FDR <0.05, 
representing 1% change in global miRNA expression upon BRCA1 reconstitution (Figure 12B). Most of 
these miRNAs were upregulated in HCC1937/BRCA1wt compared to HCC1937, while only miR-138 
was down-regulated in HCC1937/BRCA1wt. Quantitative RT-PCR analysis performed on selected 
miRNAs confirmed the pattern of differential expression shown by microarray analysis (Figure 11).  
 
 
Figure 11. Quantitative RT-PCR validation of microarray results demonstrating consistently reduced 
expression of miR-205, miR-146a and miR-125a-3p in HCC 1937 cells in comparison to 
HCC1937/BRCA1wt.  
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Figure 12.  mRNA and miRNA transcriptional changes upon BRCA1 reconstitution. A) mRNA expression 
heatmap of differentially expressed genes (DEG) with FDR<0.01 between HCC1937 and HCC 1937/BRCA1wt 
cells. Upregulated genes in HCC1937/BRCA1wt are shown in red, downregulated genes in green. B) Differentially 
expressed miRNAs (FDR<0.05) between HCC1937 and HCC 1937/BRCA1wt cells. Upregulated miRNAs in 
HCC1937/BRCA1wt are shown in red, downregulated in green. C) Correlation plot between miRNA expression in 
HCC1937 and HCC 1937/BRCA1wt cells. Linear regression analysis of global miRNA expression in the two 
isogenic cell lines; squared correlation coefficient of R2=0.93 indicates high similarity of the two datasets. 
 
 
94 | P a g e   
1.3. miRNA and mRNA integration analysis reveal significant miRNA-
mRNA target pairs and pathways 
Once the initial observation that miRNAs are differentially expressed between BRCA1-proficient 
and deficient cells; an integrated analysis of the miRNA and mRNA expression profiles was carried out 
to identify putative miRNA targets. The integrated analysis of miRNA and mRNA expression levels has 
been based on the assumption that increased or decreased expression of a specific miRNA results in at 
least partially decreased or increased expression of corresponding target mRNAs (Lim et al., 2005). To 
identify statistically significant associations between differentially expressed miRNAs (DEmiRs, 
FDR<0.05) and differentially expressed genes (DEGs, FDR<0.01), we tested whether predicted miRNA-
mRNA targeting pairs were non-randomly associated by Fisher’s exact test (Figure 13). Gene target 
predictions for human miRNAs were obtained using miRBase Targets Release v5.0 
(http://www.miRBase.org, Faculty of Life Sciences, University of Manchester). Results of Fisher’s exact 
test indicated that miR-138, miR-146a, miR-146b and miR-99b were significantly associated with 
differentially expressed mRNA targets within the gene expression signature. Significant miRNAs 
upregulated in HCC1937/BRCA1wt (miR-146a, miR-146b and miR-99b) were collectively targeting 160 
downregulated DEGs. Interestingly, five genes SURF1, TRAF2, FBXW2, HIST1H4I and MARK1 were 
identified as common targets for all 3 significant upregulated miRNAs. On the other hand miR-138 was 
significantly associated to 75 upregulated DEG.  
To explore the biological significance for observed changes, significant miRNA-mRNA target pairs 
were evaluated for representation of relevant functional biological processes and pathways using 
Ingenuity Pathway Analysis.  The pathway analysis over the 160 significant downregulated DEG 
revealed statistically significant enrichment for 15 pathways related to proliferation signaling and 
inflammation. Among the most interesting were p38/MAPK, MAPK/JNK and NF-κB signaling 
pathways. Interestingly, TRAF2 (TNF receptor associated-factor 2) gene, a well established mediator of 
both NF-κB and MAPK pathway activation (Carpentier et al., 1998), was predicted to be a target of the 3 
significant miRNAs (miR-146a, miR-146b and miR-99b) along with another two out of the 9 
differentially expressed miRNAs, miR-99a and miR-205. On the other hand, there were only two 
pathways (Clathrin-mediated Endocytosis Signaling and IL-10 Signaling) that were significantly 
enriched within 75 significant upregulated DEG, targets of miR-138. Full list of pathways is represented 
in Supplementary Table 4. 
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Figure 13. Outline of miRNA and mRNA expression integration analysis following BRCA1 gene re-
expression. Significantly differentially expressed miRNA (FDR<0.05) and mRNAs (FDR<0.01) upon 
BRCA1 expression, were investigated the existence of inverse correlation between upregulated 
expression of a microRNA and its predicted mRNA target genes. Gene target predictions for human 
miRNAs were obtained using miRBase Targets Release v5.0 implementing miRanda target prediction 
algorithm. Those miRNAs found to be significantly associated on the basis of the Fisher’s exact test 
(FDR<0.05) with the gene expression signature of interest were selected. Ingenuity Pathway Analysis 
(IPA) was used to find enriched pathways for the mRNA targets significantly associated to differentially 
expressed miRNAs. Functional validation of the significantly enriched pathways (FDR<0.05) was 
performed with Luciferase reporter assay.  
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An interaction network (Figure 14) was built to represent connections of significant upregulated 
DEmiRs, their DE-mRNA targets and the associated pathways. This approach allowed us to infer 
experimental microarray gene expression data to predict the effects of miRNA expression on the global 
behavior of biological pathways. 
 
 
 
 
 
Figure 14. Interaction network showing upregulated miRNAs in HCC 1937/BRCA1wt cells with connections to 
downregulated genes and pathways. miRNAs are indicated by red triangles, miRNA target genes are depicted as 
green (1-2 connections of coding genes to miRNAs) and yellow circles (3 connections), whereas pathways are 
represented by blue diamonds. The size is proportional to their degree of connectivity. All the connections 
represent statistically significant relationships with FDR<0.05 set as threshold. 
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1.4. Changes in pathway activation between BRCA1-profficient and deficient 
HCC1937 cells 
We quantitatively assessed signal transduction pathway activation by measuring the activities of 
downstream transcription factors in vitro in the isogenic cell lines deficient and proficient for BRCA1. 
Transcription factor (TF) responsive luciferase construct encodes the firefly luciferase reporter gene 
under the control of a minimal (m) CMV promoter and tandem repeats of the TF transcriptional response 
element (TRE). Reporter transcription factors used for assessment of NFκB, MAPK/ERK, MAPK/JNK 
pathway signaling, were NFκB, Elk-1/SRF and AP-1, respectively; Interestingly, the results revealed 
that MAPK/JNK pathway were significantly down-regulated in HCC1937/BRCA1wt compared to the 
BRCA1-null HCC1937 cell line (Figure 15). In addition, NF-κB and MAPK/ERK showed also reduced 
activity when BRCA1 was expressed in HCC1937 cells, although this was not statistically significant. 
Reduction in the in vitro activity of these pathways supports the findings obtained by Ingenuity Pathway 
analysis.  
 
 
 
Figure 15. Luciferase reported assay for activation of signaling pathways. MAPK/ERK, MAPK/JNK and NFκB 
signaling pathways show decreased activation upon BRCA1 reconstitution. Pathway activation in the BRCA1-
deficient and proficient isogenic HCC1937 cell lines was assessed by measuring the activities of downstream 
transcription factors.  
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Consistent with this finding, these cell lines had markedly different proliferation rates, with BRCA1-
deficient cells proliferating considerably faster than their isogenic BRCA1-proficient counterparts 
(Figure 16), suggesting that the increased activity of the NF-κB and/or MAPK pathways in HCC1937 
cells might play an important role in cell survival and proliferation in context of BRCA1. 
 
 
Figure 16. Growth curves of HCC1937 and HCC1937 BRCA1-expressing cells. BRCA1 reconstitution impacts 
proliferation of HCC1937 cells. BRCA1wt-expressing HCC1937 cells showed a lower increase in the number of 
growing cells comparing to the HCC1937 BRCA1-null cells. 
 
1.5. TRAF2 is regulated by miR-146, miR-99 and miR-205 
The computational analyses revealed TRAF2 gene as a common target for 5 out of 9 differentially 
expressed miRNAs, miR-146a, miR146b, miR-99a, miR-99b and miR-205, with several predicted 
binding sites in its 3’UTR (Figure 18A). In addition, we observed that TRAF2 had higher endogenous 
expression, at both protein (Figure 18C) and mRNA level (Figure 17), in HCC1937, which expresses 
lower levels of miR-146a/b, miR-99a/b and miR-205. To validate TRAF2 as a bona fide target of these 
miRNAs we performed luciferase reporter assays to check binding of these miRNAs to the 3’UTR of 
TRAF2 gene.  Cells transfected with miR-146 showed 50% reduction in normalized luciferase signal 
compared to scramble control, while miR-99 and miR-205 transfected cells exhibited approximately 
30% decrease in luciferase activity (Figure 18B). Combination of all three miRNAs did not affect any 
further the expression of TRAF2.  
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Figure 17. mRNA levels of TRAF2 in HCC1937 and HCC1937/BRCA1wt cells. Endogenous TRAF2 mRNA 
levels are higher in BRCA1-null HCC1937 than HCC1937/BRCA1wt. Bars represent mean expression values and 
error bars represent standard deviation from three different experiments. 
 
To study the effect of miRNA on the TRAF2 mRNA and protein level changes, we have transfected 
HCC1937 cells with pre-miRNA oligonucleotides for miR-146a, miR-99b and miR-205. Although 
mRNA levels of TRAF2 did not show a significant changes after miRNA re-expression (Figure 8C), 
western blot analyses demonstrated a reduction in TRAF2 protein levels in cells transfected with pre-
miR-146a, pre-miR-205, and pre-miR-99b, compared to scramble control and mock transfection (Figure 
8C). Collectively, luciferase reporter assay and western blot results showed that miR-146a, miR-99b and 
miR-205 act as negative regulators of TRAF2 expression. 
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Figure 18.  Negative regulation of TRAF2 expression by miR-146a, miR99a and miR-205. A) Schematic 
representation of miRNA binding sites within the TRAF2 3’UTR region. Complementary binding sites for miR-
146a, miR-146b, miR-99a, miR-99b and miR-205 are based on miRanda target prediction software. B)  Luciferase 
activity of a reporter construct carrying the TRAF2 3’-UTR downstream of the luciferase gene. The construct was 
co-transfected with each of the indicated miRNA precursors and pool combination of all 3 pre-miRNAs into 
HCC1937 cells. The pool contains an equimolar mixture of all indicated miRNAs in which the sum of all these 
miRNAs equals 50nM as in the scramble vectors or the previous assays. All data are normalized versus the 
luciferase levels generated by scramble sequences. (* , p<0.05)  C) TRAF2 protein levels after miRNA expression. 
The effect of miR-146a, miR-99a and miR-205 on TRAF2 protein levels was assessed by western blot. HCC1937 
cells were transfected with 50nM miR-146a, miR-99a, miR-205 or scramble control, or mock transfected. TRAF2 
levels in non-transfected HCC1937 and HCC1397/BRCA1wt are also represented. GAPDH was used as a loading 
control. 
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1.6. NF-κB pathway activity is modulated by miR-146, miR-99 and miR-205.  
In order to determine whether miR-146a, miR-99b and miR-205 could have a direct effect on the 
NF-κB, MAPK/ERK and MAPK/JNK pathway activation, we re-expressed these miRNAs individually 
in HCC1937 cells and assayed for signaling pathway activation using the Multi-Pathway Reporter 
Assay. Our results demonstrated that all three miRNAs significantly reduced NF-κB pathway activity 
compared to negative control (Figure 19). Similarly, MAPK/ERK pathway exhibited significant 
reduction in activity only upon transfection with miR-146a. On the other hand, MAPK/JNK pathway 
showed no differences in activity levels compared to negative control, indicating that expression of just 
one miRNA is not sufficient to modulate activity of this pathway.  
 
 
Figure 19. miRNA expression effects on pathway activation. Box plots showing the effect of miR-146a/b, miR-
199a/b and miR-205 on NFκB, MAPK/ERK, MAPK/JNK pathway activation was assessed by measuring the 
activities of downstream transcription factors in the BRCA1-deficient HCC1937 cell line transfected with 200pm 
of each of these miRNAs. (*p<0.05) 
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1.7. Down-regulation of miR-99a, miR146b and miR-205 in primary 
BRCA1-mutated breast tumors. 
To further explore the significance of miRNAs found to be associated with BRCA1 re-expression in 
HCC1937, their level of expression was analyzed in a group of 13 BRCA1 mutated primary tumors 
comparing to expression in normal breast tissue. Significant down-regulation of three of these miRNAs, 
miR-99a, miR146b and miR-205 was confirmed in BRCA1 tumors (Figure 10), indicating that these 
BRCA1-dependent miRNAs could be important also for tumor development in vivo. 
 
 
Figure 20. Box plots representing level of expression determined by microarray in a set of 13 BRCA1-mutated 
tumors comparing to normal breast tissue (NT) for three significant miRNAs, miR-99a, miR-146b, and miR-205 
showed significant down regulation in tumors.  
 RESULTS PART II  
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2. DEREGULATED MIRNAS IN HEREDITARY BREAST CANCER  
2.1. miRNA expression profiling in primary hereditary breast tumors and 
normal breast tissue. 
miRNA deregulation in sporadic breast carcinomas has been well established, but to date, there are 
no reports describing miRNA deregulated in hereditary breast tumors. In order to establish the miRNA 
profile of hereditary breast tumors, we used LNA based microRNA microarrays. After initial 
preprocessing we obtained data from 1276 hsa-miRNAs (831 hsa-miR and 434 hsa-miRPlus). A filter 
procedure to eliminate genes with low expression variation across the experiments (SD<0.3) and with 
uniformly low expression, reduced the number of miRNAs to a total of 327 hsa-miRNAs (198 hsa-miR 
and 118 miRPlus). In an effort to detect significant differences in miRNA expression between normal 
breast tissue and hereditary breast tumors, we performed a differential expression analysis. We identified 
19 miRNA significantly differentially expressed (FDR<0.05) between normal breast tissue and 
hereditary tumoral samples (Table 3). Almost all differentially expressed miRNAs were found to be 
down-regulated in tumor tissues, with the exception of miR-21 and miR-300 that were up-regulated in 
breast tumors compared to normal breast tissue.  Among miRNAs that demonstrated more than two-fold 
changes in expression in hereditary breast tumors were miR-99a, miR-100, miR-195 and miR-143, while 
miR-205 and miR-125b showed almost 6-fold lower expression in hereditary tumors.  
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Table 3.  miRNAs differentially expressed between normal breast and hereditary tumor tissue 
miRNA 
Chromosomal 
location 
Median 
Normal 
Breast 
Median 
Tumor 
Tissue 
Fold 
change 
Unadjusted p 
value 
FDR- adjusted 
p value 
hsa-miR-205 1q32.2 9.9 7.4 5.9 ↓ 3.00E-07 7.82E-05 
hsa-miR-125b 11q24.1/21q11.2 11.4 8.9 5.8 ↓ 6.00E-07 7.82E-05 
hsa-miR-99a 21q11.2 7.4 6.3 2.2 ↓ 1.30E-06 0.0001 
hsa-miR-100 11q24.1 7.6 6.4 2.2 ↓ 2.00E-06 0.0001 
hsa-miR-145 5q32-33 7.3 6.4 1.8 ↓ 4.95E-05 0.0024 
hsa-miR-195 17p13 9.1 7.4 3.4 ↓ 0.000152 0.0062 
hsa-miR-10b 2q31 7.6 6.8 1.7 ↓ 0.00024 0.0084 
hsa-miR-320c 18q11.2 7.6 6.9 1.6 ↓ 0.000412 0.0127 
hsa-miR-320d 13q14.11/Xq27.1 7.4 6.7 1.6 ↓ 0.000512 0.014 
hsa-miR-101 1p31.3 7.4 6.4 2.0 ↓ 0.000787 0.0185 
hsa-miR-130a 11q12 7.5 6.8 1.6 ↓ 0.000887 0.0185 
hsa-miR-320b 1p13.1/1q42.11 8.1 7.3 1.8 ↓ 0.000938 0.0185 
hsa-miR-125a-5p 19q13.4 8.8 8.1 1.6 ↓ 0.000976 0.0185 
hsa-miR-335 7q32.2 7.1 6.5 1.4 ↓ 0.001195 0.021 
hsa-miR-320a 8p21.3 8.1 7.3 1.8 ↓ 0.001669 0.0257 
hsa-miR-143 5q32-33 9.7 8.2 2.8 ↓ 0.002078 0.0301 
hsa-miR-21 17q23.1 9.1 10.1 2.0 ↑ 0.003822 0.0495 
hsa-miR-30c 6q13 8.4 7.8 1.5 ↓ 0.004283 0.0504 
hsa-miR-300 14q32.31 7.1 8 2.0 ↑ 0.004306 0.0504 
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Supervised clustering over the 19 differentially expressed miRNAs in normal breast tissue, tumor 
tissue and normal Human Mammary Epithelial Cells (HMEC) is shown in Figure 21.  Expression of 
these 19 differentially expressed miRNAs in immortalized but not transformed HMEC cells was similar 
to the expression in normal breast tissue although some differences existed for specific miRNAs. HMEC 
cells represent normal proliferating cells while normal breast tissue represent preferentially non 
proliferating cells, suggesting that down regulation of some miRNAs, such as miR-21, miR-99a, miR-
101, miR-143 or miR-145, might be related to proliferation in both normal and tumoral cells. However, 
down-regulation of other miRNAs, miR-205, miR-125a/b, miR-100 or miR-30c, could have a role in 
more specific tumoral processes. 
 
 
Figure 21. Heat map showing 19 differentially expressed miRNAs between normal breast samples and hereditary 
breast tumors; expression higher than median in red, lower in green. Expression of these miRNAs in Human 
Mammary Epithelial Cells (HMEC) cells is also represented. 
 
108 | P a g e   
2.2. miRNAs commonly deregulated in hereditary and sporadic breast 
cancer 
Interestingly, several miRNAs that we found to be deregulated in hereditary breast cancer were 
previously described to be deregulated in sporadic breast tumors. Thus, 11 of the 19 miRNAs (miR-10b, 
-100, -101, -125a, -125b, 130a, -143, -145, -21, -205, and -30c) were previously identified in two key 
studies as being  aberrantly expressed in sporadic breast tumors in comparison to normal tissue (Iorio et 
al., 2005; Volinia et al., 2006), suggesting that these miRNAs may play a general role in breast 
carcinogenesis (Figure 22). Deregulation of some of these miRNAs in sporadic tumors was also 
confirmed by qRT-PCR analysis in an independent set of 18 sporadic breast tumors (Figure 23).  
 
 
 
Figure 22. Venn diagrams representing commonly deregulated miRNAs in two different studies carried out in 
sporadic breast cancer samples and in the present study on hereditary breast tumors. Regardless of the genetic 
background or histopathological features of the tumors, there are miRNAs consistently altered in breast tumor 
samples in comparison to normal breast tissue.  
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Figure 23. Validation of miRNA expression by qRT-PCR in hereditary and sporadic tumors.  Expression levels of 
miR-125b, miR-100, miR-320a in normal breast tissue comparing with hereditary tumor samples (FamBC) and 
sporadic breast cancer (SpoBC). Differences were estimated by t-test and p values are shown for each case.  
 
2.3. Pathway enrichment analysis 
Given the fact that a single miRNA can target a large number of mRNA transcripts, aberrant 
expression of a set of miRNAs could have significant effect on cellular function by affecting multiple 
signaling pathways. To assess the potential impact of deregulated miRNA in hereditary breast tumors on 
biological processes and pathways, we used Diana miRPath web-based computational tool for biological 
interpretation of miRNA profiling data using over-representation analysis of biological processes and 
signaling pathways that are targeted collectively by co-expressed miRNAs. KEGG pathway enrichment 
analysis has revealed that the set of differentially expressed miRNAs between normal tissues and 
hereditary breast tumors, targets multiple effectors of pathways involved in ubiquitylation, cell 
proliferation and migration. Full list of pathways that have significantly overrepresented genes (p<0.05) 
collectively targeted by the set of 19 differentially expressed miRNAs is shown in Table 4. Observed 
down regulation of miRNAs in tumors regulating expression of these genes may result in abnormally 
activated pathways leading to increased proliferation and/or migration abilities.  
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Table 4. Significantly enriched signaling pathways associated to the differentially expressed miRNAs 
KEGG Pathway Nº of miRNA Target Genes  -ln(p-value) Gene Names 
Ubiquitin mediated proteolysis 20 17.18 
UBE2D1, SOCS1, UBE2D2, UBE3C, UBE1, MAP3K1, BIRC6, UBE2J1, UBE2I, 
SMURF1, UBE2W, CBL, BTRC, WWP1, CUL2, SOCS3, CBLB, NEDD4L, 
NEDD4, ITCH 
Axon guidance 17 11.88 
SRGAP3, PLXNA2, GNAI2, DPYSL2, ITGB1, UNC5C, EFNA3, SEMA4D, 
EPHB2, SEMA6D, KRAS, CFL2, NRP1, PPP3CA, RASA1, SEMA3A, NFAT5 
Insulin signaling pathway 16 7.96 
PPARGC1A, SOCS1, MAPK8, TSC1, PDPK1, KRAS, CBL, FRAP1, CRKL, 
SORBS1, SOS1, FOXO1, SOCS3, CBLB, PIK3CD, AKT3 
O-Glycan biosynthesis 6 7.23 GALNT2, GALNT7, GALNT1, GALNT3, GCNT1, B4GALT5 
mTOR signaling pathway 7 5.31 TSC1, PDPK1, FRAP1, ENSG00000164327, RPS6KA3, PIK3CD, AKT3 
ErbB signaling pathway 10 4.74 MAPK8, NRG3, KRAS, CBL, FRAP1, CRKL, SOS1, CBLB, PIK3CD, AKT3 
Glycan structures - biosynthesis 1 12 4.35 
GALNT2, GALNT7, GALNT1, GALNT3, CHST2, STT3B, CHST1, GCNT1, 
EXTL2, B4GALT5, MAN1A2, XYLT1 
MAPK signaling pathway 20 3.84 
MAP4K4, MAPK8, MAP3K1, KRAS, MEF2C, BDNF, CRKL, TAOK1, STK4, 
SOS1, FGFR1, RPS6KA5, FGF2, RAP1B, PPP3CA, NF1, RASA1, MAP3K12, 
RPS6KA3, AKT3 
Regulation of actin cytoskeleton 17 3.61 
ITGB1, WASL, ARHGEF6, KRAS, PIP4K2B, CRKL, CFL2, PIP4K2A, ITGA6, 
SOS1, FGFR1, FGF2, ITGB3, GNA13, ACTC1, PIK3CD, PFN2 
Adherents junction 8 3.55 IGF1R, SNAI1, WASL, SMAD2, SORBS1, FGFR1, SSX2IP, PVRL1  
Focal adhesion 16 3.54 
BCL2, MAPK8, ITGB1, IGF1R, PDPK1, CRKL, ITGA6, SOS1, PTEN,PTENP1, 
RAP1B, ITGB3, ARHGAP5, CCND2, PIK3CD, AKT3, CCND1 
T cell receptor signaling pathway 9 3.2 KRAS, CBL, SOS1, PPP3CA, CBLB, PDCD1, NFAT5, PIK3CD, AKT3 
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We focused our further analysis on the MAPK signaling pathway since a large number of genes 
within this pathway were found to be commonly targeted by 8 out of 19 deregulated miRNAs in our 
study suggesting that these miRNAs might cooperate to affect gene expression and consequentially 
activation or repression of signaling pathways (Table 5). Interestingly, miR-30c has potential binding 
sites on 12 different target genes involved in MAPK pathway. This miRNA potentially targets 
important mediators of MAPK signaling, such as KRAS, RASA1, MAP3K1 and MAPK8. 
Furthermore, KRAS gene has been previously validated as a target of several miRNAs, including let-
7, miR-143 and miR-145 previously found to be significantly down-regulated in breast tumors (Chen 
et al., 2009; Johnson et al., 2005; Yu et al., 2010b). Therefore, we investigated whether miR-30c 
could be regulating KRAS expression in hereditary breast tumors. Thus, we confirmed by QRT-PCR 
that miR-30c had decreased expression in both hereditary and sporadic breast tumors comparing to 
normal samples (Figure 24). Although mutations in KRAS are infrequent in breast tumors, activation 
of KRAS pathway in breast cancer have been frequently found. All these data suggests that 
deregulation of miRNAs could represent a potential mechanism to explain KRAS overexpression in 
breast tumors.  
 
 
Figure 24. Validation of miR-30c expression by qRT-PCR in an independent set of 12 hereditary (FamBC) and 
8 sporadic breast tumors (SpoBC) comparing to normal breast tissue expression. Differences were estimated by 
t-test and p values are shown for each comparison. 
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 Table 5. Genes within MAPK pathway predicted by DIANA microT 4.0 to be targeted by deregulated 
miRNAs in hereditary breast cancer tumors. 
miRNA Name Gene Gene Definition 
hsa-miR-205 RPS6KA3 ribosomal protein S6 kinase, 90kDa, polypeptide 6 
hsa-miR-99a PPP3CA calcium binding protein P22 
  FGFR1 fibroblast growth factor receptor 1 
hsa-miR-100 PPP3CA calcium binding protein P22 
  FGFR1 fibroblast growth factor receptor 1 
hsa-miR-195 FGF2 fibroblast growth factor 2 
 
MAPK8  mitogen-activated protein kinase 8 
  AKT3 
v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, 
gamma) 
hsa-miR-101 RAP1B RAP1A, member of RAS oncogene family 
  STK4 serine/threonine kinase 3 
hsa-miR-130a RPS6KA5 ribosomal protein S6 kinase, 90kDa, polypeptide 6 
hsa-miR-300 PPP3CA calcium binding protein P22 
  MEF2C myocyte enhancer factor 2C 
hsa-miR-30c SOS1 son of sevenless homolog 1 (Drosophila) 
 
KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
 
NF1 neurofibromin 1 
 
RASA1 RAS p21 protein activator (GTPase activating protein) 1 
 
RAP1B RAP1A, member of RAS oncogene family 
 
PPP3CA calcium binding protein P22 
 
MAPK8 mitogen-activated protein kinase 8 
 
MAP4K4 mitogen-activated protein kinase kinase kinase kinase 4 
 
MAP3K1 mitogen-activated protein kinase kinase kinase 1 
 
TAOK1 TAO kinase 3 
 
BDNF brain-derived neurotrophic factor 
 
CRKL v-crk sarcoma virus CT10 oncogene homolog (avian) 
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2.4. miR-30c regulates KRAS expression  
The role of miR-143 and miR-145 in regulating KRAS expression was already described; 
however KRAS was not previously reported as miR-30c target. Therfore, we explored the role of 
miR-30c in regulation of KRAS expression. We observed a negative correlation between miR-30c 
expression and KRAS protein level in two breast cancer cell lines (Figure 25). In addition, several 
bioinformatic target prediction algorithms (DIANA microT4.0, TargetScan, PITA, PicTar, 
miRANDA) indicated existence of a broadly conserved putative binding site for miR-30c in the 
3’UTR of the KRAS gene (Figure 26A). To test the hypothesis that KRAS is a bona fide target of 
miR-30c, we constructed a reporter plasmid harboring 300bp of the wild-type 3’UTR region of KRAS 
flanking miR-30c binding site downstream of the luciferase coding region. MDA-MB-436 cells were 
co-transfected with luciferase reporter and pre-miR-30c or scramble control. As a result, pre-miR-30c 
transfected cells showed a marked reduction (52%) of luciferase activity compared to scramble 
control, confirming the interaction between miR-30c and KRAS 3’UTR binding site (Figure 26B).  
Next, we checked whether miR-30c has an effect on KRAS mRNA stability by performing qRT-PCR 
analysis in MDA-MB-436 cells transiently transfected with either pre-miR-30c or scramble control. 
Indeed, we observed a sharp decrease in KRAS mRNA levels upon transfections with pre-miR-30c 
(Figure 26C). In addition, pre-miR-30c or pre-miR- control were transfected into MDA-MB-436 
cells, and we confirmed a reduction of about 44% of KRAS protein level in MDA-MB-436 cells over-
expressing miR-30c, in comparison to control (Figure 26D). 
 
 
 
Figure 25. Correlation of expression of miR-30c and KRAS in two breast cancer cell lines. Inverse correlation 
between the expression level of miR-30 determine by qRT-PCR (A) and detection of KRAS protein in MCF7 
and MDA-MB-436 cells (B). 
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2.5. miR-30c affects breast cancer cell proliferation  
To gain more insight into the biological effects of miR-30c on breast tumorigenesis given that 
KRAS plays a role in regulation of cell proliferation, we transfected MDA-MB-436 cells, which 
previously showed elevated levels of KRAS protein, with pre-miR-30c or scramble control and 
analyzed the cell growth by MTT assay. As shown in Figure 15E, ectopic expression of miR-30c 
resulted in reduced proliferation in comparison to scramble control transfected cells. Therefore, 
modulation of KRAS protein level by miR-30c may explain at least in part, how down-regulation of 
miR-30c can promote proliferation and contribute to tumorigenesis. 
 
 
 
Figure 26. miR-30c effects on KRAS expression and cell proliferation. A) Schematic representation of miR-30c 
binding site within the KRAS 3’UTR region. B) Luciferase activity of a reporter construct carrying the KRAS 
3’UTR downstream of the luciferase gene. The construct was co-transfected with pre-miR-30c or scramble 
control in MDA-MB-436 cells. C) KRAS expression at transcription level. Significant reduced level of KRAS 
mRNA expression was detected by qRT-PCR after pre-miR-30c transfection, comparing with scramble control. 
D) Regulation of KRAS protein level by miR-30c. MDA-MB-436 cells were transfected with pre-miR-30c or 
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pre-miR-scramble oligonucleotides. After 48 hours KRAS protein was evaluated by western blot. GAPDH was 
used as loading control. The signal in each line was quantified and the ratio of KRAS to GAPDH was 
determined. E) Effect of miR-30c expression on proliferation of MDA-MB-436 cells. MTT cell viability assay 
was performed at 48, 72, 96, 120 or 144 hours after transfection of MDA-MB-436 cells with pre-miR-30c or 
pre-miR-scramble oligonucleotides. 
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 RESULTS PART III  
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3. MIRNA EXPRESSION PROFILING OF BREAST TISSUE SAMPLES 
The objective of the third part of the study was to characterize hereditary breast tumors based on 
their miRNA expression profiles. To this end, we performed global miRNA expression analysis of 
more than 800 human miRNA genes   in a large series of 80 FFPE breast tissue samples. The series 
included 66 hereditary breast primary tumors from 13 BRCA1 mutation carriers, 10 BRCA2 mutation 
carriers and 43 non-BRCA12 tumors denominated hereafter as BRCAX tumors. In addition we have 
analyzed 10 sporadic breast carcinomas and 6 normal breast tissues obtained after breast reduction 
surgery from healthy donors with no family history of breast cancer. To avoid contamination with 
normal breast tissue, tumoral area on FFPE blocks was marked by a pathologist and macrodissected 
for subsequent total RNA extraction. Histopathological characteristics (ER, PR, HER2, EGFR, CK5, 
Ki-67), tumor subtype and age at diagnosis of BRCA1, BRCA2 and BRCAX tumors in this series 
(Table 6) are fully representative to what has been reported in literature. However our series has 
higher proportion of high grade tumors among BRCAX cases to what has been reported previously, 
potentially due to stringent ascertainment criteria for selection of hereditary breast tumor applied in 
this series.  
3.1. Unsupervised hierarchical clustering of all breast tissue samples 
Specific miRNA profiles have been associated to different tumor types (Lu et al., 2005) and it 
has been documented that miRNAs can discriminate between molecular subgroups and 
histopathological features in sporadic breast cancer. To assess whether there are differences in 
miRNA expression profiles between different groups, namely BRCA1 and BRCA2 mutated and non-
BRCA1/2 hereditary breast tumors, sporadic breast carcinomas and normal breast tissue, we 
performed an unsupervised hierarchical clustering analysis. After removing gene patterns containing 
missing values, an additional filter procedure was applied eliminating miRNAs with uniformly low 
expression (log2<6.5) or with low expression variation across the experiments (V<0.1), retaining 444 
miRNA genes. Unsupervised hierarchical clustering over 444 miRNAs, applied to the whole series of 
breast tissues demonstrated clear separation of different tumor groups. Strikingly, BRCA1 and 
BRCA2 tumors were clustered together in a homogenous group separated from BRCAX and sporadic 
tumors, and apart from normal breast tissue. Furthermore, both sporadic breast tumors and normal 
breast tissues were maintained as two homogenous groups, while BRCAX tumors exhibited 
heterogeneous miRNA expression profiles (Figure 27).  
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Table 6. Summary of clinico-pathological characteristics for familial breast tumors      BRCA1   BRCA2   BRCAX 
Total No. n=13   n=10   n=43     n   %    n   %    n   %  
Age at diagnosis 9   6   40   mean 40.33   42.5   47.75   range 28-55   35-56   25-95 
Lymph Node 13   10   37   positive 5 50%   4 57.10%   18 48.60%   negative 5 50%   3 42.90%   17 51.40% 
Grade  12   10   43   1 0 0%   2 20%   4 9.30%   2 1 8.30%   3 30%   20 48.80%   3 11 91.70%   5 50%   17 41.50% 
Estrogen Receptor  13   10   37   positive 2 15.40%   7 70%   18 48.60%   negative 11 84.60%   3 30%   19 51.40% 
Progesteron Receptor 12   10   38   positive 2 15.40%   7 70%   14 36.80%   negative 11 84.60%   3 30%   24 63.20% 
HER2 13   10   38   positive 0 0%   2 20%   9 23.70%   negative 13 100%   8 80%   29 76.30% 
EGFR 13   8   38   positive 6 46.20%   0 20%   1 23.70%   negative 7 53.80%   8 100%   37 97.40% 
p53 12   6   31   positive 7 58.30%   2 33.30%   10 32.30%   negative 5 41.70%   4 66.70%   21 67.70% 
CK5 13   10   38   positive 9 69.20%   1 14.30%   4 14.80%   negative 4 30.80%   6 85.70%   23 85.20% 
Ki-67 13   7   31   1  0-5%  4 30.80%   3 42.90%   15 48.30%   2  6-25%  5 23.10%   2 28.60%   11 35.50%   3  >25%  4 30.80%   2 28.60%   5 21.60% 
Subtype 13   10   35   Luminal A 2 15.40%   6 60%   13 37.10%   Luminal B  0 0%   2 20%   6 17.10%   HER2  0 0%   0 0%   3 8.60%   Triple Negative  11 84.60%   2 20%   13 37.10% Breast cancer cases were classified into four subtypes based on IHC-model Tang P. et al, 2009. 
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Figure 27. Heatmap showing unsupervised hierarchical clustering (average linkage clustering, Pearson 
correlation coefficient, median centered) of 80 FFPE breast samples over 444 miRNAs. BRCA1-mutated 
samples are marked in blue, BRCA2-mutated in purple, BRCAX in black, sporadic breast tumors in green and 
normal breast tissues in yellow. Heatmap is representing miRNA expression in red-black green pseudo scale. 
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3.2. miRNA molecular profiles in hereditary breast tumors 
Unsupervised hierarchical clustering of 66 hereditary breast tumors (Figure 28) was performed 
over 444 miRNAs that were retained after filtering out miRNAs with low expression variation (VAR 
<0.1)  and low expression (log2 <6.5). Clustering analysis revealed very heterogeneous miRNA 
profiles among hereditary breast tumors that were separated in two main branches with contrasting 
miRNA expression profiles. This bi-partition correlates with the tumor grade with the left branch, 
consisted almost exclusively of BRCAX tumors, being predominantly low and moderate grade 
tumors, while the right branch, is consisted of mainly high grade tumors. The right branch was further 
partitioned in two sub-branches; one consisted exclusively of BRCA1 and BRCA2 tumors, and the 
other mainly of BRCAX tumors and two BRCA1 samples. It is been well documented that breast 
tumors can be classified into four stable molecular subtypes by mRNA profiling, with the most 
prominent discriminators being ER, HER2 and tumor differentiation. Interestingly, the partitioning 
based on miRNA expression is not mainly driven by ER status. We observed clustering of HER2 
positive tumors, while triple negative (ER-, PR- and HER-) tumors were dispersed across the cluster.  
Unsupervised clustering of hereditary breast tumors over 444 miRNA genes (v>0.1)  showed that 
BRCA1 and BRCA2 tumors clustered in the same sub-branch representing a homogenous group with 
very similar miRNA expression profiles, and clearly separated from the BRCAX tumors. Of note, two 
out of tree BRCA1 outliers were ER positive tumors and both BRCA2 tumors that do not cluster in 
the “BRCA” group were the only two of luminal B subtype (ER+, PR+, HER2+). BRCAX tumors 
were separated into two branches with heterogeneous miRNA expression profiles that demarcate 
several subgroups.  One group of BRCAX samples was clustering along BRCA1 and BRCA2 mutated 
tumors, while samples in other branch had markedly different miRNA expression profile.  
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Figure 28.  Unsupervised hierarchical clustering (average linkage clustering, Pearson correlation coefficient, 
median centered) of 66 hereditary breast tumors including 13 BRCA1 (blue), 10 BRCA2 (purple) and 43 
BRCAX (black) over 444 miRNAs (v>0.1). Immunohistochemistry markers (pathology report or tissue 
microarray) for ER, PR and HER2, as well as tumor grade are represented. In such cases where the pathology 
report and TMA results were discrepant, the pathology report was used. 
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3.3.  miRNAs differentially expressed between breast tumor groups 
In order to find miRNAs discriminating between different genetic subgroups we performed 
differential expression analysis applying limma t-test, with significance threshold set to 5% after 
correction for multiple testing by Benjamini and Hoceberg method. The analysis revealed a large 
number of differentially expressed miRNAs between most classes compared. The results are 
summarized in Table 7. Importantly, a large number of miRNAs (151) was found to be differentially 
expressed between BRCA1/2 mutated tumors and both BRCAX and sporadic breast tumors, as well 
as between BRCA1/2 mutated and BRCAX tumors (150), or sporadic (138), respectively. 
Surprisingly, no miRNA genes were significantly differentially expressed between BRCA1 and 
BRCA2 mutated tumors, in contrast to what has been observed by gene expression profiling [13]. 
Only two miRNAs, miR-125a and miR-7, had significant unadjusted p-values, but after correction for 
multiple testing this significance was lost. Hereditary tumors a whole had much less differentially 
expressed miRNAs (38). In addition; only 22 miRNAs were differentially expressed between BRCAX 
hereditary breast tumors and sporadic tumors, suggesting higher similarity of miRNA expression 
profiles between BRCAX and sporadic breast tumors. However, due to high heterogeneity of BRCAX 
tumors some differences might be hindered in the analysis. 
 
Table 7. Summary of differentially expressed miRNAs (FDR adjusted p-value <0.05) by limma t-test 
analysis  between breast carcinomas with different BRCA1/2 status 
TUMOR 
TYPE 
TUMOR TYPE 
COMPARED 
TO 
Upregulated 
miRNAs 
Downregulated 
miRNAs 
Total differentially 
expressed miRNAs 
BRCA1 and 
BRCA2 BRCAX 63 87 150 
BRCA1 BRCAX 55 71 126 
BRCA2 BRCAX 38 41 79 
BRCA1 BRCA2 0  0* 
*2 miRNAs with 
unadjusted p-value <0.05  
HEREDITARY SPORADIC 6 32 38 
BRCA1 and 
BRCA2 SPORADIC 44 94 138 
BRCA1 SPORADIC 43 82 125 
BRCA2 SPORADIC 36 67 103 
BRCAX SPORADIC 2 20 22 
BRCA1 and 
BRCA2 
BRCAX and 
SPORADIC 62 89 151 
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Among miRNAs differentiating between BRCA1/2, BRCAX and sporadic tumors, large fraction 
of miRNAs exhibited a gradual change in their expression levels between the groups, in the formerly 
specified order. This was manifested in a large overlap between miRNAs differentiating between 
BRCA1/2 tumors vs. both BRCAX and sporadic, or just BRCAX tumors as represented in the Venn 
diagram (Figure 29), and those differentiating BRCAX tumors from sporadic ones, indicating that 
only few miRNAs can serve as specific markers for each subgroup. 
 
Figure 29.Venn diagram representing overlap of miRNA genes differentially expressed between different 
subtypes of breast tumors. miRNAs differentially expressed between BRCA1/2 tumors vs. both BRVCAX and 
sporadic breast tumors are represented in blue circle, those differentially expressed between BRCA1/2 tumors 
and BRCAX are in green, and the ones differentially expressed between BRCAX tumors and sporadic breast 
carcinomas in yellow. 
 
Supervised clustering  over  151  miRNA genes found to be differentially expressed between 
tumors harboring mutation in either BRCA1 or BRCA2 gene, and non-BRCA1/2 and sporadic tumors 
is represented in Figure 18.  Among 151 miRNAs that were found to be differentially expressed 
between tumors from BRCA mutation-carriers versus non-carriers, 89 miRNAs were downregulated 
and 62 were upregulated in BRCA1/2 tumors, out of which 5 miRNAs were downregulated and 2 
upregulated with higher than 2 fold-change differences in expression.  
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Figure 30.Supervised clustering of breast tumors over 151 miRNAs differentiating between BRCA1 and 
BRCA2 tumors versus BRCAX and sporadic breast tumors. Heatmap representing median centered miRNA 
gene expression in rows, red indicating higher green lower than median expression. Samples are represented in 
columns, BRCA1 tumors in blue, BRCA2 in pink, BRCAX in gray and sporadic in green. 
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3.4. Class discovery algorithms reveal subgroups of BRCAX tumors 
In order to gain more insight into intrinsic characteristics of BRCAX tumors we performed 
unsupervised hierarchical clustering of 43 BRCAX tumor samples over 444 miRNA genes (v>0.1)  
that revealed clear heterogeneity in their miRNA expression profiles (Figure 31A) with several 
apparent subgroups.  Consensus clustering (GenePattern 2.0, Broad Institute) bioinformatic tool has 
been used for class discovery to obtain the most robust classification of BRCAX tumors, by 
reiteration of a selected clustering algorithm (KNN means with 2,3,4,5 centroids) and by assessing the 
stability of discovered clusters. This analysis indicated the existence of 4 different subgroups among 
BRCAX tumors, namely BRCAX- A, -B, -C and -D (Figure 31B and C).  
 
Figure 31. A) Unsupervised hierarchical clustering of 43 BRCAX tumors over 444 miRNAs (v>0.1). B) 
Resampling of the BRCAX series by Consensus Clustering algorithm   (KNN Means, Euclidian distance). Plot 
is showing the change in free energy (ΔGn) with each additional subgroup added, indicating that optimal 
number of clusters within this series is four.  C) Red squares in the consensus matrix are representing subgroups 
of BRCAX tumors in which the samples were more robustly distributed based on their miRNA expression 
profile. Four subgroups of tumors were identified and denominated as BRCAX-A (yellow), BRCAX-B (green), 
BRCAX-C (blue) and BRCAX-D (pink).  
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3.5. miRNA signatures defining BRCAX subgroups 
To further characterize BRCAX subgroups we have selected co-expressed miRNAs with 
correlation coefficient higher than R2>0.77 that best discriminate between the groups (Figure 31 A). 
Three main miRNA clusters were identified namely, Cluster 1 consisting of 62 miRNAs, Cluster 2 
consisting of 48 miRNAs, and Cluster 3 with 73 miRNAs.  Full list of miRNA genes within each 
cluster and their average values in each tumor group are shown in Supplementary Tables 5,6 and 7. 
Supervised clustering of 43 BRCAX tumors according to their subgroup, 23 BRCA1 and 
BRCA2  mutated tumors, 10 sporadic breast tumors and 10 normal breast tissue samples over  180 
miRNAs belonging to miRNA Clusters 1, 2 and 3 is represented in Figure 32. By visual inspection 
we observed lower expression of Cluster 1 and Cluster 2 miRNAs in BRCAX-C group compared to 
normal breast tissue, and higher expression of Cluster 3 miRNAs. This expression profile resembles 
that of BRCA1/2 tumors. In BRCAX-B group we also detect loss of expression of Cluster 2, but not 
of Cluster 1 or Cluster 3 compared to normal breast tissue. BRCAX-A group exhibited a similar 
pattern of expression to that of normal breast tissue. BRCAX-D group lacks any specific miRNA 
signature and in that respect it resembles sporadic breast tumors. 
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Figure 32. Supervised clustering of 43 BRCAX tumors, 23 BRCA1/2-mutated tumors, 10 sporadic breast 
tumors and 10 normal breast tissues over  180 miRNAs belonging to signature miRNA Cluster 1 (62 miRNAs), 
Cluster 2 (48 miRNAs) and Cluster 3 (70 miRNAs). Tumor samples are represented in columns and miRNA 
gene expression in rows in a read-black-green pseudo-color scale. Red corresponds to expression higher than 
media, black equal to median and green lower than median.  
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In order to quantify these observations we have analyzed the expression correlation of BRCAX 
subgroup specific miRNA signature consisting of all tree miRNA Clusters (185 miRNAs), with their 
expression in BRCA1/2 mutated tumor, sporadic breast tumors and normal breast tissues by linear 
regression using standard least-square correlation metrics (Figure 33). Highest correlation in miRNA 
expression for BRCAX-A group was observed with normal breast tissue (R2=0.78). Expression of 
signature miRNAs in BRCAX-B tumors did not correlate with any of the groups compared. BRCAX-
C tumors demonstrated highest correlation in miRNA expression with BRCA1/2 mutated tumors 
(R2=0.0.79), while BRCAX-D tumors had highest correlation in expression to sporadic breast 
carcinomas (R2=0.90). 
 
 
Figure 33. Plot of miRNA expression correlation for 180 miRNAs belonging to   three signature clusters 
(Cluster 1, Cluster 2 and Cluster 3) between BRCAX subgroups (A, B, C and D), BRCA1 and BRCA2 – 
mutated tumors, sporadic breast tumors and normal breast tissue. Highlighted in red are most highly correlated 
expression profiles for each of the subgroups. 
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Table 8. Summary of differentially expressed miRNAs (FDR adjusted p-value <0.05) by 
limma t-test analysis  comparing miRNA expression profiles of BRCAX subgroups to 
normal breast tissue 
TUMOR TYPE 
Up-regulated 
miRNAs 
Down-regulated 
miRNAs 
Total differentially 
expressed miRNAs BRCAX-A 7 7 14 BRCAX-B 1 37 38 BRCAX-C 67 85 152 BRCAX-D 18 56 74 
 
In order to quantify the level miRNA of deregulation within each of BRCAX subgroups we have 
performed differential expression analysis comparing each subgroup to normal breast tissue 
(Supplementary table 5, 6 and 7). Only 14 miRNAs were differentially expressed between BRCAX-
A and normal breast tissue samples, while other BRCAX subgroups demonstrated much greater 
miRNA deregulation, with BRCAX-C having the largest number of deregulated miRNAs (Table 8). 
In addition BRCAX-C tumors had 64 miRNAs specifically deregulated in this subgroup (Figure 
23A), while only two miRNAs, miR-143 and miR-125b, were commonly deregulated in all four 
groups showing low levels of expression within each subgroup (Figure 23B). 
 
 
Figure 34.  A) Venn diagram showing the number of common and specifically deregulated miRNAs in each 
subgroup  B) Bar plot showing expression levels of commonly differentially expressed miRNAs in all BRCAX 
subgroups relative to normal breast tissue  
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3.6. Deregulated miRNA families and clusters 
The identified miRNA Clusters show subtype specific pattern of expression. Both BRCAX-B 
and BRCAX-C subgroups are characterized by loss of expression of miRNA Cluster 2 in comparison 
to normal breast tissue. This miRNA cluster is composed of 48 miRNAs among which are 5 broadly 
conserved miRNA families, including 7 out of 9 known members of let-7 family (let-7a, let7b, let7-c, 
let-7d, let-7f, , let-7g, let-7i),  all know miR-30 family  members (miR-30a, miR-30c, miR-30d, miR-
30b, miR-30e), all miR-15 family members (miR-15a, miR-16, miR-15b, miR-195), 4 out of 5 miR-8 
family members (miR-200b, miR-200c, miR-200a, miR-141) and all miR-29 family members (miR-
29a, miR-29b, miR-29c),  in addition to miR-125b and miR-143. Interestingly, miR-8 family is 
upregulated in BRCAX-A tumors, and downregulated in BRCAX-C and BRCAX-B subgroup. Within 
miRNA Cluster 1, which was specifically downregulated in BRCAX-C tumors, we observed an 
enrichment of very large miRNA cluster located at 19q13.41-42 consisted of 9  primate-specific 
miRNAs (miR-99b*, miR-373, miR-517c, miR-519c-3p, miR-519d, miR-520d-3p, miR-520h, miR-
522 and miR-526b). Members of the miRNA Cluster 3, overexpressed specifically in BRCAX-C 
group, included 6 out of 11 members of the primate-specific miR-506 family (miR-508-5p, miR-509-
3-5p, miR-510, miR-513b, miR-509-5p, miR-513a-5p) located at a very large miRNA cluster at 
chromosome Xq27.3 region, and miR-154 family members (miR-381, miR-323-3p and miR-494)  and 
miR-299-3p  located at miRNA cluster at 14q32.31.  
Full list of miRNAs within each Cluster, their genomic location, FDR-corrected p-values and 
fold change in expression comparing to normal breast tissue within each tumor group is represented in 
Supplementary Tables 5, 6 and 7. 
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3.7. Pathway enrichment analysis of miRNA cluster target genes 
Each miRNA is predicted to regulate a large number of genes, and each gene can be a target of 
many different miRNAs. To determine the potential biological impact of differential expression of 
these miRNA clusters between BRCAX subgroups we south to identify their target genes and 
associated pathways. Available target prediction algorithms have high false positive rates which, 
given the large number of miRNAs per cluster, gave unreasonably high number of potential target 
genes (several thousands) hindering any pathway enrichment analysis. Therefore we have focused our 
analysis only on confirmed miRNA targets. For each miRNA in a cluster we have compiled a list of 
experimentally validated target genes from TarBase (http://diana.cslab.ece.ntua.gr/tarbase)(Vergoulis 
et al.) , miRTarBase (http://mirtarbase.mbc.nctu.edu.tw), miRecords (http://mirecords.biolead.org) 
and Ingenuity Systems Knowledge database (http://www.ingenuity.com). We performed gene-set 
enrichment analysis  to highlight the most relevant Gene Ontology (GO) terms associated with a given 
gene list of mRNA targets within each miRNA cluster, using DAVID 6.7 bioinformatic algorithm 
(http://david.abcc.ncifcrf.gov)  (Huang da et al., 2009).  Top 10 statistically significant GO functional 
categories enriched in each dataset are represented in Table 9. Analysis of target genes for miRNA 
Cluster 2 revealed enrichment in terms related to cell death regulation, cell cycle regulation, and cell 
proliferation. This miRNA cluster is commonly downregulated in BRCAX-B and BRCAX-C group 
implying that their target genes are upregulated.  Cluster 1 miRNA target genes were significantly 
associated in addition to regulation of cell proliferation and cell death, to regulation of cell motility 
and migration. This miRNA cluster is specifically lost in BRCAX-C tumors, suggesting that the 
mRNA targets would be upregulated.  Target genes for miRNA Cluster 3, upregulated in BRCAX-C 
group, showed most significant association to functional terms related to regulation of cell cycle, 
protein kinase activity and biosynthesis of macromolecules.   
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Table 9. Top 10 significant GO terms enriched in miRNA Clusters 
 
 Cluster 1 GO Term FDR  
1 regulation of programmed cell death 3.8636E-12 
2 regulation of cell death 4.6296E-12 
3 regulation of apoptosis 6.5259E-11 
4 positive regulation of cell motion 7.1054E-11 
5 regulation of cell proliferation 6.8739E-10 
6 regulation of cell motion 9.2683E-10 
7 positive regulation of cell migration 3.6592E-09 
8 positive regulation of locomotion 1.5643E-08 
9 regulation of cell migration 6.5907E-08 
10 regulation of locomotion 6.7346E-08 
      
Cluster 2 GO Term FDR  
1 regulation of cell proliferation 2.3163E-23 
2 positive regulation of macromolecule metabolic process 1.2576E-18 
3 regulation of programmed cell death 7.4208E-17 
4 regulation of cell death 9.7426E-17 
5 regulation of apoptosis 3.6393E-16 
6 positive regulation of developmental process 6.7366E-15 
7 regulation of phosphate metabolic process 1.2121E-14 
8 regulation of phosphorus metabolic process 1.2121E-14 
9 positive regulation of macromolecule biosynthetic process 1.4034E-14 
10 organelle lumen 1.5989E-14 
      
Cluster 3 GO Term FDR  
1 regulation of cell cycle 1.3737E-05 
2 positive regulation of macromolecule biosynthetic process 0.00039839 
3 positive regulation of cellular biosynthetic process 0.00061206 
4 positive regulation of biosynthetic process 0.00069981 
5 positive regulation of nitrogen compound metabolic process 0.00393855 
6 positive regulation of macromolecule metabolic process 0.00474381 
7 regulation of protein kinase activity 0.00578571 
8 transmembrane receptor protein tyrosine kinase signaling pathway 0.006535 
9 regulation of kinase activity 0.00725011 
10 regulation of transferase activity 0.00950461 
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3.8. Histopathological characteristics of BRCAX subgroups 
It is well known that histology of BRCA1 and BRCA2 tumors differs from that of both BRCAX 
and sporadic tumors.  Given that here identified BRCAX subgroups have specific miRNA signatures 
associated to different cellular functions, we wanted to examine whether any differences were present 
between subgroups on histological level. In order to test for the homogeneity of distribution of 
imunochistochemical markers for ER, PR, HER2, Ki-67; tumor grade and molecular subtype between 
subgroups of BRCAX tumors we used Fisher’s exact test. No significant differences were found in 
the distribution of ER or PR markers, while there were significant differences in expression of HER2 
and molecular subtype between different BRCAX subgroups (Figure 4). BRCAX-A tumors are 
significantly enriched for HER2 positive tumors (P=0.008) and have significantly higher proportion of 
Luminal B subtype (P=0.004). Of note, BRCAX-A tumors are clustering along other HER2 positive 
tumors in the unsupervised analysis (Figure 19) Furthermore, BRCAX-A tumors are significantly of 
lower grade tumors (only of grade 1 and grade 2) in comparison to other BRCAX subgroups.  
Although not reaching statistical significance, it is worth noticing that BRCAX-C tumors are 
consisted exclusively of grade 2 and grade 3 (Table 10) and are associated to lymph node positive 
tumors (P=0.075), while BRCAX-A tumors tend to be lymph node negative (P=0.088). 
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Table 10. Clinico-pathological data for BRCAX hereditary breast tumors by subtype 
    BRCAX-A   BRCAX-B   BRCAX-C   BRCAX-D     
Total No. n=8   n=5   n=13   n=17   P1 P2 P3 P4   
    n  %   n  %   n  %   n  %             
                                      
Age at diagnosis 7   5   12   16   NS NS NS NS   
  mean 44.71   46.60   47.25   49.81             
  range 31-54   26-64   33-68   25-95             
                                      
Grade  7   5   12   17   0.031 NS NS NS   
  1 1 14.3%   1 20.0%   0 .0%   2 11.8%             
  2 6 85.7%   2 40.0%   5 41.7%   7 41.2%             
  3 0 .0%   2 40.0%   7 58.3%   8 47.1%             
                                      
Estrogen 
Receptor  4   4   12   17   NS NS NS NS   
  positive 3 75.0%   2 50.0%   4 33.3%   9 52.9%             
  negative 1 25.0%   2 50.0%   8 66.7%   8 47.1%             
                                      
Progesteron 
Receptor 4   4   13   17   NS NS NS NS   
  positive 1 25.0%   1 25.0%   4 30.8%   8 47.1%             
  negative 3 75.0%   3 75.0%   9 69.2%   9 52.9%             
                                      
HER2 5   5   13   15   0.008 NS NS NS   
  positive 4 80.0%   1 20.0%   1 7.7%   3 20.0%             
  negative 1 20.0%   4 80.0%   12 92.3%   12 80.0%             
                                      
Subtype 3   4   13   15   0.004 NS NS NS   
  Luminal A 0 .0%   2 50.0%   4 30.8%   7 46.7%             
  Luminal B  3 100%   0 .0%   1 7.7%   2 13.3%             
  HER2  0 .0%   1 25.0%   1 7.7%   1 6.7%             
  Triple Negative  0 .0%   1 25.0%   7 53.8%   5 33.3%             
                                      
Lymph Node 6   3   12   14   0.088 NS 0.075 NS   
  positive 1 16.7%   2 66.7%   9 75.0%   6 42.9%             
  negative 5 83.3%   1 33.3%   3 25.0%   8 57.1%             
                                      
Only P-values<0.1 obtained by two sided Fisher's exact test are represented, with significant p-values (<0.05) in bold letters, NS=not 
significant.  P1= BRCAX-A vs rest,  P2= BRCAX-B vs rest, P3= BRCAX-C vs rest, P4=BRCAX-D vs rest. Differences in mean age at 
diagnos were compared by student t-test. 
 DISCUSSION 
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1. BRCA1 MEDIATED REGULATION OF MICRORNAS AND 
RELATED PATHWAYS 
Central role of BRCA1 deregulation in the pathogenesis of both hereditary breast and ovarian 
cancer is well documented, and versatile BRCA1 functions have been demonstrated so far (Bertwistle 
and Ashworth, 1999; Starita and Parvin, 2003) including DNA damage repair/recombination, cell 
cycle control (Deng, 2006), chromatin remodeling and ubiquitylation (Huen et al., 2010) and 
regulation of both transcriptional activation and repression (Cable et al., 2003; Chapman and Verma, 
1996). Previous studies using large scale genomic approaches have identified relevant genes 
important for tumorigenesis in relation to BRCA1 expression (Andrews et al., 2002; Furuta et al., 
2006; Harkin et al., 1999; Hartman and Ford, 2002; Lamber et al., 2010; MacLachlan et al., 2000; 
MacLachlan et al., 2002). However, no studies so far have looked into BRCA1 mediated regulation of 
miRNA expression.  
miRNAs play critical roles in control of various biological processes and are extensively 
implicated in cancer pathogenesis (Croce, 2009; Lima et al., 2011; Lu et al., 2005; Schmittgen, 2008; 
Thomson et al., 2006). Individual miRNAs can have multiple targets, and each mRNA may be 
regulated by multiple miRNAs. Still, due to the scarcity of experimentally validated miRNA target 
genes, much remains to be discovered about the cellular circuits controlled by miRNAs and their 
biological role. The combined effects of a miRNA on multiple targets emphasize the need to examine 
the net result of the complex modulation of multiple targets belonging to multiple pathways. 
The first objective of this thesis was to identify miRNAs and miRNA-mRNA networks 
dependent on BRCA1 expression, by performing an integration analysis of genome-wide miRNA and 
gene expression data, in isogenic breast cancer cell lines differing in BRCA1 expression status. By 
applying functional studies we south to establish miRNA regulation of new genes and pathways that 
might be important in BRCA1 related breast tumors. 
1.1. BRCA1-modulated miRNA and gene transcriptional profiles 
Whole genome transcriptional profiling covering >45,000 mRNA sequences and global miRNA 
expression profiling with >800 human miRNAs was performed on a BRCA1 deficient, HCC1937 
breast cancer cell line, and the isogenic HCC1937 stably expressing wt BRCA1. Reconstitution of 
BRCA1 expression in BRCA1-null cells had profound impact on gene expression, with a large 
number of genes being regulated representing 29% of the analyzed transcripts. These findings are in 
line with previously published results showing that depletion of BRCA1 induces large changes in 
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transcriptional profile (Horwitz et al., 2007; Horwitz et al., 2006; Lamber et al., 2010). It is known 
that BRCA1 can modulate gene expression by acting as a transcriptional co-factor. Still, the observed 
shift in gene expression could be also due to indirect effects of BRCA1, including potential gene 
expression regulation by miRNAs. Although BRCA1 reconstitution modulated approximately one 
third of genes, only 1% of analyzed miRNAs exhibited significant changes in expression, indicating 
more subtle effects. 
Among miRNAs that were found to be upregulated upon BRCA1 reconstitution were miR-146a 
and miR-146b. These miRNAs were previously reported to regulate the expression of BRCA1 
indicating an existence of a negative feedback loop (Shen et al., 2008).  In addition, in silico 
predictions show a widely conserved binding site within BRCA1 3’UTR for miR-205, which was also 
significantly upregulated upon BRCA1 reconstitution. The mechanisms by which BRCA1 may induce 
the expression of miRNAs could be either through direct or indirect effects, and must be explored in 
further studies. 
1.2.  BRCA1 modulated miRNA-mRNA networks and related pathways 
One of the challenges in interpretation of miRNA profiling data is the identification of miRNA 
target genes due to large percentage of false positive and false negative results provided by available 
target prediction algorithms (Alexiou et al., 2009; Maziere and Enright, 2007). Therefore, integrative 
studies trying to establish correlative relationships between miRNAs and mRNA expression would 
improve our understanding of the role of miRNAs in control of biological networks in cancer. Some 
studies have tried to jointly analyze miRNA expression data with its matching mRNA data to better 
understand the role of miRNA in breast cancer pathogenesis and progression (Blenkiron et al., 2007). 
In addition, integration of miRNA and mRNA expression data has been useful to establish an 
important role for miRNAs in regulating particular cellular processes such as proliferation, cell 
adhesion or immune response in primary breast cancer (Enerly et al., 2011). 
We have performed integration analysis based on non-random association of miRNAs with their 
negatively correlated predicted target genes in an effort to identify statistically significant miRNA 
target genes relevant to our dataset. This approach revealed that several differentially expressed 
miRNAs (miR-99b, miR-146a, miR-146b) significantly associated to down-regulated mRNA targets. 
Gene set enrichment analysis allowed us to obtain an overview of key pathways likely to be 
modulated by BRCA1, among which were NF-κB, JNK and p38/MAPK pathways. Increased 
activation of MAPK/JNK in the BRCA1-null cell line was validated by in vitro pathway reporter 
assay, confirming at least in part the bioinformatic predictions.  
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The MAPK pathways are major signal transduction pathways that have been implicated in 
mammary epithelial cells and breast disease (Hori et al., 2000; Whyte et al., 2009). Increased 
activation of MAPK/JNK and MAPK/ERK in BRCA1-deficient cells is consistent with higher 
proliferation rates exhibited by these cells. NF-κB is a transcription factor that promotes the 
expression of genes involved in inflammatory and anti-apoptotic response (Baldwin, 1996; Beg and 
Baltimore, 1996; Van Antwerp et al., 1996; Wang et al., 1996). It has been demonstrated that NF-κB 
plays a critical role in development and progression of breast cancer (Madhusoodhanan et al., 2009; 
Zhou et al., 2008; Zhou et al., 2005). Furthermore, it has been proposed that BRCA1 acts as a co-
activator of NF-κB (Benezra et al., 2003). Interestingly, it has been previously reported that miR-
146a/b acts as a negative regulator of constitutive NF-κB activity in breast cancer setting (Bhaumik et 
al., 2008). In addition, NF-κB dependent induction of miR-146a/b has been established, that along 
with miR-146 negative regulation of IRAK1 and TRAF6, constitutes a negative-feedback loop that 
controls the activity of NF-κB pathway (Taganov et al., 2006).   
1.3. NF-κB pathway activity is modulated by miR-146a/b 
In support of the aforementioned findings, we have demonstrated that miR-146a/b along with 
newly identified miR-99b and miR-205 can modulate NF-κB pathway activation, while MAPK/ERK 
can be modulated only by miR-146a. On the other hand, individually none of these miRNAs were 
sufficient to modulate MAPK/JNK pathway whose activity was increased in BRCA1-null cells.  This 
result could be explained by diverse and/or contrasting functions of many target genes for each 
individual miRNA, emphasizing the notion that different combinations of deregulated miRNAs could 
have very different biological outputs. 
Consistent with the bioinformatic predictions, we have shown that TRAF2 had higher expression 
in BRCA1-null cells. Moreover, overexpression of genes related to immune response, including 
TRAF2 gene, is one of the intrinsic characteristics of in ER-negative BRCA1-mutated tumors 
(Fernandez-Ramires et al., 2009). Numerous studies have implicated TRAF2 as a critical mediator of 
NF-κB (Arch and Thompson, 1998; Duckett et al., 1997; Hsu et al., 1996; Reinhard et al., 1997; 
Rothe et al., 1995; Takeuchi et al., 1996), JNK and p38 activation (Liu et al., 1996; Natoli et al., 1997; 
Reinhard et al., 1997) and it has been reported that overexpressed native TRAF2 can activate JNK, 
p38 and NF-κB in the absence of extracellular stimuli (Cao et al., 1996; Liu et al., 1996; Rothe et al., 
1995; Song et al., 1997). Up-regulation of TRAF2 expression in BRCA1-deficient cells due to release 
of negative regulation by miR-146a/b, miR-99 and miR-205 could contribute to NF-κB and MAPK 
pathway activation. Significantly, further validation of microarray results in the cell model, showing 
the down-regulation of miRNAs in HCC1937 BRCA1-null cells, came from our finding that three of 
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these miRNAs, miR-99a, miR-146b and miR-205, were also down-regulated in BRCA1-mutated 
primary breast tumors. 
 
 
Figure 35. miRNA-gene network of NFkB pathway regulation 
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2. MIRNA DEREGULATION IN HEREDITARY BREAST CANCER  
miRNA profiling studies in various tumor types have demonstrated a widespread miRNA 
deregulation, providing for new insights in tumor biology and opening new avenues for development 
of novel targeted therapies in cancer (Lujambio and Lowe, 2012). In the second study we have looked 
into the miRNA molecular profiles altered in hereditary breast tumors in comparison to normal breast 
tissue. The normal breast tissue series was obtained from healthy individuals, both from BRCA1/2- 
mutation carriers belonging to high risk families, and from mutation-free individuals undergoing 
breast reduction surgery. This has enabled us to pinpoint miRNAs important for tumorigenesis, by 
removing the bias induced through effects of BRCA1/2 mutation on miRNA expression. We have 
defined down-regulation for 17 miRNAs and up-regulation of miR-21 and miR-300 in hereditary 
breast tumors in comparison to normal breast tissue.  
It was expected that comparing tumor samples with normal tissue, characterized by largely 
quiescent cells, would uncover miRNAs that may be mainly involved in proliferation. Expression 
analysis of the 19 differentially expressed miRNAs in HMEC cells, which represent normal 
proliferating cells, have allowed finding some miRNAs overexpressed in normal tissues that were not 
overexpressed in normal HMEC cells, such as miR-99a, miR-101 or miR-145, which could have a 
role in the control of proliferation processes in general. Other miRNAs expressed by both HMEC and 
normal breast and down-regulated in tumors tissue may be involved in other signaling pathways 
related to tumoral behavior.  
2.1. Commonly deregulated miRNAs in hereditary and sporadic breast 
carcinomas 
A high proportion of deregulated miRNAs in hereditary tumors were commonly found in 
previous studies with sporadic breast tumors, suggesting that there are miRNAs that likely regulate 
important oncogenes and tumor suppressor genes involved in both hereditary and sporadic tumor 
progression, irrespective of their genetic background or molecular subtype (Iorio et al., 2005; Volinia 
et al., 2006). These included miR-21, let-7a, miR-125b, miR-10b, miR-100, miR-101, miR-143, miR-
145, miR-205 and miR-210. We shall discuss functional roles for some of them more in detail. 
The let-7 family of 12 miRNAs is often cited as the archetypal tumor- suppressing miRNA. Let-7 
is essential for cell type determination during embryogenesis in C. elegans and in the adult human 
(Reinhart et al., 2000). Its expression is highest in terminally differentiated epithelial tissues. Let-7 
expression is lost at an early stage in breast cancer progression (Sempere et al., 2007), and continued 
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expression is associated with low-grade, ER-positive, luminal A tumours (Blenkiron et al., 2007). Let-
7 is downregulated in subpopulations of murine breast cells with stem-like properties (Ibarra et al., 
2007), and during epithelial to mesenchymal transition (EMT) (Dangi-Garimella et al., 2009). Several 
functional targets of let-7 have been identified, including the classical proto-oncogene RAS (Johnson 
et al., 2005), and the oncofoetal proteins HMGA2 (Mayr et al., 2007) and IMP-1 (Boyerinas et al., 
2008). The manipulation of let-7 levels in breast cancer cell lines affects proliferation and metastasis, 
and both H-RAS and HMGA2 are involved in these responses (Yu et al., 2007). 
miR-21 was one of the first oncogenic miRs to be characterized, being upregulated in numerous 
tumors, including breast cancer (Iorio et al., 2005). Overall, miR-21 expression in breast tumors 
correlates with advanced stage, and metastasis, and with poor survival independently of grade and 
stage (Huang et al., 2009; Yan et al., 2008). Knockdown of miR-21 inhibits MCF7-derived tumor 
growth in xenograft models via reduced proliferation and increased apoptosis (Si et al., 2007). 
Validated miR-21 targets include tropomyosin 1 (TPM1), which suppresses anchorage-independent 
growth in vitro (Zhu et al., 2007), programmed cell death 4 (PDCD4), (Lu et al., 2008; Frankel et al., 
2008), and maspin, a tumor suppressing serpin protein (Zhu et al., 2008). miR-21 also targets the 
tumor suppressor PTEN in hepatocellular carcinoma, and there is a correlation between miR-21 
expression and loss of PTEN expression in breast cancer (Huang et al., 2009).  
Similarly, miR-125b, which was identified early in the development of the field as being 
downregulated in breast tumors (Iorio et al., 2005),  is located at chromosome 11q23-24, one of the 
regions most frequently deleted in breast, ovarian, and lung tumors (Negrini et al., 1995). miR-125 
suppresses cell growth and favors apoptosis in breast cancer cell lines via targeting of HuR (Guo et 
al., 2009), itself an independent prognostic marker in breast cancer (Heinonen et al., 2005). It also 
suppresses the growth of HER2-dependent SKBR3 cells when artificially over-expressed, via the 
targeting of HER2 and HER3 (Scott et al., 2007). Finally, miR-125b has also been shown to target the 
tumor-associated protein CYP24, which metabolizes antiproliferative calcitriol (Komagata et al., 2009 
In the normal breast expression of miR-205 is restricted to basal epithelium (Sempere et al., 
2007). Its expression is generally lost early in breast cancer progression, but persistent (albeit 
lowered) expression is linked to the presence of basal immunohistochemical markers. Within 
ER/PR/HER2-negative tumors, loss of miR-205 is a poor prognostic indicator (Sempere et al., 2007). 
miR-205 is downregulated in EMT, along with the miR-200 family, and like miR-200 targets both 
ZEB1 and ZEB2 (Gregory et al., 2008). It also targets HER3, which co-operates in the mitogenic 
HER2 pathway (Iorio et al., 2009), and miR-205 overexpression both reduces proliferation in cell 
culture, and increases sensitivity to tyrosine kinase inhibitors. Another study showed that miR-205 
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suppresses lung metastasis in an animal model, and implicates HER3 and VEGF-A (Wu et al., 
2009a,b).  
miRNAs can function both as oncogenes or tumor suppressor via negative inhibition of tumor 
suppressor genes or oncogenes in pathways that control cellular differentiation, proliferation or 
apoptosis. All these findings overwhelmingly implicate the let-7 family, miR-205, miR-125b as a 
tumor-suppressive miRNAs in breast setting, while in general, miR-21 up-regulation is considered to 
be a common feature of proliferative tissues. 
2.2. Analysis of miRNA- associated pathways  
Moreover, the pathway enrichment analysis suggested that miRNAs co-expressed in our series, 
seem to collectively target a broad range of signaling pathways related to proliferation and cell 
migration/motility. Altered cell signaling has long been recognized as a mechanism employed by cells 
in the development and progression of cancer (Hanahan and Weinberg, 2000).  
Importantly, 20 genes within MAPK signaling pathway were significantly associated with our set 
of deregulated miRNAs, suggesting that the inhibition of these miRNAs would result in a concomitant 
activation of MAPK signaling.  In breast cancer, MAPKs play a key role in transducing growth 
signals from the extracellular environment (Dunn et al., 2005; Haagenson and Wu, 2010). The 
activation of the KRAS/MAPK pathway generates a plethora of responses in breast cancer tumors and 
cell lines, affecting cell growth, proliferation, differentiation and transformation (Atanaskova et al., 
2002). In breast cancer development, up-regulation of the KRAS/MAPK signaling can occur through 
multiple facets, and it has been shown to be increased in many breast cancer samples either by over-
expression of growth-factor-receptor tyrosine kinases primarily HER2/ErbB-2, EGFR, and IGFR or 
by activating mutations (Eckert et al., 2004; Lo et al., 2006; McCubrey et al., 2007; Salh et al., 1999). 
Although KRAS is frequently mutated in human cancers including pancreatic, colorectal and lung 
cancers, KRAS mutations are very rare in breast cancer (Clark and Der, 1995; Koffa et al., 1994). 
However wild-type KRAS is significantly activated in breast cancers that over-express EGFR and 
HER2 (von Lintig et al., 2000). Additionally many investigators have reported over-expression of the 
KRAS-encoded p21 proteins in breast malignancies in comparison to normal breast tissue (Agnantis 
et al., 1994; Spandidos, 1987) although the role of this over-expression in breast carcinogenesis has 
not been determined. 
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2.3. KRAS oncogene is a target of miR-30c in breast cancer  
Interestingly, KRAS was found to be a target of multiple miRNAs found to be down-regulated in 
breast tumors. The let-7 family of miRNAs has been shown to regulate multiple oncogenes, including 
KRAS and c-MYC (Johnson et al., 2005), and miR-143/145 are involved in feed-forward mechanism 
that potentiates RAS signaling through down-regulation of KRAS and RAS-responsive element-
binding protein (RREB1), which represses the miR-143/145 promoter (Kent et al., 2010). Here we 
have identified a novel broadly conserved miRNA, miR-30c, as a direct negative regulator of KRAS 
expression. Interestingly, miR-30 and let-7 were reported to be markedly reduced in breast tumor-
initiating cells and contribute to their self-renewal capacity and undifferentiated state, and ectopic 
expression of these miRNAs in breast tumor-initiating cell xenografts decreases their tumorigenic and 
metastatic potential (Yu et al., 2010a). Furthermore, it has been shown recently that higher expression 
of miR-30c was significantly associated to benefit of tamoxifen treatment and with longer 
progression-free survival (Rodriguez-Gonzalez et al., 2011). Altogether, decreased expression of 
these miRNAs may release the negative regulation of KRAS. Interestingly, our results showed that at 
least three KRAS regulating miRNAs (miR-30c, miR-143, and miR-145) had significantly reduced 
expression in hereditary tumors implying that these miRNAs may act together in the regulation of 
KRAS oncogene.  
Signal transduction pathways integrate signals from extracellular stimuli including mitogens, 
growth factors, hormones and environmental stresses- signals required for tumorigenesis. miRNA 
deregulation results in the complex modulation of multiple targets belonging to multiple pathways. 
Commonly deregulated miRNAs in both hereditary and sporadic breast cancer suggest that commonly 
altered pathways could be important for tumor progression. Here, we have demonstrated that KRAS 
inhibition through direct regulation by miR-30c leads to reduced proliferation in breast cancer cells. 
Similarly, other studies have identified KRAS as a target of several miRNAs down-regulated in 
tumors (let-7, miR-145 and miR-143), that also have an effect on cancer cell proliferation and tumor 
invasiveness (Chen et al., 2009; Johnson et al., 2005; Yu et al., 2010b). Therefore, coordinated down-
regulation of miRNAs found in breast tumors would be not only affecting KRAS oncogene 
expression but also may be targeting other genes of the KRAS/MAPK signaling pathway to 
cooperatively activate tumorigenic downstream signals. 
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3. MIRNA MOLECULAR SIGNATURES IN HEREDITARY BREAST 
TUMORS 
Breast cancer is a heterogeneous disease, and in the past two decades great advances have been 
made by use of mRNA expression profiling for stratification of sporadic breast tumors into subgroups 
with distinctive clinico-pathological features, prognosis and responses to therapy (Perou et al., 2000; 
Sorlie et al., 2001; Sorlie et al., 2003). However, molecular characteristics of hereditary breast tumors, 
especially those arising in non-BRCA1/2 mutation carriers are still largely obscure. miRNA 
expression profiling has proven to be a useful tool for molecular classification of human cancer (Lu et 
al., 2005; Lujambio and Lowe, 2012). Therefore, the third objective of this thesis was to explore the 
molecular phenotype of BRCA1, BRCA2 and BRCAX hereditary breast tumors based on their 
intrinsic molecular characteristics by miRNA expression profiling.  
Studies of transcriptional profiles in hereditary breast tumors were limited largely by the 
requirement of the fresh-frozen tumor material, resulting in only few publications describing mRNA 
expression profiles in these tumors. On the other hand, miRNA expression profiling has proven to be 
a very useful tool for cancer classification, and, due to the remarkable stability of miRNAs in formalin 
fixed paraffin embedded tissue samples (Hasemeier et al., 2008), it has opened up an opportunity to 
use large collections of archived FFPE samples. In this study, we have analyzed by miRNA 
expression profiling a cohort of 66 hereditary breast tumors (13 BRCA1, 10 BRCA2 and 43 
BRCAX), 10 sporadic breast carcinomas and 6 normal breast tissues from healthy individuals with no 
personal of family history of breast cancer. Since contamination with normal breast tissue and stroma 
is one of the major issues in gene expression profiling studies, all samples analyzed in our series were 
macrodissected and isolated tumoral area was used for the total RNA extraction. All patents’ samples 
originate from Spanish hospitals, reducing the heterogeneity due to potential population-specific 
founder mutation effects. 
3.1. miRNA expression profiles differ between breast tissue types. 
The unsupervised clustering analysis of the miRNA expression data demonstrated clear 
separation between normal breast tissue, sporadic carcinomas, BRCA1 and BRCA2 tumors, and 
BRCAX tumors, supporting the presence of unique molecular differences between these groups. 
BRCAX tumors show large heterogeneity in their miRNA expression profiles, but overall they differ 
from both BRCA1/2 and sporadic tumors.  
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In line with our results, a recent study of a large series of hereditary breast samples and sporadic 
carcinomas (58 BRCAX, 28 BRCA1, 28 BRCA2, 49 sporadic) by aCGH, demonstrated that BRCAX 
tumors constitute a heterogeneous class, and are distinct from both sporadic and BRCA1/2 tumors 
(Didraga et al., 2011). In addition, the analysis of methylation profiles in a series of 33 hereditary 
breast cancers, also demonstrated that methylation profiles for hereditary breast cancers are defined 
by mutation status and are distinct from the intrinsic subtype determined by gene expression profiling 
in the same sample series (Flanagan et al., 2010) 
Interestingly, these findings are in contrast to results obtained by gene expression profiling and 
IHC-based profiling of hereditary breast tumors (Bane et al., 2009; Melchor et al., 2008; Waddell et 
al., 2010). Gene expression profiling of 75 hereditary breast tumors revealed that majority of BRCA2 
and BRCAX tumors were more similar to each other than to BRCA1 tumors. However this clustering 
was mainly driven by molecular subtypes given the enrichment of basal-like subtype within BRCA1 
tumors (Waddell et al., 2010). Here we have shown that clustering of hereditary tumors based on their 
miRNA expression profiles did not correlate with the IHC-based subtypes. These results are in 
concordance with previous findings on miRNA and gene expression profiling data in sporadic breast 
carcinomas (Rothe et al.), indicating that the miRNAs-based clustering of hereditary breast tumors is 
not driven by molecular subtypes and may carry additional information on these tumors. 
However, clustering analysis of miRNA expression data showed bi-partitioning that correlated 
with tumor grade, dividing the samples into a “low-moderate” grade cluster containing mainly 
BRCAX tumors and a “high grade” cluster consisted of two subgroups, one made of exclusively 
BRCA tumors and other mainly with BRCAX tumors and two BRCA1 samples. The separation into a 
“high grade” and “low grade” clusters was also reported in study of BRCAX tumors by IHC Honrado 
et al. implying that tumor differentiation level is driving the main stratification (Honrado et al., 2007). 
3.2. miRNA signature of “BRCAness” 
In the unsupervised clustering analysis it was shown that BRCA1 and BRCA2 tumors have very 
similar miRNA expression profiles, which was further supported by the lack of significantly 
differentially expressed miRNAs between these two groups. Furthermore, a large number of miRNAs 
(152) demonstrated significant differential expression between BRCA tumors and other mutation-
negative breast tumors constituting a signature of “BRCAness”.   
Of note, in a study of miRNA expression profiles in high grade ovarian serous carcinomas in 
relation to BRCA1/2 mutation status, no differentially expressed miRNAs were found between 
BRCA1 and BRCA2 tumors (Lee et al., 2009). However, the homogeneity of BRCA1/2 group 
determined by their miRNA expression profiles is in contrast to studies of gene expression in 
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hereditary tumors (Bane et al., 2009; Hedenfalk et al., 2001; Waddell et al., 2010). Hedenfalk et al. 
identified 173 differentially expressed genes between the two tumor types and a more recent study 
comparing expression in 19 BRCA1 and 30 BRCA2 tumors identified 393 genes (Hedenfalk et al., 
2001; Waddell et al., 2010).  It is well established that BRCA1-associated tumors differ from BRCA2 
in terms of their morphological, immunohistochemical and molecular characteristics (Honrado et al., 
2006; Honrado et al., 2005; Lacroix and Leclercq, 2005; Mavaddat et al., 2011; Tan et al., 2008; 
Tischkowitz and Foulkes, 2006; Turner and Reis-Filho, 2006; Vargas et al., 2011). Interestingly, one 
of the two miRNAs downregulated in BRCA1 tumors in comparison to BRCA2, although not 
significant after multiple corrections testing, miR-7, is known to regulate EGFR gene expression. 
EGFR mutations are a frequent even in BRCA1 tumors, but not in BRCA2, and downregulation of 
EGFR repressor, miR-7, could result in its overexpression. 
Cancers that develop in patients with BRCA germline mutations are characterized by distinctive 
morphology and clinical behavior. Both genes are involved in a common pathway of genome 
protection by homologous recombination of double-stranded DNA brakes (Roy et al., 2012). 
However, the two proteins work at different stages in the DNA damage response and DNA repair. 
The links between the two proteins are not well understood but they must exist to explain the marked 
similarity of human cancer susceptibility that arises with germline mutations in these genes. High 
similarity in miRNA expression profiles of BRCA1 and BRCA2 tumors possibly reflects the 
overlapping functions of these two genes in the DNA double strand break repair pathway, implying 
that miRNA expression profile is in function of a biological pathway deregulation rather than of a 
specific gene functions. 
The high homogeneity of BRCA1 and BRCA2 tumors and a large number of differentially 
expressed miRNAs in these tumor group versus BRCAX and sporadic breast carcinomas could allow 
for the development of biomarkers of diagnosis that would potentially discriminate between mutation 
positive and negative tumors and facilitate identification of individuals at risk of being mutation 
carriers that would benefit from genetic testing and would be amenable to DNA damage-inducing 
therapy, such as platinum and PARP inhibitors. Identifying BRCA1/2 specific biomarkers would be of 
great clinical value for pre-selection of candidate patients for BRCA1/2 mutation screening, especially 
among patients with lack of affirmative family history due to small pedigree or paternal transmission.  
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4. MIRNA-BASED MOLECULAR CLASSIFICATION OF BRCAX 
TUMORS 
The underlying biology of BRCA1/2-negative hereditary breast cancer is still largely unknown 
despite intensive research in past two decades. The notorious heterogeneity of BRCAX tumors has 
been demonstrated using various technological platforms including gene expression profiling, 
comparative genomic hybridization (CGH), immunohistochemistry, LOH and methylation studies 
(Honrado et al., 2007). Understanding the biology behind BRCAX tumor heterogeneity could allow 
for guiding optimal therapeutic and preventive options, and may help stratify BRCAX families for 
linkage analysis. Here we have examined weather the heterogeneous genetic background of BRCAX 
tumors could be resolved using miRNA expression profiling. 
4.1. miRNA expression signatures define BRCAX subgroups 
Unsupervised clustering of BRCAX tumors based on their miRNA expression demonstrated 
once again the heterogeneous nature of these tumors, with several apparent subgroups. Class 
discovery algorithm confirmed the existence of 4 different subgroups of tumors, characterized by a 
specific miRNA signature. Three miRNA clusters based on their co-expression were defined. 
BRCAX-A tumors showed overall similar levels of miRNA expression to normal breast tissue. 
BRCAX-B tumors on the other hand were differentiated from normal tissue only by the down-
regulation of Cluster 2 miRNAs. The miRNA expression profile of BRCAX-C tumor group 
demonstrated inverse expression levels to that of normal breast tissue. It was characterized by 
downregulation of Cluster 1 and Cluster 2 miRNAs, and overexpression of Cluster 3 miRNAs. 
However, BRCAX-D tumors exhibited very heterogeneous profiles. Only two miRNAs, miR-125b 
and miR-143, were commonly deregulated in all four subgroups in comparison to normal breast 
tissue. Interestingly, miR-125b, which is downregulated in breast cancer, is located at chromosome 
11q23-24, one of the regions most frequently deleted in breast, ovarian, and lung tumors (Negrini et 
al., 1995). Functional roles of these tumor suppressor miRNAs have been previously discussed. 
Cluster 1, specifically downregulated in BRCAX-C tumors, was enriched for a large number of 
primate-specific miRNAs localized at chromosome 19q13.41-42 (Zhang et al., 2008). Interestingly, 
this region is genetically altered in a variety of tumors featuring deletions, amplifications and 
translocations(Forzano et al., 2012; Toledo et al., 2010), and C19MC miRNA cluster has been 
extensively implicated in cancer and other diseases (Pfister et al., 2009; Rippe et al., 2010; Vaira et 
al., 2012). Bioinformatic analysis of Cluster 1 miRNA target genes related their function to positive 
regulation of cell migration and motility, in addition to regulation of cell proliferation and apoptosis. 
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Cluster 2, downregulated in BRCAX-B and BRCAX-C tumors, contained well known tumor 
suppressor miRNAs implicated in breast pathogenesis of both sporadic and hereditary cancer (Le 
Quesne and Caldas, 2010; Tanic et al., 2012), including all members of let-7 and miR-30 family, that 
are controlling cell proliferation and differentiation in breast setting, as discussed in previous chapters. 
Other tumor suppressor miRNAs in this cluster included commonly altered miR-125b, miR-143. Loss 
of tumor suppressor miRNAs would lead to concomitant increase in proliferation rates and de- 
differentiation, hallmarks of cancer. Interestingly, the miR-8 family members (miR-
141/200a/200b/200c) were more than 2-fold upregulated in BRCAX-A tumors, while being 
downregulated in BRCAX-B and BRCAX-C subgroups. This miRNA family acts as suppressors of 
epithelial to mesenchymal transition (EMT) (Burk et al., 2008), and is also implicated in the 
maintenance of stem cell phenotype, and downregulated in mammary progenitor cells (Shimono et al., 
2009). As expected, genes related to miRNA Cluster 2 were associated to pathways regulating cell 
death, cell proliferation, developmental processes and macromolecule metabolism.  
Cluster 3 miRNAs were specifically overexpressed in BRCAX-C tumors and contained a very 
large  primate-specific miRNA cluster located at chromosome Xq27.3 (Zhang et al., 2008). 
Notewotrhy, this region was linked to testicular germ cell tumors (Rapley, 200, Nat Genet), hereditary 
prostate cancer (Peters, Hum Hered, 2001; Lange ClinCancRes, 1999) and miRNAs in the cluster 
were implicated in clear cell renal crrcinoma (Zhou et al., 2010). Biological functions associated to 
target genes of Cluster 3 miRNAs were regulation of cell cycle, protein kinase activity and 
biosynthesis of macromolecules. 
4.2. miRNA profiles may indicate differences in tumor etiology  
It is known that miRNA expression is highly specific for the tissue of origin and developmental 
stage (Landgraf et al., 2007; Niwa and Slack, 2007). In effect, miRNA profiling is emerging as a 
powerful diagnostic tool to characterize features of different tumor types and has been particularly 
useful in breast cancer as miRNA signatures can unequivocally distinguish normal ad malignant 
breast tissue. Furthermore, we have shown that BRCA1 and BRCA2 germline mutations involved in 
the specific pathway give rise to a very characteristic miRNA signature. Therefore, we can 
hypothesize that deregulation of specific miRNA could indicate different pathways of tumor evolution 
in each of the BRCAX subgroups that may harbor predisposing mutations in the same pathway. 
Deregulation of two different processes is converging in of the same macro-phenotype, the 
occurrence breast cancer. Genomic instability driven by inactivation of functional BRCA1, BRCA2 
and other “care-taker” proteins important for DNA damage repair are common cause of highly 
penetrant hereditary breast cancer syndromes. It is currently believed that accumulation of genetic and 
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genomic alterations over the years, due to faulty DNA repair mechanisms is causing the malignant 
phenotype. On the other hand, over-activation of signaling pathways regulating cellular growth and 
proliferation is a very frequent event in breast cancer. Deregulation of MAPK pathway via HER2 
receptor overexpression is a well known driver of breast tumorigenesis in approximately 20% of 
breast tumors. Another frequent event is deregulation of PI3K/AKT signaling evidenced by the 
highest frequency of somatic mutations in breast tumors in PIK3CA gene (26% of tumors) according 
to data from the Catalogue of The Somatic Mutations in Cancer  (COSMIC,  
http://www.sanger.ac.uk/genetics/CGP/cosmic/). 
Lack of association of hormone receptor status with a specific tumor subgroup excludes the 
possibility that miRNA signatures characterizing these tumor subgroups are associated with endocrine 
response to estrogen or progesterone. However, other underlying genetic alterations or external 
signaling could be reflected in the observed miRNA profiles. BRCAX-A tumors were the only 
subgroup significantly associated with specific histopathological features, specifically to HER2 
overexpression. Although HER2 overexpression is associated to poor prognosis, these tumors were 
significantly of moderate grade (p=0.03) and lymph node negative (p=0.08) both of which are clinical 
parameters for good prognosis. miRNA expression profile in these tumors closely resembles that of 
normal breast tissue, with only few differentially expressed genes unlike massive miRNA 
deregulation observed in other tumor subgroups, implying that in these tumors overactive HER2 
signaling is sufficient for tumorigenesis process. The BRCAX-B subgroup of tumors was not 
significantly different in terms of histopathological characteristics from the rest of tumors. In fact 
these tumors are characterized by the downregulation of tumor suppressor miRNAs, important for 
pathogenesis of both hereditary and sporadic tumors. On the other hand, BRCAX-C tumors in 
addition to downregulation of Cluster 2 tumor suppressor miRNAs had subtype-specific aberrantly 
expressed miRNAs. These tumors were consisted only of high and moderate grade tumors, although 
not statistically significant, and were enriched for lymph node positive tumors (p=0.075), both 
characteristics being related to poor prognosis. Given the high similarity in miRNAs expression 
profiles between BRCAX-C tumors and BRCA1/2 mutated ones, this subgroup of tumors would 
represent good candidates for resequencing studies focused on the DNA-damage repair pathway. 
It is very likely that the group of BRCAX cases is attributable to multiple genetic defects. It is 
not known how many additional breast cancer susceptibility genes exist, nor how many may fall into 
the class of rare high-risk (BRCA-like) or common low susceptibility alleles. However, given that 
linkage studies have failed to identify new susceptibility genes, it is to assume that even if more 
highly penetrant genes exist, they will not explain more than 20% of remaining families. The power 
of linkage analysis would increase dramatically if we were able to select a sub-group of patients that 
would increase the proportion of this potential high-risk gene to over 50%. Differences in tumor 
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etiology reflected in the miRNA expression profile, evidenced by specific signature associated to 
BRCA1 and BRCA2 tumors, could be exploited patients stratification for linkage analysis or allow for 
studies of interaction of low-susceptibility alleles in homogenous set of tumors. 
5. FINAL REMARKS 
Although miRNA deregulation is well established phenomenon in cancer, and the downstream 
effects of miRNAs are an intensive object of study, there are surprisingly few studies focused on the 
underlying causes of miRNA deregulation. The genomic abnormalities found to influence the activity 
of miRNAs are the same as those previously described for protein-coding genes, such as 
chromosomal rearrangements, genomic amplifications or deletions, and somatic or germline 
mutations (Calin et al., 2004a; Calin et al., 2004b). Weather massive miRNA deregulation is the cause 
or the consequence of tumorigenesis is still an open question. Recurrent deregulation of specific 
miRNAs in breast cancer located across different regions of the genome implies that either there is a 
common factor regulating their expression, or that deregulation of specific miRNAs through random 
genetic or epigenetic alterations arising over the years is a necessary event for the breast 
tumorigenesis. This question will undoubtedly be a matter intense investigation in years to come and 
will hopefully shed some light on the functional role of miRNA in cancer pathogenesis. 
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 CONCLUSIONS 
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1. Reconstitution of wild type BRCA1 expression in HCC1937 cell lines induces large changes 
in cellular transcriptional profile and only subtly modulates miRNA expression. Integration of 
the global miRNA and mRNA profiles allowed us to define genes and pathways controlled by 
differentially expressed miRNA upon BRCA1 re-expression. MAPK and NF-κB pathways 
were differentially activated between BRCA1-profficient and deficient HCC1937 cell lines 
2. We have identified TRAF2, a well known mediator of both NF-κB and MAPK pathway 
activation, as a novel common target gene for miR-146, miR-99 and miR-205, upregulated 
upon BRCA1 reconstitution. We demonstrated that these miRNAs individually are sufficient 
to modulate NF-κB pathway activity in breast cancer cells.  Furthermore, we observed that 
miR-146, miR-99 and miR-205 were also downregulated in primary BRCA1 tumors in 
comparison to normal breast tissue. 
3. We have analyzed, for the first time, miRNA expression profiles in hereditary breast tumors 
and defined a set of 19 miRNAs deregulated in hereditary breast tumors, many of them 
commonly deregulated in sporadic breast cancer.  
4. Gene set enrichment analysis indicated that this set of co-expressed miRNAs regulates 
pathways related to cell proliferation and cell migration. We identified KRAS a novel target 
gene of miR-30c in breast cancer cells. Re-expression of miR-30c in MDA MB 436 breast 
cancer cells inhibited cell proliferation. 
5. Classification of breast tissues based on their miRNA expression profiles demonstrated clear 
separation of BRCA1/2 tumors, BRCAX tumors, sporadic carcinomas and normal breast 
tissue. 
6. Hereditary breast tumors from BRCA1/2 mutation carriers represented a highly homogenous 
group, with no differentially expressed miRNAs between BRCA1 and BRCA2 tumors.  A 
large number of miRNAs was differentially expressed between BRCA1/2 mutation positive 
and mutation negative breast tumors that can serve as a starting point for the development of 
biomarkers of diagnosis for triage of individuals at risk of being mutation carriers that would 
benefit from genetic testing and emerging therapies. 
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7. The group of hereditary BRCAX tumors can be subclassified into 4 homogenous groups, 
BRCAX-A, BRCAX-B, BRCAX-C and BRCAX-D determined by specific miRNA 
expression signatures. BRCAX-A tumors demonstrated high correlation in miRNA 
expression profile with normal breast tissue, were enriched for Luminal B subtype 
(HER2+,ER/PR+) and consisted of only grade 1 and 2 tumors. BRCAX-B tumors represented 
a homogenous group characterized by loss of expression of “tumor suppressor” miRNA 
Cluster 2. BRCAX-C tumors showed similar miRNA expression profile to BRCA1/2 mutated 
tumors and clustered in the same branch; were characterized by loss of “tumor suppressor” 
miRNA cluster, loss of miRNA Cluster 3 related to migratory functions and overexpression 
of miRNA Cluster 3 associated to metabolism of macromolecules. BRCAX-D tumors were 
lacking a specific miRNA signature and were dispersed across the cluster. Their miRNA 
expression profile resembles that of sporadic breast tumors. 
 
 
 
 
 
 
 
 
 CONCLUSIONES 
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1. La recuperación de la expresión del gen BRCA1 wt  en HCC1937 líneas celulares provoca 
grandes cambios en el perfil transcripcional y sólo modula sutilmente la expresión de los 
miRNAs. La integración del perfil global de miRNA y de mRNA nos permitió definir los 
genes y las vías controladas por miRNA expresados diferencialmente tras la re-expresión de 
BRCA1. Existen diferencias en la activaci’on de las v’ias MAPK y NF-kB entre Las líneas 
celulares isogenicas HCC1937 que expresan BRCA1 y que carecen de esta expresión. 
2. Hemos identificado TRAF2, un mediador  del activación de las vías  NF-kB y MAPK, como 
un nuevo gen diana común para los miR-146, miR-99 y miR-205 que están sobre-expresados 
en la línea HCC1937/ BRCA1 wt. Hemos demostrado que cada  miRNA individualmente es 
suficiente para modular la actividad de la vía NF-kB en células de cáncer de mama. 
Asimismo, se observó que el miR-146, miR-99 y miR-205 también se expresan menos en los 
tumores BRCA1 en comparación con el tejido normal mamario. 
3. Hemos analizado, por primera vez, los perfiles de expresión de los miRNAs en los tumores de 
mama hereditarios pudiendo definir así un conjunto de 19 miRNAs que están desregulados en 
estos tumores de los cuales la gran mayoría son comunes a los miRNAs desregulados en 
cáncer de mama esporádico. 
4.  Análisis de enriquecimiento de las vías de señalización en el conjunto de genes  asociados a 
los  miRNAs co-expresadas nos indicó que estos miRNAs regulan indirectamente las vías 
relacionadas con la proliferación celular y la migración celular. Hemos identificado el 
oncogén KRAS como nueva diana del miR-30c en las células de cáncer de mama. La re-
expresión del miR-30c en las células de cáncer de mama MDA MB 436 inhibe la 
proliferación celular. 
5. Clasificación de los tejidos mamarios en función de sus perfiles de expresión de los miRNAs 
ha demostrado una clara separación entre los tumores BRCA1 / 2, tumores BRCAX, 
carcinomas esporádicos y el tejido mamario normal. 
6. Los tumores de mama hereditarios de los portadores de mutaciones BRCA1 / 2 representan 
un grupo muy homogéneo, sin ningún miRNA expresados diferencialmente entre los tumores 
BRCA1 y BRCA2. Un gran número de los miRNAs mostraron una expresión diferencial 
entre tumores positivos y negativas para la mutación BRCA1 /2, que podrían servir como 
arranque para el desarrollo de los biomarcadores de diagnóstico para la clasificación de los 
individuos en riesgo de ser portadores de la mutación que se beneficiarían de las pruebas 
genéticas y terapias emergentes. 
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7. Entre el grupo de los tumores hereditarios BRCAX se pueden distingir 4 grupos homogéneos, 
BRCAX-A, BRCAX B, BRCAX-C y BRCAX-D determinados por las específicas firmas de 
expresión de los miRNAs. Los tumores BRCAX-A han demostrado una alta correlación en el 
perfil de expresión de los miRNAs con el tejido mamario normal, y están enriquecidos por el 
subtipo luminal B (HER2 +, ER / PR +), además que consisten sólo de los tumores de grado 1 
y 2. Los tumores BRCAX-B representan un grupo homogéneo, caracterizado por la pérdida 
de expresión de "supresor tumoral" miRNA Cluster 2. Los tumores BRCAX-C mostraron un 
perfil de expresión del los miRNAs similar al  de los tumores BRCA1 / 2 y se agrupaban en la 
misma rama. Estos tumores,  se caracterizan por la pérdida del  "supresor tumoral"  miRNA 
Cluster 2 y la pérdida de miRNA Cluster 3 relacionado con las funciones migratorias, y la 
sobreexpresión del miRNA Cluster 3 asociado con el metabolismo de las macromoléculas. 
Los tumores BRCAX-D carecían de una firma de expresión de los miRNAs específica, y 
fueron dispersados por todo el clúster. Su perfil de expresión de miRNA se asemeja al de los 
tumores de mama esporádicos. 
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SUPPLEMENTARY MATERIAL 
 
Supplementary Table 1. Histopathological data of fresh frozen hereditary breast tumor series. 
Number ID 
Germline 
mutation Lymph node Grade ER PR HER2 Molecular Subtype 
1 01T163 BRCA1 Positive 3 - - - Triple Negative 
2 01T167 BRCA1 Negative 3 - - - Triple Negative 
3 01T185 BRCA1 Positive 3 - - - Triple Negative 
4 02T124 BRCA1 Negative 3 - - - Triple Negative 
5 02T144 BRCA1 NA NA NA NA NA NA 
6 05T126 BRCA1 NA 3 - - - Triple Negative 
7 01T265 BRCA2 NA NA NA NA NA NA 
8 05T312 BRCA2 Positive 2 + - - Luminal A 
9 09T155 BRCA2 NA NA NA NA NA NA 
10 01T248 BRCAX NA NA + + + Luminal B  
11 01T306  BRCAX Negative 1 + + - Luminal A 
12 02T328 BRCAX Negative 3 - - + HER2+  
13 04T59 BRCAX NA NA NA NA NA NA 
14 05T129 BRCAX Negative 2 + - + Luminal B 
15 05T132 BRCAX NA NA NA NA NA NA 
16 05T134 BRCAX NA 3 + - - Luminal A 
17 05T136 BRCAX Negative 1 + + - Luminal A 
18 09T154 BRCAX NA NA NA NA NA NA 
19 09T79 BRCAX Negative 2 - - + HER2+  
NA: Not available data; (+) – Positive; (-) - Negative 
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Supplementary table 2. Clinico-pathological information for FFPE hereditary breast tumor series included in the array analysis 
# Tumor Mutated Gene 
Age at 
diagnosis 
Histological 
type  
Lymph 
Node Grade ER  PR   
HER2/ 
ErbB2  EGFR 
CK5 
(10%) 
p53 
(25%) 
MIB1/
Ki-67  
IHC-based molecular 
subtype 
1 12908 BRCA1 NA NA NA NA 0 0 0 0 1 1 2 Triple Negative 
2 01T154 BRCA1 51 DIC 1 3 0 0 0 1 1 0 3 Triple Negative 
3 01T163 BRCA1 35 DIC 1 3 0 0 0 NA 1 1 2 Triple Negative 
4 01T167 BRCA1 32 DIC 0 3 0 0 0 1 1 1 1 Triple Negative 
5 01T185 BRCA1 38 DIC 1 3 0 0 0 1 1 1 2 Triple Negative 
6 02T124 BRCA1 55 DIC 0 3 0 0 0 0 1 0 2 Triple Negative 
7 02T19 BRCA1 47 DIC 1 2 1 1 0 0 0 0 1 Luminal A 
8 03T158 BRCA1 30 DIC 0 3 0 0 0 0 1 1 3 Triple Negative 
9 03T326 BRCA1 47 DIC 0 3 1 1 0 0 0 0 1 Luminal A 
10 04T270 BRCA1 NA NA NA 3 0 0 0 1 0 0 2 Triple Negative 
11 04T327 BRCA1 NA DIC 0 3 0 0 0 1 1 NA 0 Triple Negative 
12 04T374 BRCA1 NA NA NA 3 0 0 0 0 0 1 3 Triple Negative 
13 04T39 BRCA1 28 DIC 1 3 0 0 0 1 1 1 3 Triple Negative 
14 02T59 BRCA2 35 DIC 1 3 1 1 0 0 1 1 3 Luminal A 
15 03T162 BRCA2 45 LIC NA 2 0 0 0 0 0 1 2 Triple Negative 
16 03T168 BRCA2 46 DIC 1 1 0 1 0 0 0 0 1 Luminal A 
17 03T238 BRCA2 37 DIC 1 1 1 0 0 0 NA 0 2 Luminal A 
18 03T239 BRCA2 56 DIC 1 3 0 0 0 0 0 0 1 Triple Negative 
19 04T309 BRCA2 36 NA 0 3 1 1 0 0 0 NA 3 Luminal A 
20 04T328 BRCA2 NA DIC 0 3 1 1 0 0 0 NA NA Luminal A 
21 04T329 BRCA2 NA DIC 0 2 1 1 0 0 0 0 1 Luminal A 
22 10T126 BRCA2 NA NA NA 2 1 1 1 NA NA NA NA Luminal B 
23 10T171 BRCA2 NA NA NA 3 1 1 1 NA NA NA NA Luminal B 
24 00T43 BRCAX 58 DIC 1 3 1 0 NA NA 0 0 1 NA 
25 00T54 BRCAX 49 DIC 1 2 0 0 0 0 0 0 1 Triple Negative 
26 01T243 BRCAX 48 DIC NA 2 0 1 0 NA NA NA NA Luminal A 
27 02T31 BRCAX 68 NA 1 2 0 0 0 0 0 0 1 Triple Negative 
28 02T343 BRCAX NA DIC NA 2 1 1 NA NA NA 0 1 NA 
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29 02T37 BRCAX 58 DIC 1 3 0 0 0 1 1 0 2 Triple Negative 
30 02T39 BRCAX 47 DIC 0 1 1 1 0 0 0 0 1 Luminal A 
31 02T41 BRCAX 34 DIC 1 3 1 0 0 0 0 1 1 Luminal A 
32 04T35 BRCAX 50 DIC NA 1 0 0 0 0 0 0 1 Triple Negative 
33 04T355 BRCAX 49 DIC NA 3 1 1 0 0 0 0 1 Luminal A 
34 04T400 BRCAX NA NA NA 2 0 0 0 0 0 0 3 Triple Negative 
35 04T55 BRCAX 45 DIC NA 1 0 0 1 0 0 1 2 HER2 
36 06T224 BRCAX 51 NA 0 2 1 0 0 0 NA NA NA Luminal A 
37 06T225 BRCAX 35 DIC 1 3 0 0 0 0 NA NA NA Triple Negative 
38 06T226 BRCAX 38 DIC 1 3 1 1 0 0 0 0 1 Luminal B 
39 06T230 BRCAX 95 DIC 0 2 1 1 0 0 0 0 1 Luminal A 
40 06T232 BRCAX 73 DIC 1 3 1 1 0 0 0 1 2 Luminal A 
41 06T238 BRCAX 39 DIC 0 3 1 0 1 0 0 1 3 Luminal B 
42 06T241 BRCAX 47 DIC 1 3 1 1 1 0 0 1 2 Luminal B 
43 06T243 BRCAX 64 NA 1 2 1 0 0 0 0 0 1 Luminal A 
44 06T246 BRCAX 55 DIC 1 3 0 0 0 0 0 0 1 Triple Negative 
45 06T250 BRCAX 52 DIC 0 2 1 1 0 0 0 0 1 Luminal A 
46 06T251 BRCAX 58 DIC 0 3 0 0 0 0 0 1 2 Triple Negative 
47 06T253 BRCAX 37 DIC 0 NA 0 0 0 0 0 0 1 Triple Negative 
48 06T255 BRCAX 59 DIC 1 2 0 0 1 0 0 0 2 HER2 
49 06T256 BRCAX 33 DIC 1 2 1 1 0 0 0 0 1 Luminal A 
50 06T258 BRCAX 40 NA 1 3 0 0 0 0 1 1 2 Triple Negative 
51 06T260 BRCAX 26 Intraductal 0 3 NA NA 0 0 0 NA NA NA 
52 06T264 BRCAX 37 DIC 1 3 0 1 0 0 0 0 2 Luminal A 
53 10T123 BRCAX 25 DIC 1 2 0 0 0 NA NA NA NA Triple Negative 
54 10T124 BRCAX 31 Intraductal 0 2 NA NA NA NA NA NA NA NA 
55 10T125 BRCAX 37 Intraductal 0 2 NA NA 1 NA NA NA NA NA 
56 10T127 BRCAX 55 DIC 0 2 0 0 1 0 NA 1 3 HER2 
57 10T136 BRCAX 44 DIC 0 2 1 1 0 0 NA 0 2 Luminal A 
58 10T137-2 BRCAX 49 DIC 0 3 0 0 0 0 1 1 3 Triple Negative 
59 10T139 BRCAX 48 DIC 0 2 1 1 1 NA NA NA NA Luminal B 
 60 10T172 BRCAX 39 Intraductal NA 1 NA NA 0 NA NA NA NA NA 
61 11T3 BRCAX 40 DIC 1 3 NA 1 0 NA NA NA NA Luminal A 
62 11T4 BRCAX 54 LIC 1 2 0 0 NA NA NA NA NA NA 
63 11T71-1 BRCAX 52 DIC 0 2 1 0 1 NA NA 0 2 Luminal B 
64 11T71-2 BRCAX 52 DIC 0 2 1 0 1 NA NA 0 2 Luminal B 
65 11T72 BRCAX NA NA  NA NA NA NA NA NA NA NA NA 
66 11T73 BRCAX 39 DIC 0 3 0 0 0 NA 1 1 3 Triple Negative 
ER- estrogen receptor, PR - progesterone receptor, HER2/ErbB2- human epidermal growth factor; DIC - ductal infiltrating carcinoma; LIC - lobular infiltrating carcinoma; NA - not available; (0) -
negative; (1) - positive;  
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*Due to the size of the “Supplementary figure 3. Full list of differentially expressed genes is shown 
in HCC1937 vs. HCC1937/BRCA1wt “, it is available only in the electronic form in the attached CD. 
 
 Supplementary Table 4. List of pathways significantly associated (FDR<0.05) to DEmiR-DEG pairs 
© 2000-2010 Ingenuity Systems, Inc. All rights reserved. 
Ingenuity Canonical Pathways  -log(p-value) Ratio Molecules 
 p38 MAPK Signaling 2.79E00 5.21E-02 
 FADD, TRAF2, IL1F9, IRAK3, 
IRAK1 
 Role of Macrophages, Fibroblasts and 
Endothelial Cells in Rheumatoid Arthritis 2.7E00 2.64E-02 
 FZD8, TRAF2, IL1F9, 
CAMK2D, WNT3, C1S, LTB, 
IRAK3, IRAK1 
 Role of PKR in Interferon Induction and 
Antiviral Response 2.3E00 6.67E-02  FADD, TRAF2, RNASEL 
 NF-κB Signaling 2.04E00 3.29E-02 
 TRAF2, IL1F9, RELB, IRAK3, 
IRAK1 
 Lymphotoxin β Receptor Signaling 1.91E00 4.92E-02  TRAF2, RELB, LTB 
 Acute Phase Response Signaling 1.77E00 2.81E-02 
 TRAF2, IL1F9, SOD2, C1S, 
IRAK1 
 Basal Cell Carcinoma Signaling 1.71E00 4.41E-02  FZD8, WNT3, BMP7 
 Human Embryonic Stem Cell Pluripotency 1.65E00 2.7E-02  FZD8, NTF4, WNT3, BMP7 
 Hepatic Cholestasis 1.52E00 2.4E-02  TRAF2, IL1F9, IRAK3, IRAK1 
 Factors Promoting Cardiogenesis in 
Vertebrates 1.44E00 3.37E-02  FZD8, WNT3, BMP7 
 Altered T Cell and B Cell Signaling in 
Rheumatoid Arthritis 1.44E00 3.45E-02  IL1F9, RELB, LTB 
 Retinoic acid Mediated Apoptosis Signaling 1.43E00 4.65E-02  FADD, DAP3 
 Role of Osteoblasts, Osteoclasts and 
Chondrocytes in Rheumatoid Arthritis 1.43E00 2.19E-02 
 FZD8, TRAF2, IL1F9, WNT3, 
BMP7 
 PPAR Signaling 1.37E00 3.06E-02  TRAF2, IL1F9, SCAND1 
 SAPK/JNK Signaling 1.33E00 3.06E-02  FADD, TRAF2, DUSP8 
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Supplementary Table 5. Cluster 1 - differentially expressed miRNAs (FDR<0.05)  in each BRCAX-subgroup in comparison to normal breast tissue 
    BRCAX-A BRCAX-B BRCAX-C BRCAX-D 
miRNA Genomic location FDR FC FDR2 FC2 FDR3 FC3 FDR4 FC4 
hsa-let-7a* 09q22.2/11q24.1/22q13.3 NS 0.81 0.0042 1.04 1E-06 0.61 4E-05 0.67 
hsa-miR-609 10q25.1 NS 0.64 NS 0.83 2E-05 0.47 3E-05 0.50 
hsa-miR-483-3p 11p15.5 0.04401 0.56 NS 2.50 0.0402 0.60 0.0044 0.59 
hsa-miR-1237 11q13.1 NS 0.86 NS 1.48 NS 0.77 NS 0.86 
hsa-miR-1279 12q15 NS 1.07 NS 1.39 NS 0.90 NS 1.06 
hsa-miR-618 12q21.31 NS 0.64 NS 0.87 2E-05 0.45 2E-05 0.49 
hsa-miR-625* 14q23.3 NS 0.96 NS 0.70 0.0139 1.50 NS 1.18 
hsa-miR-493* 14q32.2 NS 0.66 NS 0.93 0.0003 0.53 0.0001 0.55 
hsa-miR-453 14q32.31 NS 0.66 NS 0.87 7E-05 0.51 3E-05 0.51 
hsa-miR-1282 15q15.3 NS 1.01 NS 1.92 NS 0.81 NS 0.89 
hsa-miR-190 15q22.2/1q21.3/11q12.2 NS 0.71 NS 1.04 0.0001 0.51 0.0001 0.57 
hsa-miR-422a 15q22.31 NS 0.70 NS 1.06 0.0017 0.64 0.0002 0.64 
hsa-miR-940 16p13.3 NS 0.86 NS 1.94 NS 1.06 NS 0.93 
hsa-miR-140-5p 16q22.1 NS 0.74 NS 1.14 NS 0.50 NS 0.58 
hsa-miR-328 16q22.1 NS 0.93 NS 1.57 NS 0.88 NS 0.93 
hsa-miR-132* 17p13.3 NS 0.69 NS 1.49 0.0019 0.54 0.0002 0.55 
hsa-miR-122 18q21.31 NS 0.90 NS 2.09 NS 0.66 NS 0.73 
hsa-miR-1238 19p13.2 NS 0.87 NS 1.40 NS 0.81 NS 0.83 
hsa-miR-1227 19p13.3 NS 0.90 NS 1.61 NS 0.86 NS 0.88 
hsa-miR-643 19q13.41 NS 0.74 NS 1.25 0.001 0.54 0.0008 0.60 
hsa-miR-99b* 19q13.41 NS 0.71 NS 1.15 NS 0.77 0.0003 0.64 
hsa-miR-373 19q13.42 0.0485 0.61 NS 0.75 2E-05 0.45 2E-05 0.50 
hsa-miR-517c 19q13.42 NS 0.69 NS 0.78 0.0003 0.54 0.0003 0.58 
hsa-miR-519c-3p 19q13.42 NS 0.95 NS 1.60 NS 0.79 NS 0.85 
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hsa-miR-519d 19q13.42 NS 0.73 NS 1.78 NS 0.66 0.0003 0.55 
hsa-miR-520d-3p 19q13.42 NS 0.73 NS 1.20 0.0008 0.56 0.0001 0.58 
hsa-miR-520h 19q13.42 NS 0.87 NS 1.37 0.0228 0.73 NS 0.78 
hsa-miR-522 19q13.42 NS 0.74 NS 1.30 0.0034 0.64 0.0004 0.66 
hsa-miR-526b 19q13.42 NS 0.91 NS 1.43 0.0341 0.77 NS 0.82 
hsa-miR-942 1p13.1 NS 0.84 NS 1.67 0.0123 0.66 NS 0.72 
hsa-miR-190b 1q21.3 NS 1.10 NS 1.29 0.0036 0.73 NS 0.82 
hsa-miR-9 1q22/5q14.3/15q26.1 NS 0.66 NS 1.10 7E-05 0.44 8E-05 0.50 
hsa-miR-135b 1q32.1 NS 0.76 NS 1.25 0.0023 0.58 0.0021 0.62 
hsa-miR-181b 1q32.1/9q33.3 NS 0.86 NS 1.19 0.0017 0.66 0.0032 0.70 
hsa-miR-664 1q41 NS 0.82 NS 1.31 NS 0.81 0.0002 0.71 
hsa-miR-1281 22q13.2 0.04028 0.58 NS 2.15 NS 0.67 0.0044 0.64 
hsa-let-7b* 22q13.3 NS 0.96 0.0044 1.71 7E-06 0.89 3E-05 0.91 
hsa-miR-1249 22q13.31 NS 0.68 NS 1.92 0.0168 0.56 0.001 0.54 
hsa-miR-885-5p 3p25.3 NS 0.98 NS 2.25 NS 1.02 NS 1.02 
hsa-miR-302a 4q25 NS 0.71 NS 0.78 3E-05 0.55 2E-05 0.58 
hsa-miR-578 4q32.3 NS 0.64 NS 1.29 0.0001 0.41 6E-05 0.47 
hsa-miR-581 5q11.2 NS 0.64 NS 1.24 0.0002 0.39 0.0001 0.45 
hsa-miR-1294 5q33.2 NS 0.91 NS 1.42 NS 0.80 NS 0.85 
hsa-miR-877* 6p21.33 NS 0.65 NS 1.62 0.0111 0.58 0.0005 0.57 
hsa-miR-196b 7p15.2 NS 0.76 NS 0.90 0.0001 0.53 0.0001 0.59 
hsa-miR-592 7q31.33 NS 0.65 NS 1.48 0.0013 0.43 0.0001 0.49 
hsa-miR-593 7q32.1 NS 0.76 NS 1.13 0.0023 0.60 0.0015 0.63 
hsa-miR-29a* 7q32.3 NS 1.05 0.0044 1.52 < 1E-08 0.89 1E-04 0.94 
hsa-miR-29b-1* 7q32.3 NS 0.79 NS 1.24 0.0008 0.60 0.0003 0.68 
hsa-miR-1207-3p 8q24.21 NS 1.14 NS 2.08 NS 1.00 NS 1.07 
hsa-miR-30b* 8q24.22 NS 0.88 0.0118 1.53 5E-06 0.77 NS 0.73 
hsa-miR-935 9q13.42 NS 0.76 NS 1.98 NS 0.85 NS 0.77 
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hsa-miR-7 9q21.32/15q26.1/9p13.3 NS 1.30 0.0328 1.98 0.0035 1.36 0.0035 1.36 
hsa-miR-601 9q33.3 NS 0.70 NS 1.13 0.0021 0.61 0.0005 0.62 
hsa-miR-188-5p Xp11.23 NS 0.72 NS 0.82 0.0002 0.56 0.0001 0.60 
hsa-miR-221 Xp11.3 NS 0.77 NS 0.93 0.0054 0.61 0.0019 0.66 
hsa-miR-651 Xp22.31 NS 0.78 NS 1.27 0.0023 0.68 0.0001 0.70 
hsa-miR-548m Xq21.33 NS 0.90 NS 1.25 0.0157 0.74 NS 0.80 
hsa-miR-450a Xq26.3/ NS 0.71 NS 1.08 0.0004 0.56 0.0001 0.59 
hsa-miR-508-3p Xq27.3 NS 0.80 NS 1.04 0.0002 0.62 6E-05 0.65 
hsa-miR-892b Xq27.3 NS 0.71 NS 0.93 0.0002 0.52 0.0001 0.55 
hsa_SNORD12 
   
NS 1.39 0.0484 0.73 NS 0.71 
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Supplementary Table 6. Cluster 2 differentially expressed miRNAs (FDR<0.05)  in each BRCAX-subgroup in comparison to normal breast tissue 
    BRCAX-A BRCAX-B BRCAX-C BRCAX-D 
miRNA Genomic location FDR FC FDR2 FC2 FDR3 FC3 FDR4 FC4 
hsa-let-7i 12q14.1 NS 0.80 0.00448 0.51 < 1.0E-08 0.31 0.0000918 0.48 
hsa-let-7c 21q21.1 NS 0.89 0.02861 0.33 0.000857 0.46 0.0023494 0.57 
hsa-let-7b 22q13.31 NS 0.92 0.00437 0.29 0.000007 0.30 0.0000258 0.44 
hsa-let-7g 3p21.1 NS 0.98 0.00264 0.39 < 1.0E-08 0.28 0.0001043 0.53 
hsa-let-7a 9q22.2/11q24.1/22q13.3 NS 0.98 0.00424 0.29 1.2E-06 0.22 0.0000401 0.46 
hsa-let-7f 9q22.2/Xp11.22 NS 1.40 0.01205 0.45 2.42E-05 0.25 0.0044077 0.56 
hsa-let-7d 9q22.32 NS 1.05 0.0054 0.38 4.83E-05 0.34 0.0039411 0.58 
hsa-miR-101 1p31.3/9p21.1 NS 0.88 NS 0.33 NS 0.37 NS 0.53 
hsa-miR-125b 11q24.1/21q21.1 0.00115 0.34 0.00066 0.12 < 1.0E-08 0.08 0.0000041 0.16 
hsa-miR-126 9q34.3 NS 0.54 NS 0.23 < 1.0E-08 0.19 NS 0.31 
hsa-miR-130a 11q12.1 NS 0.59 0.00019 0.23 < 1.0E-08 0.25 0.0002739 0.37 
hsa-miR-143 5q32 0.04401 0.58 0.0035 0.21 < 1.0E-08 0.13 0.0000041 0.24 
hsa-miR-15a 13q14.2 NS 1.33 NS 1.06 0.000194 0.56 NS 0.87 
hsa-miR-195 17p13.1 NS 0.62 0.00474 0.22 1.2E-06 0.23 0.0001118 0.31 
hsa-miR-15b 3q25.33 NS 1.09 NS 0.75 0.003658 0.71 NS 0.92 
hsa-miR-16 17p13.1/3q25.33 NS 1.48 0.03115 0.36 0.000739 0.38 NS 0.81 
hsa-miR-17 13q31.3 NS 0.99 NS 0.76 0.000568 0.65 NS 0.97 
hsa-miR-106b 7q22.1 NS 1.55 0.01511 0.55 0.00235 0.65 NS 0.93 
hsa-miR-106a Xq26.2 NS 0.98 0.00772 0.65 0.00029 0.65 NS 0.95 
hsa-miR-191 3p21.31 0.00115 3.28 0.04451 0.64 0.038274 0.72 NS 1.07 
hsa-miR-193a-3p 17q11.2 NS 1.76 NS 0.73 NS 0.69 NS 1.01 
hsa-miR-199a-3p 19p13.2 NS 0.97 0.00448 0.45 0.000068 0.48 NS 0.70 
hsa-miR-199a-5p 19p13.2 NS 0.82 0.00038 0.39 < 1.0E-08 0.31 0.0010598 0.48 
hsa-miR-22 17p13.3 NS 1.54 0.02104 0.44 0.001856 0.51 NS 0.98 
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hsa-miR-222 Xp11.3 NS 0.75 0.00683 0.51 1.95E-05 0.49 NS 0.70 
hsa-miR-23a 19p13.13 NS 1.09 0.00836 0.37 0.000005 0.32 NS 0.70 
hsa-miR-23b 9q22.32 NS 1.03 0.00264 0.42 1.4E-06 0.37 NS 0.64 
hsa-miR-24 9q22.32/19p13.13 NS 1.06 0.02104 0.54 1E-07 0.29 NS 0.68 
hsa-miR-26b 2q35 NS 0.95 0.02697 0.28 9E-07 0.21 0.0001849 0.42 
hsa-miR-26a 3p22.2/12q14.1 NS 0.87 0.0054 0.19 1E-07 0.15 0.0000401 0.30 
hsa-miR-29c 1q32.2 NS 1.61 NS 0.53 0.016764 0.58 NS 0.93 
hsa-miR-29a 7q32.3 NS 0.80 0.00436 0.22 < 1.0E-08 0.16 0.0000972 0.41 
hsa-miR-29b 7q32.3/1q32.2 NS 1.71 NS 0.77 NS 0.75 NS 1.17 
hsa-miR-30e 1p34.2 NS 1.50 NS 0.85 0.011948 0.70 NS 0.96 
hsa-miR-30a 6q13 0.00903 2.05 0.00297 0.26 4.5E-06 0.26 NS 0.61 
hsa-miR-30c 6q13/1p34.2 NS 1.04 0.03909 0.59 < 1.0E-08 0.30 0.0000401 0.47 
hsa-miR-30b 8q24.22 NS 1.64 0.01184 0.27 4.5E-06 0.26 NS 0.52 
hsa-miR-30d 8q24.22 NS 1.21 NS 0.82 6.9E-06 0.56 0.0005759 0.67 
hsa-miR-34a 1p36.22 NS 1.07 0.00772 0.56 0.00068 0.62 NS 0.81 
hsa-miR-374a Xq13.2 NS 1.42 NS 0.68 0.004224 0.68 NS 0.89 
hsa-miR-768-3p snoRNA, HBII-239 NS 1.20 0.03277 0.48 0.000787 0.49 NS 0.85 
hsa-miR-141 12p13.31 0.00122 2.71 NS 0.72 0.014291 0.56 NS 1.07 
hsa-miR-200c 12p13.31 0.00442 2.22 0.00683 0.49 0.020487 0.63 NS 0.96 
hsa-miR-200a 1p36.33 0.00115 2.19 NS 0.82 NS 0.79 NS 1.10 
hsa-miR-200b 1p36.33 0.00115 2.21 NS 0.71 0.019219 0.67 NS 1.08 
hsa-miR-1264 Xq23 NS 1.72 NS 0.68 NS 1.00 NS 1.28 
hsa-miR-93 7q22.1 NS 1.39 NS 0.92 0.015206 0.78 NS 1.03 
hsa_SNORD10 
 
NS 1.23 NS 0.66 0.00128 0.59 NS 0.99 
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Supplementary Table . Cluster 3 differentially expressed miRNAs (FDR<0.05)  in each BRCAX-subgroup in comparison to normal breast tissue 
    BRCAX-A BRCAX-B BRCAX-C BRCAX-D 
miRNA Genomic location FDR FC FDR2 FC2 FDR3 FC3 FDR4 FC4 
hsa-miR-938 10p11.23 NS 1.34 NS 0.93 2.03E-05 2.68 NS 1.67 
hsa-miR-146b-3p 10q24.32 NS 1.25 NS 0.93 0.000442 1.69 3.3E-05 1.53 
hsa-miR-202 10q26.3 NS 1.03 NS 1.08 0.004028 1.95 NS 1.17 
hsa-miR-483-5p 11p15.5 NS 0.98 NS 0.81 0.000777 2.01 NS 1.48 
hsa-miR-485-3p 11p15.5 NS 1.21 NS 0.89 0.003089 1.62 0.00013 1.66 
hsa-miR-675 11p15.5 NS 0.66 NS 0.50 0.019869 1.95 NS 0.82 
hsa-miR-1261 11q14.3 NS 1.21 NS 0.91 0.000487 1.85 0.00027 1.64 
hsa-miR-920 12p12.1 NS 1.05 NS 0.89 0.012382 1.35 NS 1.25 
hsa-miR-492 12q22 NS 0.92 NS 0.87 0.005645 1.70 NS 1.08 
hsa-miR-617 12q32.31 NS 1.01 NS 0.90 0.000137 2.30 NS 1.39 
hsa-miR-623 13q32.3 NS 0.81 NS 0.83 0.049947 1.45 NS 0.81 
hsa-miR-208a 14q11.2 NS 1.16 NS 0.93 0.000777 2.15 0.00381 1.46 
hsa-miR-381 14q32.31 NS 1.10 NS 0.86 0.00211 2.02 NS 1.31 
hsa-miR-299-3p 14q32.31 NS 0.96 NS 0.86 0.025988 1.40 NS 1.15 
hsa-miR-323-3p 14q32.31/14q32.31 NS 0.95 NS 0.90 0.048284 1.31 NS 1.06 
hsa-miR-494 14q32.31/14q32.31 NS 1.98 NS 1.00 0.000166 4.79 NS 2.58 
hsa-miR-628-3p 15q21.3 NS 1.63 NS 1.03 3.21E-05 3.38 0.00042 2.27 
hsa-miR-184 15q25.1 NS 1.03 NS 1.14 6.7E-06 2.09 0.00338 1.33 
hsa-miR-549 15q25.1 0.04401 1.74 NS 1.11 3.5E-06 3.55 6.2E-06 2.58 
hsa-miR-423-3p 17q11.2 NS 1.02 NS 0.72 NS 1.23 NS 1.08 
hsa-miR-423-5p 17q11.2 NS 0.86 NS 0.75 0.000347 1.95 NS 1.04 
hsa-miR-638 19p13.2 NS 0.68 NS 0.47 NS 1.15 NS 0.58 
hsa-miR-498 19q13.42 NS 0.88 NS 0.65 0.005846 1.63 NS 0.94 
hsa-miR-516a-5p 19q13.42 NS 1.58 NS 0.78 1.44E-05 4.65 NS 2.12 
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hsa-miR-516b 19q13.42 NS 1.11 NS 0.99 8.63E-05 2.34 NS 1.57 
hsa-miR-525-5p 19q13.42 NS 0.84 0.03404 0.60 0.003556 1.59 NS 0.94 
hsa-miR-518a-5p 19q13.42/19q13.42 NS 1.04 NS 0.64 0.002269 2.06 NS 1.28 
hsa-miR-518e*/hsa-
miR-519a*/hsa-miR-
519b-5p/hsa-miR-
519c-5p/hsa-miR-
522*/hsa-miR-523* 
19q13.42 NS 0.94 NS 0.73 NS 1.85 NS 1.21 
hsa-miR-519e* 19q13.42 NS 0.99 NS 0.67 0.000913 2.21 NS 1.17 
hsa-miR-552 1p34.3 NS 1.12 NS 0.92 0.000083 2.15 NS 1.51 
hsa-miR-551a 1p36.32 NS 0.82 NS 0.97 0.012946 1.33 NS 0.91 
hsa-miR-765 1q23.1 NS 0.98 NS 1.16 0.000388 1.87 NS 1.44 
hsa-miR-921 1q24.1 NS 1.23 NS 1.03 7.76E-05 2.50 0.00047 1.86 
hsa-miR-557 1q24.2 NS 0.71 0.03277 0.55 0.020576 2.07 NS 0.94 
hsa-miR-215 1q41 NS 1.02 NS 0.91 0.004186 1.54 NS 1.12 
hsa-miR-659 22q13.1 NS 0.74 NS 0.67 NS 1.23 NS 0.80 
hsa-miR-933 2q31.1 NS 1.36 NS 0.67 0.00021 2.86 NS 1.53 
hsa-miR-1284 3p13 NS 1.04 NS 0.83 0.006484 1.55 NS 1.23 
hsa-miR-198 3q13.33 NS 0.78 NS 0.72 0.015405 1.47 NS 0.94 
hsa-miR-574-3p 4p14 NS 1.17 NS 0.88 0.049584 1.39 NS 1.51 
hsa-miR-874 5p31.2 NS 0.82 NS 0.72 0.010297 1.87 NS 0.96 
hsa-miR-583 5q15 NS 1.04 NS 0.88 0.001657 2.00 NS 1.53 
hsa-miR-340 5q35.3 NS 1.29 NS 0.94 0.001647 1.65 0.00038 1.46 
hsa-miR-1275 6p21.31 NS 0.60 NS 0.62 0.000332 3.04 NS 1.22 
hsa-miR-877 6p21.33 NS 1.10 NS 0.98 0.000325 1.72 NS 1.27 
hsa-miR-1285 7q21.2/2p13.3 NS 1.70 NS 1.33 0.000011 3.86 0.00019 2.35 
hsa-miR-489 7q21.3 NS 0.98 NS 0.84 0.00013 2.12 NS 1.33 
hsa-miR-490-3p 7q33 NS 1.09 NS 0.99 0.001613 1.53 0.00452 1.34 
hsa-miR-671-5p 7q36.1 NS 0.82 NS 0.71 0.01849 1.71 NS 0.98 
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hsa-miR-1273 
8q22.2/6q25.2/1p36.2
2/1p32.3/1p32.3 
NS 1.18 NS 1.03 0.000249 1.96 0.00338 1.63 
hsa-miR-602 9q34.3 NS 0.93 NS 0.53 0.000204 2.32 NS 1.09 
hsa-miR-663 centromere/2q21.2 NS 0.92 NS 0.84 0.005726 1.64 NS 1.00 
hsa-miR-542-5p Xq26.3 NS 0.90 NS 0.86 0.003777 1.72 NS 1.08 
hsa-miR-934 Xq26.3 NS 1.09 NS 0.93 0.005483 1.45 0.00027 1.39 
hsa-miR-508-5p Xq27.3 NS 1.03 NS 0.85 0.000899 2.17 NS 1.34 
hsa-miR-509-3-5p Xq27.3 NS 1.01 NS 0.75 0.002727 1.63 NS 1.18 
hsa-miR-510 Xq27.3 NS 0.86 NS 0.84 0.020576 1.35 NS 0.98 
hsa-miR-513b Xq27.3 NS 1.33 NS 1.18 1.44E-05 2.37 2.9E-05 1.61 
hsa-miR-509-5p Xq27.3/Xq27.3 NS 1.17 NS 0.75 0.001856 1.85 NS 1.41 
hsa-miR-513a-5p Xq27.3/Xq27.3 NS 1.45 NS 1.32 2.6E-06 3.17 0.00027 2.15 
hsa-miR-149* 2q37.3 0.00903 0.64 NS 0.56 NS 1.21 NS 0.68 
hsa-miR-183* 7q32.2 NS 1.12 NS 0.81 2.95E-05 2.93 NS 1.57 
hsa-miR-187* 18q12.22 NS 1.12 NS 0.80 0.000164 2.52 NS 1.46 
hsa-miR-193b* 16p13.12 NS 0.79 0.0211 0.57 NS 1.30 NS 0.90 
hsa-miR-196a* 12q13.13 NS 1.19 NS 0.98 0.002269 1.51 NS 1.25 
hsa-miR-200b* 1p36.33 NS 2.21 NS 0.71 0.019219 0.67 NS 1.08 
hsa-miR-25* 7q22.1 NS 1.10 NS 0.93 1E-07 3.58 0.0003 1.72 
hsa-miR-302c* 4q25 NS 0.78 0.01738 0.68 NS 1.17 0.00027 0.73 
hsa-miR-30c-1* 6q13/1p34.2 NS 0.79 NS 0.80 NS 1.25 NS 0.90 
hsa-miR-550* 7p14.3/7p14.3/7p14.3 NS 1.59 NS 1.01 0.009972 1.48 0.00019 1.78 
hsa-miR-551b* 3q26.2 NS 1.01 NS 0.85 0.001466 1.88 NS 1.31 
hsa-miR-629* 15q23 NS 0.96 NS 0.93 0.038274 1.36 NS 1.07 
hsa-miR-92b* 1q22 NS 0.98 NS 0.88 0.011746 1.46 NS 1.07 
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